[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fQ9ztD012W0mosFvdsvXb8jBc_nQSqNQZYWOwW2W-3EM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"Chong Kun Dang Pharmaceutical",[4],298,false,13,36,72776,27,2,[14,17,20,22,24,27,30,33],{"name":15,"count":16},"Hypertension",44,{"name":18,"count":19},"Dyslipidemias",15,{"name":21,"count":8},"Hypertension and Dyslipidemia",{"name":23,"count":8},"Type 2 Diabetes Mellitus",{"name":25,"count":26},"Healthy",12,{"name":28,"count":29},"Essential Hypertension",10,{"name":31,"count":32},"Type 2 Diabetes",9,{"name":34,"count":35},"Dyslipidemia",8,[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT06492655","To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers","2024-08-01","CKD-383",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06643819","Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A","2026-03-31","Sacubitril∙Valsartan",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT07404735","A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846","2026-05-27","CKD-846",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT05193565","Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients","2026-07","Sirolimus",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT07258745","Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants","2026-09-30","SKYRIZI",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT07358156","A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.","2026-11-16","CKD-706",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06916793","A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia","2026-12-19","CKD-843 dose#1",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT06838286","Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes","2026-12-31","SGLT2 inhibitor",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT07215637","Phase Ia\u002FIb Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors","2027-03","CKD-512",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT07532148","Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","2027-06","CKD-215",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,147,185,214,240,258,276,298,316,340,358,376,401,473,504,526,549,567,585,607,625,647,665,688,706,730,748,766,835,871,893,928,964,1002,1035,1070,1096,1114,1132,1157,1175,1200,1225,1248,1266,1291,1317,1335,1361,1379,1404,1429,1447,1471,1489,1507,1533,1551,1575,1593,1611,1629,1647,1672,1696,1714,1732,1758,1776,1803,1821,1894,1971,2031,2090,2120,2169,2216,2246,2268,2300,2329,2358,2392,2428,2459,2481,2519,2558,2587,2609,2631,2657,2675,2693,2711,2729,2755,2773,2791,2817,2835,2853,2871,2889,2907,2933,2951,2969,2987,3005,3030,3057,3075,3093,3118,3136,3165,3183,3201,3219,3237,3255,3273,3297,3315,3333,3351,3376,3394,3412,3430,3456,3474,3492,3510,3537,3555,3573,3591,3617,3635,3653,3671,3754,3780,3823,3845,3871,3905,3934,3966,3988,4012,4030,4048,4066,4084,4102,4120,4138,4156,4174,4192,4210,4228,4254,4272,4290,4319,4337,4355,4373,4391,4415,4433,4525,4608,4646,4703,4744,4778,4830,4866,4908,4948,4992,5034,5060,5086,5112,5141,5187,5220,5242,5274,5296,5323,5358,5395,5417,5452,5474,5509,5545,5567,5593,5623,5645,5677,5707,5737,5765,5787,5823,5860,5890,5912,5939,5970,5992,6021,6050,6085,6107,6137,6155,6179,6197,6215,6233,6257,6275,6293,6317,6342,6360,6382,6400,6418,6446,6464,6482,6500,6518,6546,6564,6582,6600,6618,6636,6654,6679,6697,6723,6741,6759,6777,6800,6818,6843,6861,6879,6897,6915,6937,6955,6973,6991,7013,7035,7053,7071,7089,7107,7130,7155,7173,7191,7215,7237,7260,7284,7302,7323,7345,7363,7388,7406,7424,7442,7460,7478,7496,7520,7543,7561,7579,7597,7621,7647,7665,7683,7706,7724,7742,7760,7778,7796,7819,7837,7855,7873,7898,7916,7934,7960,7978,7996,8014,8032,8050,8072,8098,8116,8134,8158,8180,8198,8223,8241,8266,8290,8313,8331,8349,8367,8392,8410,8432,8456,8474,8499,8517,8541,8564,8582,8600,8624,8642,8663,8685,8703,8721,8739,8757,8775,8801,8819,8846,8864,8887,8905,8930,8948,8966,8988,9006,9029,9047,9068,9086,9111,9129,9152,9170,9188,9206,9229,9247,9269,9287,9305,9332,9350,9368,9386,9404,9428,9446,9464,9482,9506,9524,9548,9570,9588,9606,9629,9647,9665,9683,9707,9725,9750,9768,9786,9804,9822,9848,9866,9891,9909,9927,9950,9968,9993,10011,10029,10055,10073,10091,10109,10136,10154,10172,10193,10211,10232,10250,10275,10293,10318,10336,10360,10383],{"intervention":96,"totalTrials":97,"cells":98},"Mycophenolate mofetil",3,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":117,"PHASE3":119,"PHASE4":121,"NA":145},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[104],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":114},"NCT01016626","Study to Evaluate the Pharmacokinetic Characteristics of CKD-4101 (Mycophenolate Mofetil) Tablet","COMPLETED",[89],"2009-08","2009-10","2009-07",28,[25],[115,116],"CKD-4101","Mycophenolate Mofetil",{"trials":118,"activeCount":101},[],{"trials":120,"activeCount":101},[],{"trials":122,"activeCount":144,"soonestReadout":55},[123,135],{"nctId":124,"briefTitle":125,"status":126,"phases":127,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":134},"NCT01766518","The Study to Evaluate Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients (MYLT1)","UNKNOWN",[92],"2014-04","2014-05","2009-11",120,[133],"Evidence of Liver Transplantation",[96],{"nctId":53,"briefTitle":54,"status":136,"phases":137,"primaryCompletion":55,"completion":138,"start":139,"enrollment":140,"conditions":141,"interventions":143},"ACTIVE_NOT_RECRUITING",[92],"2026-11","2021-11-19",206,[142],"Kidney Transplantation",[56,96],1,{"trials":146,"activeCount":101},[],{"intervention":148,"totalTrials":12,"cells":149},"Everolimus",{"EARLY_PHASE1":150,"PHASE1":152,"PHASE2":154,"PHASE3":156,"PHASE4":158,"NA":183},{"trials":151,"activeCount":101},[],{"trials":153,"activeCount":101},[],{"trials":155,"activeCount":101},[],{"trials":157,"activeCount":101},[],{"trials":159,"activeCount":144,"soonestReadout":165},[160,172],{"nctId":161,"briefTitle":162,"status":163,"phases":164,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":168,"interventions":170},"NCT06942156","Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea","NOT_YET_RECRUITING",[92],"2030-12","2025-08-14",140,[169],"Heart Transplant",[148,171],"Mycophenolate mofetil Tablet\u002FCapsule",{"nctId":173,"briefTitle":174,"status":126,"phases":175,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":180,"interventions":182},"NCT04867720","Efficacy and Safety of CertiroBell® Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant Recipients",[92],"2022-10-10","2023-02-22","2021-03-16",112,[181],"Liver Transplant",[148],{"trials":184,"activeCount":101},[],{"intervention":171,"totalTrials":12,"cells":186},{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":195,"NA":212},{"trials":188,"activeCount":101},[],{"trials":190,"activeCount":101},[],{"trials":192,"activeCount":101},[],{"trials":194,"activeCount":101},[],{"trials":196,"activeCount":144,"soonestReadout":165},[197,201],{"nctId":161,"briefTitle":162,"status":163,"phases":198,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":199,"interventions":200},[92],[169],[148,171],{"nctId":202,"briefTitle":203,"status":107,"phases":204,"primaryCompletion":205,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":210},"NCT06044493","MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients",[92],"2025-10-29","2023-11-14",158,[209],"Kidney Transplant",[211,171],"Myreptic-N",{"trials":213,"activeCount":101},[],{"intervention":215,"totalTrials":144,"cells":216},"empagliflozin 10mg",{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":223,"PHASE4":225,"NA":238},{"trials":218,"activeCount":101},[],{"trials":220,"activeCount":101},[],{"trials":222,"activeCount":101},[],{"trials":224,"activeCount":101},[],{"trials":226,"activeCount":144,"soonestReadout":231},[227],{"nctId":228,"briefTitle":229,"status":163,"phases":230,"primaryCompletion":231,"completion":231,"start":232,"enrollment":233,"conditions":234,"interventions":236},"NCT07365358","Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients",[92],"2027-08","2026-03",200,[235],"Diabete Type 2",[215,237],"Glimepiride 1mg",{"trials":239,"activeCount":101},[],{"intervention":237,"totalTrials":144,"cells":241},{"EARLY_PHASE1":242,"PHASE1":244,"PHASE2":246,"PHASE3":248,"PHASE4":250,"NA":256},{"trials":243,"activeCount":101},[],{"trials":245,"activeCount":101},[],{"trials":247,"activeCount":101},[],{"trials":249,"activeCount":101},[],{"trials":251,"activeCount":144,"soonestReadout":231},[252],{"nctId":228,"briefTitle":229,"status":163,"phases":253,"primaryCompletion":231,"completion":231,"start":232,"enrollment":233,"conditions":254,"interventions":255},[92],[235],[215,237],{"trials":257,"activeCount":101},[],{"intervention":56,"totalTrials":144,"cells":259},{"EARLY_PHASE1":260,"PHASE1":262,"PHASE2":264,"PHASE3":266,"PHASE4":268,"NA":274},{"trials":261,"activeCount":101},[],{"trials":263,"activeCount":101},[],{"trials":265,"activeCount":101},[],{"trials":267,"activeCount":101},[],{"trials":269,"activeCount":144,"soonestReadout":55},[270],{"nctId":53,"briefTitle":54,"status":136,"phases":271,"primaryCompletion":55,"completion":138,"start":139,"enrollment":140,"conditions":272,"interventions":273},[92],[142],[56,96],{"trials":275,"activeCount":101},[],{"intervention":46,"totalTrials":144,"cells":277},{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":284,"PHASE4":294,"NA":296},{"trials":279,"activeCount":101},[],{"trials":281,"activeCount":101},[],{"trials":283,"activeCount":101},[],{"trials":285,"activeCount":144,"soonestReadout":45},[286],{"nctId":43,"briefTitle":44,"status":287,"phases":288,"primaryCompletion":45,"completion":75,"start":289,"enrollment":290,"conditions":291,"interventions":292},"RECRUITING",[91],"2024-10-14",324,[28],[46,46,293],"Valsartan",{"trials":295,"activeCount":101},[],{"trials":297,"activeCount":101},[],{"intervention":293,"totalTrials":144,"cells":299},{"EARLY_PHASE1":300,"PHASE1":302,"PHASE2":304,"PHASE3":306,"PHASE4":312,"NA":314},{"trials":301,"activeCount":101},[],{"trials":303,"activeCount":101},[],{"trials":305,"activeCount":101},[],{"trials":307,"activeCount":144,"soonestReadout":45},[308],{"nctId":43,"briefTitle":44,"status":287,"phases":309,"primaryCompletion":45,"completion":75,"start":289,"enrollment":290,"conditions":310,"interventions":311},[91],[28],[46,46,293],{"trials":313,"activeCount":101},[],{"trials":315,"activeCount":101},[],{"intervention":71,"totalTrials":144,"cells":317},{"EARLY_PHASE1":318,"PHASE1":320,"PHASE2":322,"PHASE3":324,"PHASE4":336,"NA":338},{"trials":319,"activeCount":101},[],{"trials":321,"activeCount":101},[],{"trials":323,"activeCount":101},[],{"trials":325,"activeCount":144,"soonestReadout":70},[326],{"nctId":68,"briefTitle":69,"status":163,"phases":327,"primaryCompletion":70,"completion":328,"start":329,"enrollment":330,"conditions":331,"interventions":333},[91],"2027-09-17","2025-04-30",288,[332],"Androgenetic Alopecia",[71,334,335],"CKD-843 dose#2","Dutasteride",{"trials":337,"activeCount":101},[],{"trials":339,"activeCount":101},[],{"intervention":334,"totalTrials":144,"cells":341},{"EARLY_PHASE1":342,"PHASE1":344,"PHASE2":346,"PHASE3":348,"PHASE4":354,"NA":356},{"trials":343,"activeCount":101},[],{"trials":345,"activeCount":101},[],{"trials":347,"activeCount":101},[],{"trials":349,"activeCount":144,"soonestReadout":70},[350],{"nctId":68,"briefTitle":69,"status":163,"phases":351,"primaryCompletion":70,"completion":328,"start":329,"enrollment":330,"conditions":352,"interventions":353},[91],[332],[71,334,335],{"trials":355,"activeCount":101},[],{"trials":357,"activeCount":101},[],{"intervention":335,"totalTrials":144,"cells":359},{"EARLY_PHASE1":360,"PHASE1":362,"PHASE2":364,"PHASE3":366,"PHASE4":372,"NA":374},{"trials":361,"activeCount":101},[],{"trials":363,"activeCount":101},[],{"trials":365,"activeCount":101},[],{"trials":367,"activeCount":144,"soonestReadout":70},[368],{"nctId":68,"briefTitle":69,"status":163,"phases":369,"primaryCompletion":70,"completion":328,"start":329,"enrollment":330,"conditions":370,"interventions":371},[91],[332],[71,334,335],{"trials":373,"activeCount":101},[],{"trials":375,"activeCount":101},[],{"intervention":377,"totalTrials":144,"cells":378},"CKD-703",{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":395,"PHASE4":397,"NA":399},{"trials":380,"activeCount":101},[],{"trials":382,"activeCount":101},[],{"trials":384,"activeCount":144,"soonestReadout":389},[385],{"nctId":386,"briefTitle":387,"status":287,"phases":388,"primaryCompletion":389,"completion":389,"start":390,"enrollment":167,"conditions":391,"interventions":394},"NCT07439094","A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer",[89,90],"2029-12","2026-04-16",[392,393],"Advanced Solid Tumors","Non-Small Cell Lung Cancer",[377],{"trials":396,"activeCount":101},[],{"trials":398,"activeCount":101},[],{"trials":400,"activeCount":101},[],{"intervention":41,"totalTrials":402,"cells":403},6,{"EARLY_PHASE1":404,"PHASE1":406,"PHASE2":465,"PHASE3":467,"PHASE4":469,"NA":471},{"trials":405,"activeCount":101},[],{"trials":407,"activeCount":144,"soonestReadout":40},[408,419,427,433,444,455],{"nctId":409,"briefTitle":410,"status":107,"phases":411,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":416,"interventions":418},"NCT06695598","Clinical Study to Evaluate the Food Effect of CKD-383 0.5\u002F25\u002F1000mg in Healthy Volunteers",[89],"2024-12-08","2024-12-19","2024-11-06",30,[417],"Type 2 Diabetes Mellitus (T2DM)",[41],{"nctId":420,"briefTitle":421,"status":107,"phases":422,"primaryCompletion":423,"completion":424,"start":414,"enrollment":415,"conditions":425,"interventions":426},"NCT06695572","Clinical Study to Evaluate the Food Effect of CKD-383 0.5\u002F10\u002F1000mg in Healthy Volunteers",[89],"2024-12-07","2024-12-13",[417],[41],{"nctId":38,"briefTitle":39,"status":163,"phases":428,"primaryCompletion":40,"completion":429,"start":430,"enrollment":112,"conditions":431,"interventions":432},[89],"2024-08-08","2024-07-04",[23],[41,41],{"nctId":434,"briefTitle":435,"status":107,"phases":436,"primaryCompletion":437,"completion":438,"start":439,"enrollment":11,"conditions":440,"interventions":442},"NCT04810676","A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.",[89],"2021-05-20","2021-05-26","2021-04-16",[441],"Type2 Diabetes Mellitus",[443,41],"CKD-501, D745, D150",{"nctId":445,"briefTitle":446,"status":107,"phases":447,"primaryCompletion":448,"completion":449,"start":450,"enrollment":451,"conditions":452,"interventions":453},"NCT05816759","Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150",[89],"2023-06-04","2023-06-22","2023-05-26",32,[31],[41,454],"CKD-501, D744, D150",{"nctId":456,"briefTitle":457,"status":107,"phases":458,"primaryCompletion":459,"completion":460,"start":461,"enrollment":415,"conditions":462,"interventions":463},"NCT05897216","Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029",[89],"2023-07-23","2023-08-08","2023-07-14",[31],[41,464],"CKD-501, D745, D150, D029",{"trials":466,"activeCount":101},[],{"trials":468,"activeCount":101},[],{"trials":470,"activeCount":101},[],{"trials":472,"activeCount":101},[],{"intervention":51,"totalTrials":12,"cells":474},{"EARLY_PHASE1":475,"PHASE1":477,"PHASE2":496,"PHASE3":498,"PHASE4":500,"NA":502},{"trials":476,"activeCount":101},[],{"trials":478,"activeCount":144,"soonestReadout":50},[479,490],{"nctId":480,"briefTitle":49,"status":107,"phases":481,"primaryCompletion":482,"completion":483,"start":484,"enrollment":485,"conditions":486,"interventions":488},"NCT06110923",[89],"2024-05-10","2025-03-25","2023-11-13",31,[487],"Benign Prostate Hypertrophy(BPH)",[51,489],"D091",{"nctId":48,"briefTitle":49,"status":163,"phases":491,"primaryCompletion":50,"completion":492,"start":493,"enrollment":451,"conditions":494,"interventions":495},[89],"2026-06-02","2026-02-23",[487],[51,489],{"trials":497,"activeCount":101},[],{"trials":499,"activeCount":101},[],{"trials":501,"activeCount":101},[],{"trials":503,"activeCount":101},[],{"intervention":489,"totalTrials":12,"cells":505},{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":518,"PHASE3":520,"PHASE4":522,"NA":524},{"trials":507,"activeCount":101},[],{"trials":509,"activeCount":144,"soonestReadout":50},[510,514],{"nctId":480,"briefTitle":49,"status":107,"phases":511,"primaryCompletion":482,"completion":483,"start":484,"enrollment":485,"conditions":512,"interventions":513},[89],[487],[51,489],{"nctId":48,"briefTitle":49,"status":163,"phases":515,"primaryCompletion":50,"completion":492,"start":493,"enrollment":451,"conditions":516,"interventions":517},[89],[487],[51,489],{"trials":519,"activeCount":101},[],{"trials":521,"activeCount":101},[],{"trials":523,"activeCount":101},[],{"trials":525,"activeCount":101},[],{"intervention":66,"totalTrials":144,"cells":527},{"EARLY_PHASE1":528,"PHASE1":530,"PHASE2":541,"PHASE3":543,"PHASE4":545,"NA":547},{"trials":529,"activeCount":101},[],{"trials":531,"activeCount":144,"soonestReadout":65},[532],{"nctId":63,"briefTitle":64,"status":287,"phases":533,"primaryCompletion":65,"completion":65,"start":534,"enrollment":535,"conditions":536,"interventions":538},[89],"2026-02-09",519,[537],"Atopic Dermatitis",[66,539,540],"US-Dupixent","EU-Dupixent",{"trials":542,"activeCount":101},[],{"trials":544,"activeCount":101},[],{"trials":546,"activeCount":101},[],{"trials":548,"activeCount":101},[],{"intervention":539,"totalTrials":144,"cells":550},{"EARLY_PHASE1":551,"PHASE1":553,"PHASE2":559,"PHASE3":561,"PHASE4":563,"NA":565},{"trials":552,"activeCount":101},[],{"trials":554,"activeCount":144,"soonestReadout":65},[555],{"nctId":63,"briefTitle":64,"status":287,"phases":556,"primaryCompletion":65,"completion":65,"start":534,"enrollment":535,"conditions":557,"interventions":558},[89],[537],[66,539,540],{"trials":560,"activeCount":101},[],{"trials":562,"activeCount":101},[],{"trials":564,"activeCount":101},[],{"trials":566,"activeCount":101},[],{"intervention":540,"totalTrials":144,"cells":568},{"EARLY_PHASE1":569,"PHASE1":571,"PHASE2":577,"PHASE3":579,"PHASE4":581,"NA":583},{"trials":570,"activeCount":101},[],{"trials":572,"activeCount":144,"soonestReadout":65},[573],{"nctId":63,"briefTitle":64,"status":287,"phases":574,"primaryCompletion":65,"completion":65,"start":534,"enrollment":535,"conditions":575,"interventions":576},[89],[537],[66,539,540],{"trials":578,"activeCount":101},[],{"trials":580,"activeCount":101},[],{"trials":582,"activeCount":101},[],{"trials":584,"activeCount":101},[],{"intervention":86,"totalTrials":144,"cells":586},{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":599,"PHASE3":601,"PHASE4":603,"NA":605},{"trials":588,"activeCount":101},[],{"trials":590,"activeCount":144,"soonestReadout":85},[591],{"nctId":83,"briefTitle":84,"status":163,"phases":592,"primaryCompletion":85,"completion":231,"start":593,"enrollment":594,"conditions":595,"interventions":597},[89],"2026-06",24,[596],"Ovarian Cancer",[86,598],"D215",{"trials":600,"activeCount":101},[],{"trials":602,"activeCount":101},[],{"trials":604,"activeCount":101},[],{"trials":606,"activeCount":101},[],{"intervention":598,"totalTrials":144,"cells":608},{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":617,"PHASE3":619,"PHASE4":621,"NA":623},{"trials":610,"activeCount":101},[],{"trials":612,"activeCount":144,"soonestReadout":85},[613],{"nctId":83,"briefTitle":84,"status":163,"phases":614,"primaryCompletion":85,"completion":231,"start":593,"enrollment":594,"conditions":615,"interventions":616},[89],[596],[86,598],{"trials":618,"activeCount":101},[],{"trials":620,"activeCount":101},[],{"trials":622,"activeCount":101},[],{"trials":624,"activeCount":101},[],{"intervention":61,"totalTrials":144,"cells":626},{"EARLY_PHASE1":627,"PHASE1":629,"PHASE2":639,"PHASE3":641,"PHASE4":643,"NA":645},{"trials":628,"activeCount":101},[],{"trials":630,"activeCount":144,"soonestReadout":60},[631],{"nctId":58,"briefTitle":59,"status":287,"phases":632,"primaryCompletion":60,"completion":60,"start":633,"enrollment":634,"conditions":635,"interventions":637},[89],"2025-11-26",213,[636],"Psoriasis",[61,61,638],"CKD-704",{"trials":640,"activeCount":101},[],{"trials":642,"activeCount":101},[],{"trials":644,"activeCount":101},[],{"trials":646,"activeCount":101},[],{"intervention":638,"totalTrials":144,"cells":648},{"EARLY_PHASE1":649,"PHASE1":651,"PHASE2":657,"PHASE3":659,"PHASE4":661,"NA":663},{"trials":650,"activeCount":101},[],{"trials":652,"activeCount":144,"soonestReadout":60},[653],{"nctId":58,"briefTitle":59,"status":287,"phases":654,"primaryCompletion":60,"completion":60,"start":633,"enrollment":634,"conditions":655,"interventions":656},[89],[636],[61,61,638],{"trials":658,"activeCount":101},[],{"trials":660,"activeCount":101},[],{"trials":662,"activeCount":101},[],{"trials":664,"activeCount":101},[],{"intervention":81,"totalTrials":144,"cells":666},{"EARLY_PHASE1":667,"PHASE1":669,"PHASE2":680,"PHASE3":682,"PHASE4":684,"NA":686},{"trials":668,"activeCount":101},[],{"trials":670,"activeCount":144,"soonestReadout":80},[671],{"nctId":78,"briefTitle":79,"status":287,"phases":672,"primaryCompletion":80,"completion":673,"start":674,"enrollment":675,"conditions":676,"interventions":678},[89],"2027-09","2025-10-16",60,[392,677],"Metastatic Solid Tumors",[81,679],"Pembrolizumab",{"trials":681,"activeCount":101},[],{"trials":683,"activeCount":101},[],{"trials":685,"activeCount":101},[],{"trials":687,"activeCount":101},[],{"intervention":679,"totalTrials":144,"cells":689},{"EARLY_PHASE1":690,"PHASE1":692,"PHASE2":698,"PHASE3":700,"PHASE4":702,"NA":704},{"trials":691,"activeCount":101},[],{"trials":693,"activeCount":144,"soonestReadout":80},[694],{"nctId":78,"briefTitle":79,"status":287,"phases":695,"primaryCompletion":80,"completion":673,"start":674,"enrollment":675,"conditions":696,"interventions":697},[89],[392,677],[81,679],{"trials":699,"activeCount":101},[],{"trials":701,"activeCount":101},[],{"trials":703,"activeCount":101},[],{"trials":705,"activeCount":101},[],{"intervention":76,"totalTrials":144,"cells":707},{"EARLY_PHASE1":708,"PHASE1":710,"PHASE2":712,"PHASE3":714,"PHASE4":716,"NA":718},{"trials":709,"activeCount":101},[],{"trials":711,"activeCount":101},[],{"trials":713,"activeCount":101},[],{"trials":715,"activeCount":101},[],{"trials":717,"activeCount":101},[],{"trials":719,"activeCount":144,"soonestReadout":75},[720],{"nctId":73,"briefTitle":74,"status":287,"phases":721,"primaryCompletion":75,"completion":722,"start":723,"enrollment":724,"conditions":725,"interventions":727},[],"2029-12-31","2024-03-16",10000,[726],"Diabetes Mellitus, Type 2",[76,728,729],"Thiazolidinedione","DPP-4 inhibitor",{"intervention":728,"totalTrials":144,"cells":731},{"EARLY_PHASE1":732,"PHASE1":734,"PHASE2":736,"PHASE3":738,"PHASE4":740,"NA":742},{"trials":733,"activeCount":101},[],{"trials":735,"activeCount":101},[],{"trials":737,"activeCount":101},[],{"trials":739,"activeCount":101},[],{"trials":741,"activeCount":101},[],{"trials":743,"activeCount":144,"soonestReadout":75},[744],{"nctId":73,"briefTitle":74,"status":287,"phases":745,"primaryCompletion":75,"completion":722,"start":723,"enrollment":724,"conditions":746,"interventions":747},[],[726],[76,728,729],{"intervention":729,"totalTrials":144,"cells":749},{"EARLY_PHASE1":750,"PHASE1":752,"PHASE2":754,"PHASE3":756,"PHASE4":758,"NA":760},{"trials":751,"activeCount":101},[],{"trials":753,"activeCount":101},[],{"trials":755,"activeCount":101},[],{"trials":757,"activeCount":101},[],{"trials":759,"activeCount":101},[],{"trials":761,"activeCount":144,"soonestReadout":75},[762],{"nctId":73,"briefTitle":74,"status":287,"phases":763,"primaryCompletion":75,"completion":722,"start":723,"enrollment":724,"conditions":764,"interventions":765},[],[726],[76,728,729],{"intervention":767,"totalTrials":768,"cells":769},"Telmisartan",5,{"EARLY_PHASE1":770,"PHASE1":772,"PHASE2":794,"PHASE3":807,"PHASE4":809,"NA":833},{"trials":771,"activeCount":101},[],{"trials":773,"activeCount":101},[774,786],{"nctId":775,"briefTitle":776,"status":107,"phases":777,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":782,"interventions":783},"NCT02358824","CKD-828 (80\u002F5mg) Pharmacokinetic Study",[89],"2015-05","2015-06","2015-02",48,[15],[784,767,785],"CKD-828","S-amlodipine",{"nctId":787,"briefTitle":776,"status":107,"phases":788,"primaryCompletion":789,"completion":789,"start":790,"enrollment":791,"conditions":792,"interventions":793},"NCT02250833",[89],"2014-12","2014-09",69,[15],[784,767,785],{"trials":795,"activeCount":101},[796],{"nctId":797,"briefTitle":798,"status":107,"phases":799,"primaryCompletion":800,"completion":800,"start":801,"enrollment":802,"conditions":803,"interventions":804},"NCT01128322","CKD-828 Primary Hypertension Trial(Dose-selection)",[90],"2011-03","2010-07",430,[15],[805,806,767],"S-Amlodipine, Telmisartan","S-Amlodipine",{"trials":808,"activeCount":101},[],{"trials":810,"activeCount":101},[811,823],{"nctId":812,"briefTitle":813,"status":126,"phases":814,"primaryCompletion":815,"completion":815,"start":816,"enrollment":817,"conditions":818,"interventions":820},"NCT06431477","Efficacy and Safety of Telmisartan Compared With Losartan",[92],"2025-10-31","2023-04-19",98,[819,15],"Diabetic Nephropathies",[821,822],"telmisartan","Losartan",{"nctId":824,"briefTitle":825,"status":126,"phases":826,"primaryCompletion":827,"completion":827,"start":828,"enrollment":829,"conditions":830,"interventions":832},"NCT05843162","A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome",[92],"2023-12-31","2023-06-01",116,[28,831],"Metabolic Syndrome",[767,822],{"trials":834,"activeCount":101},[],{"intervention":836,"totalTrials":12,"cells":837},"Imotun",{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":842,"PHASE3":844,"PHASE4":846,"NA":869},{"trials":839,"activeCount":101},[],{"trials":841,"activeCount":101},[],{"trials":843,"activeCount":101},[],{"trials":845,"activeCount":101},[],{"trials":847,"activeCount":101},[848,859],{"nctId":849,"briefTitle":850,"status":107,"phases":851,"primaryCompletion":852,"completion":852,"start":853,"enrollment":854,"conditions":855,"interventions":857},"NCT01743287","The Study to Evaluate Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee",[92],"2015-04","2012-12",234,[856],"Osteoarthritis of the Knee",[836,858],"Imotun capsule placebo",{"nctId":860,"briefTitle":861,"status":107,"phases":862,"primaryCompletion":863,"completion":864,"start":865,"enrollment":866,"conditions":867,"interventions":868},"NCT01756937","Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee",[92],"2016-10","2017-02","2013-01",287,[856],[836],{"trials":870,"activeCount":101},[],{"intervention":822,"totalTrials":12,"cells":872},{"EARLY_PHASE1":873,"PHASE1":875,"PHASE2":877,"PHASE3":879,"PHASE4":881,"NA":891},{"trials":874,"activeCount":101},[],{"trials":876,"activeCount":101},[],{"trials":878,"activeCount":101},[],{"trials":880,"activeCount":101},[],{"trials":882,"activeCount":101},[883,887],{"nctId":812,"briefTitle":813,"status":126,"phases":884,"primaryCompletion":815,"completion":815,"start":816,"enrollment":817,"conditions":885,"interventions":886},[92],[819,15],[821,822],{"nctId":824,"briefTitle":825,"status":126,"phases":888,"primaryCompletion":827,"completion":827,"start":828,"enrollment":829,"conditions":889,"interventions":890},[92],[28,831],[767,822],{"trials":892,"activeCount":101},[],{"intervention":894,"totalTrials":12,"cells":895},"TacroBell SR cap.",{"EARLY_PHASE1":896,"PHASE1":898,"PHASE2":900,"PHASE3":902,"PHASE4":904,"NA":926},{"trials":897,"activeCount":101},[],{"trials":899,"activeCount":101},[],{"trials":901,"activeCount":101},[],{"trials":903,"activeCount":101},[],{"trials":905,"activeCount":101},[906,916],{"nctId":907,"briefTitle":908,"status":107,"phases":909,"primaryCompletion":910,"completion":911,"start":912,"enrollment":913,"conditions":914,"interventions":915},"NCT03749356","Study to Evaluate the Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant Recipients",[92],"2020-07-30","2020-12-04","2018-09-05",141,[209],[894],{"nctId":917,"briefTitle":918,"status":126,"phases":919,"primaryCompletion":910,"completion":920,"start":921,"enrollment":922,"conditions":923,"interventions":924},"NCT04224350","Study to Evaluate the Efficacy and Safety of Tacrolimus in Kidney Transplant Recipients (BLOSSOM)",[92],"2020-11-30","2018-12-17",184,[209],[894,925],"Tacrolimus cap.",{"trials":927,"activeCount":101},[],{"intervention":929,"totalTrials":12,"cells":930},"Atorvastatin",{"EARLY_PHASE1":931,"PHASE1":933,"PHASE2":947,"PHASE3":949,"PHASE4":951,"NA":962},{"trials":932,"activeCount":101},[],{"trials":934,"activeCount":101},[935],{"nctId":936,"briefTitle":937,"status":107,"phases":938,"primaryCompletion":939,"completion":940,"start":941,"enrollment":415,"conditions":942,"interventions":945},"NCT02066207","CKD-337 Drug Interaction Study",[89],"2014-04-07","2014-05-29","2014-03-18",[943,944],"Dyslipidemia (Fredrickson Type Ⅱa)","Dyslipidemia (Fredrickson Type Ⅱb)",[946,929],"Fenofibrate",{"trials":948,"activeCount":101},[],{"trials":950,"activeCount":101},[],{"trials":952,"activeCount":101},[953],{"nctId":954,"briefTitle":955,"status":107,"phases":956,"primaryCompletion":957,"completion":130,"start":958,"enrollment":959,"conditions":960,"interventions":961},"NCT01029522","Dyslipidemia in Cardiovascular Disease",[92],"2008-10","2008-08",244,[34],[929,929],{"trials":963,"activeCount":101},[],{"intervention":965,"totalTrials":12,"cells":966},"tacrolimus",{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":971,"PHASE3":973,"PHASE4":975,"NA":1000},{"trials":968,"activeCount":101},[],{"trials":970,"activeCount":101},[],{"trials":972,"activeCount":101},[],{"trials":974,"activeCount":101},[],{"trials":976,"activeCount":101},[977,986],{"nctId":978,"briefTitle":979,"status":107,"phases":980,"primaryCompletion":981,"completion":981,"start":982,"enrollment":983,"conditions":984,"interventions":985},"NCT04102943","Study to Evaluate the Pharmacokinetics and Tolerability of Tacrolimus in Kidney Transplant Recipients.",[92],"2020-09-29","2017-11-30",128,[209],[965,965],{"nctId":987,"briefTitle":988,"status":107,"phases":989,"primaryCompletion":990,"completion":991,"start":992,"enrollment":993,"conditions":994,"interventions":995},"NCT03794492","Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome",[92],"2022-07-22","2023-04-27","2018-03-31",169,[209],[996,997,998,999],"Mycophenolate mofetil 500mg Tab. or 250mg Cap.","Tacrolimus","Methylprednisolone\u002Fprednisolone","Basiliximab",{"trials":1001,"activeCount":101},[],{"intervention":1003,"totalTrials":12,"cells":1004},"Telminuvo®Tab. 40\u002F2.5mg",{"EARLY_PHASE1":1005,"PHASE1":1007,"PHASE2":1009,"PHASE3":1011,"PHASE4":1013,"NA":1033},{"trials":1006,"activeCount":101},[],{"trials":1008,"activeCount":101},[],{"trials":1010,"activeCount":101},[],{"trials":1012,"activeCount":101},[],{"trials":1014,"activeCount":101},[1015,1023],{"nctId":1016,"briefTitle":1017,"status":126,"phases":1018,"primaryCompletion":1019,"completion":1019,"start":852,"enrollment":1020,"conditions":1021,"interventions":1022},"NCT02526875","Efficacy of a Telmisartan\u002FS-Amlodipine on 24-hour BP Control in Hypertensive Patients Inadequately Controlled",[92],"2017-11",208,[15],[1003],{"nctId":1024,"briefTitle":1025,"status":107,"phases":1026,"primaryCompletion":1027,"completion":1027,"start":1028,"enrollment":1029,"conditions":1030,"interventions":1031},"NCT02231788","The Efficacy of a Combination of Telmisartan\u002FS-Amlodipine Compared With Telmisartan Monotherapy",[92],"2018-03","2014-06",217,[15],[1003,1032],"Telmitrend®Tab. 80mg",{"trials":1034,"activeCount":101},[],{"intervention":1036,"totalTrials":12,"cells":1037},"Candemore",{"EARLY_PHASE1":1038,"PHASE1":1040,"PHASE2":1042,"PHASE3":1044,"PHASE4":1046,"NA":1068},{"trials":1039,"activeCount":101},[],{"trials":1041,"activeCount":101},[],{"trials":1043,"activeCount":101},[],{"trials":1045,"activeCount":101},[],{"trials":1047,"activeCount":101},[1048,1058],{"nctId":1049,"briefTitle":1050,"status":107,"phases":1051,"primaryCompletion":1052,"completion":1052,"start":1053,"enrollment":993,"conditions":1054,"interventions":1056},"NCT01682564","To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure",[92],"2014-10","2012-01",[15,1055],"Congestive Heart Failure",[1036,1057],"Atacand",{"nctId":1059,"briefTitle":1060,"status":1061,"phases":1062,"primaryCompletion":1063,"completion":1063,"start":1064,"enrollment":451,"conditions":1065,"interventions":1066},"NCT01766505","The Study to Evaluate Efficacy and Safety of Candesartan vs Losartan in Hypertension With Heart Failure (HONOR)","TERMINATED",[92],"2014-03","2012-06",[15],[1036,1067],"Cozzar",{"trials":1069,"activeCount":101},[],{"intervention":1071,"totalTrials":144,"cells":1072},"Eupasidin-s Tab",{"EARLY_PHASE1":1073,"PHASE1":1075,"PHASE2":1077,"PHASE3":1079,"PHASE4":1081,"NA":1094},{"trials":1074,"activeCount":101},[],{"trials":1076,"activeCount":101},[],{"trials":1078,"activeCount":101},[],{"trials":1080,"activeCount":101},[],{"trials":1082,"activeCount":101},[1083],{"nctId":1084,"briefTitle":1085,"status":107,"phases":1086,"primaryCompletion":779,"completion":779,"start":1087,"enrollment":1088,"conditions":1089,"interventions":1092},"NCT02356679","Efficacy and Safety of Eupasidin-s Tab.(EUPASIDIN-S) in Gastritis Patients",[92],"2014-08",230,[1090,1091],"Acute Gastritis","Chronic Gastritis",[1071,1093],"Stillen Tab.",{"trials":1095,"activeCount":101},[],{"intervention":1093,"totalTrials":144,"cells":1097},{"EARLY_PHASE1":1098,"PHASE1":1100,"PHASE2":1102,"PHASE3":1104,"PHASE4":1106,"NA":1112},{"trials":1099,"activeCount":101},[],{"trials":1101,"activeCount":101},[],{"trials":1103,"activeCount":101},[],{"trials":1105,"activeCount":101},[],{"trials":1107,"activeCount":101},[1108],{"nctId":1084,"briefTitle":1085,"status":107,"phases":1109,"primaryCompletion":779,"completion":779,"start":1087,"enrollment":1088,"conditions":1110,"interventions":1111},[92],[1090,1091],[1071,1093],{"trials":1113,"activeCount":101},[],{"intervention":858,"totalTrials":144,"cells":1115},{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1122,"PHASE4":1124,"NA":1130},{"trials":1117,"activeCount":101},[],{"trials":1119,"activeCount":101},[],{"trials":1121,"activeCount":101},[],{"trials":1123,"activeCount":101},[],{"trials":1125,"activeCount":101},[1126],{"nctId":849,"briefTitle":850,"status":107,"phases":1127,"primaryCompletion":852,"completion":852,"start":853,"enrollment":854,"conditions":1128,"interventions":1129},[92],[856],[836,858],{"trials":1131,"activeCount":101},[],{"intervention":1133,"totalTrials":144,"cells":1134},"Everolimus Tab.",{"EARLY_PHASE1":1135,"PHASE1":1137,"PHASE2":1139,"PHASE3":1141,"PHASE4":1143,"NA":1155},{"trials":1136,"activeCount":101},[],{"trials":1138,"activeCount":101},[],{"trials":1140,"activeCount":101},[],{"trials":1142,"activeCount":101},[],{"trials":1144,"activeCount":101},[1145],{"nctId":1146,"briefTitle":1147,"status":107,"phases":1148,"primaryCompletion":1149,"completion":1149,"start":1150,"enrollment":1151,"conditions":1152,"interventions":1153},"NCT04471441","Efficacy and Safety of Everolimus Versus Mycophenolate Mofetil in Liver Transplant Recipients.",[92],"2024-07-24","2020-06-30",150,[181],[1133,1154],"Mycophenolate mofetil Tab.\u002FCap.",{"trials":1156,"activeCount":101},[],{"intervention":1154,"totalTrials":144,"cells":1158},{"EARLY_PHASE1":1159,"PHASE1":1161,"PHASE2":1163,"PHASE3":1165,"PHASE4":1167,"NA":1173},{"trials":1160,"activeCount":101},[],{"trials":1162,"activeCount":101},[],{"trials":1164,"activeCount":101},[],{"trials":1166,"activeCount":101},[],{"trials":1168,"activeCount":101},[1169],{"nctId":1146,"briefTitle":1147,"status":107,"phases":1170,"primaryCompletion":1149,"completion":1149,"start":1150,"enrollment":1151,"conditions":1171,"interventions":1172},[92],[181],[1133,1154],{"trials":1174,"activeCount":101},[],{"intervention":1176,"totalTrials":144,"cells":1177},"Choline Alfoscerate 400mg",{"EARLY_PHASE1":1178,"PHASE1":1180,"PHASE2":1182,"PHASE3":1184,"PHASE4":1186,"NA":1198},{"trials":1179,"activeCount":101},[],{"trials":1181,"activeCount":101},[],{"trials":1183,"activeCount":101},[],{"trials":1185,"activeCount":101},[],{"trials":1187,"activeCount":101},[1188],{"nctId":1189,"briefTitle":1190,"status":126,"phases":1191,"primaryCompletion":1192,"completion":1192,"start":1193,"enrollment":1194,"conditions":1195,"interventions":1197},"NCT05050604","A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment Patients",[92],"2024-11","2021-09",418,[1196],"Vascular Cognitive Impairment",[1176],{"trials":1199,"activeCount":101},[],{"intervention":1201,"totalTrials":144,"cells":1202},"Experimental",{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1207,"PHASE3":1209,"PHASE4":1211,"NA":1223},{"trials":1204,"activeCount":101},[],{"trials":1206,"activeCount":101},[],{"trials":1208,"activeCount":101},[],{"trials":1210,"activeCount":101},[],{"trials":1212,"activeCount":101},[1213],{"nctId":1214,"briefTitle":1215,"status":107,"phases":1216,"primaryCompletion":1217,"completion":1217,"start":1218,"enrollment":1219,"conditions":1220,"interventions":1222},"NCT04539652","Clinical Trial to Evaluate the Efficacy and Safety of TenofoBell® Tablet in Chronic Hepatitis B Patients",[92],"2021-06-22","2018-09-20",78,[1221],"Chronic Hepatitis B",[1201],{"trials":1224,"activeCount":101},[],{"intervention":1226,"totalTrials":144,"cells":1227},"Mycophenolate Mofetil 500mg",{"EARLY_PHASE1":1228,"PHASE1":1230,"PHASE2":1232,"PHASE3":1234,"PHASE4":1236,"NA":1246},{"trials":1229,"activeCount":101},[],{"trials":1231,"activeCount":101},[],{"trials":1233,"activeCount":101},[],{"trials":1235,"activeCount":101},[],{"trials":1237,"activeCount":101},[1238],{"nctId":1239,"briefTitle":1240,"status":107,"phases":1241,"primaryCompletion":852,"completion":852,"start":865,"enrollment":1242,"conditions":1243,"interventions":1244},"NCT01842269","Evaluate the Efficacy and Safety of My-Rept® Tablet vs. My-Rept® Capsule in Combination With Tacrolimus in Kidney Transplant Patients",[92],156,[142],[1226,1245],"Mycophenolate Mofetil 250mg",{"trials":1247,"activeCount":101},[],{"intervention":1245,"totalTrials":144,"cells":1249},{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1254,"PHASE3":1256,"PHASE4":1258,"NA":1264},{"trials":1251,"activeCount":101},[],{"trials":1253,"activeCount":101},[],{"trials":1255,"activeCount":101},[],{"trials":1257,"activeCount":101},[],{"trials":1259,"activeCount":101},[1260],{"nctId":1239,"briefTitle":1240,"status":107,"phases":1261,"primaryCompletion":852,"completion":852,"start":865,"enrollment":1242,"conditions":1262,"interventions":1263},[92],[142],[1226,1245],{"trials":1265,"activeCount":101},[],{"intervention":1267,"totalTrials":144,"cells":1268},"EsoDuo Tab. 20\u002F800mg",{"EARLY_PHASE1":1269,"PHASE1":1271,"PHASE2":1273,"PHASE3":1275,"PHASE4":1277,"NA":1289},{"trials":1270,"activeCount":101},[],{"trials":1272,"activeCount":101},[],{"trials":1274,"activeCount":101},[],{"trials":1276,"activeCount":101},[],{"trials":1278,"activeCount":101},[1279],{"nctId":1280,"briefTitle":1281,"status":107,"phases":1282,"primaryCompletion":1283,"completion":1283,"start":1284,"enrollment":1285,"conditions":1286,"interventions":1288},"NCT03928470","Clinical Trial to Evaluate the Efficacy and Safety of EsoDuo Tab. 20\u002F800mg",[92],"2019-12-20","2019-01-29",379,[1287],"Non-erosive Reflux Disease(NERD)",[1267],{"trials":1290,"activeCount":101},[],{"intervention":1292,"totalTrials":144,"cells":1293},"EntecaBell ODT. 0.5mg",{"EARLY_PHASE1":1294,"PHASE1":1296,"PHASE2":1298,"PHASE3":1300,"PHASE4":1302,"NA":1315},{"trials":1295,"activeCount":101},[],{"trials":1297,"activeCount":101},[],{"trials":1299,"activeCount":101},[],{"trials":1301,"activeCount":101},[],{"trials":1303,"activeCount":101},[1304],{"nctId":1305,"briefTitle":1306,"status":126,"phases":1307,"primaryCompletion":864,"completion":1308,"start":1309,"enrollment":1310,"conditions":1311,"interventions":1313},"NCT02588937","Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients",[92],"2017-06","2015-10",76,[1312],"Hepatitis B, Chronic",[1292,1314],"Baraclude Tab. 0.5mg",{"trials":1316,"activeCount":101},[],{"intervention":1314,"totalTrials":144,"cells":1318},{"EARLY_PHASE1":1319,"PHASE1":1321,"PHASE2":1323,"PHASE3":1325,"PHASE4":1327,"NA":1333},{"trials":1320,"activeCount":101},[],{"trials":1322,"activeCount":101},[],{"trials":1324,"activeCount":101},[],{"trials":1326,"activeCount":101},[],{"trials":1328,"activeCount":101},[1329],{"nctId":1305,"briefTitle":1306,"status":126,"phases":1330,"primaryCompletion":864,"completion":1308,"start":1309,"enrollment":1310,"conditions":1331,"interventions":1332},[92],[1312],[1292,1314],{"trials":1334,"activeCount":101},[],{"intervention":1336,"totalTrials":144,"cells":1337},"Lipilou®(generic atorvastatin drug) 20 mg",{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1342,"PHASE3":1344,"PHASE4":1346,"NA":1359},{"trials":1339,"activeCount":101},[],{"trials":1341,"activeCount":101},[],{"trials":1343,"activeCount":101},[],{"trials":1345,"activeCount":101},[],{"trials":1347,"activeCount":101},[1348],{"nctId":1349,"briefTitle":1350,"status":107,"phases":1351,"primaryCompletion":1352,"completion":1352,"start":1353,"enrollment":1354,"conditions":1355,"interventions":1357},"NCT04511000","Clinical Trial to to Compare of the Efficacy and Safety of Lipilou® 20 mg and Lipilou® 10 mg",[92],"2019-05-20","2017-10-11",250,[1356],"Hypercholesterolemia",[1336,1358],"Lipilou®(generic atorvastatin drug) 10 mg",{"trials":1360,"activeCount":101},[],{"intervention":1358,"totalTrials":144,"cells":1362},{"EARLY_PHASE1":1363,"PHASE1":1365,"PHASE2":1367,"PHASE3":1369,"PHASE4":1371,"NA":1377},{"trials":1364,"activeCount":101},[],{"trials":1366,"activeCount":101},[],{"trials":1368,"activeCount":101},[],{"trials":1370,"activeCount":101},[],{"trials":1372,"activeCount":101},[1373],{"nctId":1349,"briefTitle":1350,"status":107,"phases":1374,"primaryCompletion":1352,"completion":1352,"start":1353,"enrollment":1354,"conditions":1375,"interventions":1376},[92],[1356],[1336,1358],{"trials":1378,"activeCount":101},[],{"intervention":1380,"totalTrials":144,"cells":1381},"Conversion to Once-daily Tacrolimus",{"EARLY_PHASE1":1382,"PHASE1":1384,"PHASE2":1386,"PHASE3":1388,"PHASE4":1390,"NA":1402},{"trials":1383,"activeCount":101},[],{"trials":1385,"activeCount":101},[],{"trials":1387,"activeCount":101},[],{"trials":1389,"activeCount":101},[],{"trials":1391,"activeCount":101},[1392],{"nctId":1393,"briefTitle":1394,"status":126,"phases":1395,"primaryCompletion":1396,"completion":1397,"start":1398,"enrollment":1399,"conditions":1400,"interventions":1401},"NCT04069065","Efficacy and Safety of Once-Daily Tacrolimus in Liver Transplant Recipients (SOUL)",[92],"2021-02-22","2021-04-08","2019-07-31",146,[181],[1380],{"trials":1403,"activeCount":101},[],{"intervention":1405,"totalTrials":144,"cells":1406},"Sirolimus Tab.",{"EARLY_PHASE1":1407,"PHASE1":1409,"PHASE2":1411,"PHASE3":1413,"PHASE4":1415,"NA":1427},{"trials":1408,"activeCount":101},[],{"trials":1410,"activeCount":101},[],{"trials":1412,"activeCount":101},[],{"trials":1414,"activeCount":101},[],{"trials":1416,"activeCount":101},[1417],{"nctId":1418,"briefTitle":1419,"status":126,"phases":1420,"primaryCompletion":1421,"completion":1422,"start":1423,"enrollment":207,"conditions":1424,"interventions":1425},"NCT04700709","Efficacy and Safety of Sirolimus Plus CNI Compared With MMF Plus CNI in ABO-i Kidney Transplant Recipients.",[92],"2024-12","2025-01","2021-01",[142],[1405,1426],"Mycophenolate Mofetil Cap.\u002FTab.",{"trials":1428,"activeCount":101},[],{"intervention":1426,"totalTrials":144,"cells":1430},{"EARLY_PHASE1":1431,"PHASE1":1433,"PHASE2":1435,"PHASE3":1437,"PHASE4":1439,"NA":1445},{"trials":1432,"activeCount":101},[],{"trials":1434,"activeCount":101},[],{"trials":1436,"activeCount":101},[],{"trials":1438,"activeCount":101},[],{"trials":1440,"activeCount":101},[1441],{"nctId":1418,"briefTitle":1419,"status":126,"phases":1442,"primaryCompletion":1421,"completion":1422,"start":1423,"enrollment":207,"conditions":1443,"interventions":1444},[92],[142],[1405,1426],{"trials":1446,"activeCount":101},[],{"intervention":1448,"totalTrials":144,"cells":1449},"Choline Alfoscerate",{"EARLY_PHASE1":1450,"PHASE1":1452,"PHASE2":1454,"PHASE3":1456,"PHASE4":1458,"NA":1469},{"trials":1451,"activeCount":101},[],{"trials":1453,"activeCount":101},[],{"trials":1455,"activeCount":101},[],{"trials":1457,"activeCount":101},[],{"trials":1459,"activeCount":101},[1460],{"nctId":1461,"briefTitle":1462,"status":126,"phases":1463,"primaryCompletion":1464,"completion":1464,"start":1465,"enrollment":1194,"conditions":1466,"interventions":1468},"NCT05041790","A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment",[92],"2024-11-30","2021-09-30",[1467],"Mild Cognitive Impairment",[1448],{"trials":1470,"activeCount":101},[],{"intervention":211,"totalTrials":144,"cells":1472},{"EARLY_PHASE1":1473,"PHASE1":1475,"PHASE2":1477,"PHASE3":1479,"PHASE4":1481,"NA":1487},{"trials":1474,"activeCount":101},[],{"trials":1476,"activeCount":101},[],{"trials":1478,"activeCount":101},[],{"trials":1480,"activeCount":101},[],{"trials":1482,"activeCount":101},[1483],{"nctId":202,"briefTitle":203,"status":107,"phases":1484,"primaryCompletion":205,"completion":205,"start":206,"enrollment":207,"conditions":1485,"interventions":1486},[92],[209],[211,171],{"trials":1488,"activeCount":101},[],{"intervention":1057,"totalTrials":144,"cells":1490},{"EARLY_PHASE1":1491,"PHASE1":1493,"PHASE2":1495,"PHASE3":1497,"PHASE4":1499,"NA":1505},{"trials":1492,"activeCount":101},[],{"trials":1494,"activeCount":101},[],{"trials":1496,"activeCount":101},[],{"trials":1498,"activeCount":101},[],{"trials":1500,"activeCount":101},[1501],{"nctId":1049,"briefTitle":1050,"status":107,"phases":1502,"primaryCompletion":1052,"completion":1052,"start":1053,"enrollment":993,"conditions":1503,"interventions":1504},[92],[15,1055],[1036,1057],{"trials":1506,"activeCount":101},[],{"intervention":1508,"totalTrials":144,"cells":1509},"Cantabell Tab",{"EARLY_PHASE1":1510,"PHASE1":1512,"PHASE2":1514,"PHASE3":1516,"PHASE4":1518,"NA":1531},{"trials":1511,"activeCount":101},[],{"trials":1513,"activeCount":101},[],{"trials":1515,"activeCount":101},[],{"trials":1517,"activeCount":101},[],{"trials":1519,"activeCount":101},[1520],{"nctId":1521,"briefTitle":1522,"status":107,"phases":1523,"primaryCompletion":1524,"completion":1525,"start":1526,"enrollment":1527,"conditions":1528,"interventions":1529},"NCT04521023","A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy",[92],"2020-01-28","2020-06-03","2017-09-20",132,[15],[1508,1530],"Candemore Plus Tab",{"trials":1532,"activeCount":101},[],{"intervention":1530,"totalTrials":144,"cells":1534},{"EARLY_PHASE1":1535,"PHASE1":1537,"PHASE2":1539,"PHASE3":1541,"PHASE4":1543,"NA":1549},{"trials":1536,"activeCount":101},[],{"trials":1538,"activeCount":101},[],{"trials":1540,"activeCount":101},[],{"trials":1542,"activeCount":101},[],{"trials":1544,"activeCount":101},[1545],{"nctId":1521,"briefTitle":1522,"status":107,"phases":1546,"primaryCompletion":1524,"completion":1525,"start":1526,"enrollment":1527,"conditions":1547,"interventions":1548},[92],[15],[1508,1530],{"trials":1550,"activeCount":101},[],{"intervention":1552,"totalTrials":144,"cells":1553},"Newrabell® Tablet 10mg",{"EARLY_PHASE1":1554,"PHASE1":1556,"PHASE2":1558,"PHASE3":1560,"PHASE4":1562,"NA":1573},{"trials":1555,"activeCount":101},[],{"trials":1557,"activeCount":101},[],{"trials":1559,"activeCount":101},[],{"trials":1561,"activeCount":101},[],{"trials":1563,"activeCount":101},[1564],{"nctId":1565,"briefTitle":1566,"status":107,"phases":1567,"primaryCompletion":778,"completion":778,"start":1568,"enrollment":1569,"conditions":1570,"interventions":1572},"NCT01860482","The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD",[92],"2013-04",39,[1571],"Reflux Esophagitis",[1552],{"trials":1574,"activeCount":101},[],{"intervention":925,"totalTrials":144,"cells":1576},{"EARLY_PHASE1":1577,"PHASE1":1579,"PHASE2":1581,"PHASE3":1583,"PHASE4":1585,"NA":1591},{"trials":1578,"activeCount":101},[],{"trials":1580,"activeCount":101},[],{"trials":1582,"activeCount":101},[],{"trials":1584,"activeCount":101},[],{"trials":1586,"activeCount":101},[1587],{"nctId":917,"briefTitle":918,"status":126,"phases":1588,"primaryCompletion":910,"completion":920,"start":921,"enrollment":922,"conditions":1589,"interventions":1590},[92],[209],[894,925],{"trials":1592,"activeCount":101},[],{"intervention":996,"totalTrials":144,"cells":1594},{"EARLY_PHASE1":1595,"PHASE1":1597,"PHASE2":1599,"PHASE3":1601,"PHASE4":1603,"NA":1609},{"trials":1596,"activeCount":101},[],{"trials":1598,"activeCount":101},[],{"trials":1600,"activeCount":101},[],{"trials":1602,"activeCount":101},[],{"trials":1604,"activeCount":101},[1605],{"nctId":987,"briefTitle":988,"status":107,"phases":1606,"primaryCompletion":990,"completion":991,"start":992,"enrollment":993,"conditions":1607,"interventions":1608},[92],[209],[996,997,998,999],{"trials":1610,"activeCount":101},[],{"intervention":998,"totalTrials":144,"cells":1612},{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1617,"PHASE3":1619,"PHASE4":1621,"NA":1627},{"trials":1614,"activeCount":101},[],{"trials":1616,"activeCount":101},[],{"trials":1618,"activeCount":101},[],{"trials":1620,"activeCount":101},[],{"trials":1622,"activeCount":101},[1623],{"nctId":987,"briefTitle":988,"status":107,"phases":1624,"primaryCompletion":990,"completion":991,"start":992,"enrollment":993,"conditions":1625,"interventions":1626},[92],[209],[996,997,998,999],{"trials":1628,"activeCount":101},[],{"intervention":999,"totalTrials":144,"cells":1630},{"EARLY_PHASE1":1631,"PHASE1":1633,"PHASE2":1635,"PHASE3":1637,"PHASE4":1639,"NA":1645},{"trials":1632,"activeCount":101},[],{"trials":1634,"activeCount":101},[],{"trials":1636,"activeCount":101},[],{"trials":1638,"activeCount":101},[],{"trials":1640,"activeCount":101},[1641],{"nctId":987,"briefTitle":988,"status":107,"phases":1642,"primaryCompletion":990,"completion":991,"start":992,"enrollment":993,"conditions":1643,"interventions":1644},[92],[209],[996,997,998,999],{"trials":1646,"activeCount":101},[],{"intervention":1648,"totalTrials":144,"cells":1649},"EsoDuo®",{"EARLY_PHASE1":1650,"PHASE1":1652,"PHASE2":1654,"PHASE3":1656,"PHASE4":1658,"NA":1670},{"trials":1651,"activeCount":101},[],{"trials":1653,"activeCount":101},[],{"trials":1655,"activeCount":101},[],{"trials":1657,"activeCount":101},[],{"trials":1659,"activeCount":101},[1660],{"nctId":1661,"briefTitle":1662,"status":126,"phases":1663,"primaryCompletion":1422,"completion":1664,"start":1665,"enrollment":1666,"conditions":1667,"interventions":1669},"NCT06430047","Efficacy and Safety of EsoDuo®",[92],"2025-05","2022-11-25",180,[1668],"Gastro Esophageal Reflux",[1648],{"trials":1671,"activeCount":101},[],{"intervention":1673,"totalTrials":144,"cells":1674},"Tacrolimus with Methotrexate",{"EARLY_PHASE1":1675,"PHASE1":1677,"PHASE2":1679,"PHASE3":1681,"PHASE4":1683,"NA":1694},{"trials":1676,"activeCount":101},[],{"trials":1678,"activeCount":101},[],{"trials":1680,"activeCount":101},[],{"trials":1682,"activeCount":101},[],{"trials":1684,"activeCount":101},[1685],{"nctId":1686,"briefTitle":1687,"status":107,"phases":1688,"primaryCompletion":779,"completion":779,"start":1689,"enrollment":1690,"conditions":1691,"interventions":1693},"NCT01746680","Efficacy and Safety Study of Tacrobell to Treat Rheumatoid Arthritis",[92],"2012-08",111,[1692],"Rheumatoid Arthritis",[1673],{"trials":1695,"activeCount":101},[],{"intervention":1032,"totalTrials":144,"cells":1697},{"EARLY_PHASE1":1698,"PHASE1":1700,"PHASE2":1702,"PHASE3":1704,"PHASE4":1706,"NA":1712},{"trials":1699,"activeCount":101},[],{"trials":1701,"activeCount":101},[],{"trials":1703,"activeCount":101},[],{"trials":1705,"activeCount":101},[],{"trials":1707,"activeCount":101},[1708],{"nctId":1024,"briefTitle":1025,"status":107,"phases":1709,"primaryCompletion":1027,"completion":1027,"start":1028,"enrollment":1029,"conditions":1710,"interventions":1711},[92],[15],[1003,1032],{"trials":1713,"activeCount":101},[],{"intervention":1067,"totalTrials":144,"cells":1715},{"EARLY_PHASE1":1716,"PHASE1":1718,"PHASE2":1720,"PHASE3":1722,"PHASE4":1724,"NA":1730},{"trials":1717,"activeCount":101},[],{"trials":1719,"activeCount":101},[],{"trials":1721,"activeCount":101},[],{"trials":1723,"activeCount":101},[],{"trials":1725,"activeCount":101},[1726],{"nctId":1059,"briefTitle":1060,"status":1061,"phases":1727,"primaryCompletion":1063,"completion":1063,"start":1064,"enrollment":451,"conditions":1728,"interventions":1729},[92],[15],[1036,1067],{"trials":1731,"activeCount":101},[],{"intervention":1733,"totalTrials":144,"cells":1734},"Lobelitazone 0.5mg",{"EARLY_PHASE1":1735,"PHASE1":1737,"PHASE2":1739,"PHASE3":1741,"PHASE4":1743,"NA":1756},{"trials":1736,"activeCount":101},[],{"trials":1738,"activeCount":101},[],{"trials":1740,"activeCount":101},[],{"trials":1742,"activeCount":101},[],{"trials":1744,"activeCount":101},[1745],{"nctId":1746,"briefTitle":1747,"status":126,"phases":1748,"primaryCompletion":1749,"completion":1750,"start":1751,"enrollment":1752,"conditions":1753,"interventions":1754},"NCT02480465","Efficacy and Safety of Lobeglitazone Versus Sitagliptin",[92],"2016-12","2017-03","2015-01",248,[726],[1733,1755],"Sitagliptin 100mg",{"trials":1757,"activeCount":101},[],{"intervention":1755,"totalTrials":144,"cells":1759},{"EARLY_PHASE1":1760,"PHASE1":1762,"PHASE2":1764,"PHASE3":1766,"PHASE4":1768,"NA":1774},{"trials":1761,"activeCount":101},[],{"trials":1763,"activeCount":101},[],{"trials":1765,"activeCount":101},[],{"trials":1767,"activeCount":101},[],{"trials":1769,"activeCount":101},[1770],{"nctId":1746,"briefTitle":1747,"status":126,"phases":1771,"primaryCompletion":1749,"completion":1750,"start":1751,"enrollment":1752,"conditions":1772,"interventions":1773},[92],[726],[1733,1755],{"trials":1775,"activeCount":101},[],{"intervention":1777,"totalTrials":144,"cells":1778},"Celecoxib 100 MG",{"EARLY_PHASE1":1779,"PHASE1":1781,"PHASE2":1783,"PHASE3":1785,"PHASE4":1787,"NA":1801},{"trials":1780,"activeCount":101},[],{"trials":1782,"activeCount":101},[],{"trials":1784,"activeCount":101},[],{"trials":1786,"activeCount":101},[],{"trials":1788,"activeCount":101},[1789],{"nctId":1790,"briefTitle":1791,"status":107,"phases":1792,"primaryCompletion":1793,"completion":1794,"start":1795,"enrollment":1796,"conditions":1797,"interventions":1799},"NCT03067194","The Study to Evaluate Efficacy and Safety of Celecoxib Capsule in Hand Osteoarthritis Patients",[92],"2017-07-10","2018-11-20","2016-12-27",117,[1798],"Osteoarthritis Hand",[1777,1800],"Celecoxib 200mg",{"trials":1802,"activeCount":101},[],{"intervention":1800,"totalTrials":144,"cells":1804},{"EARLY_PHASE1":1805,"PHASE1":1807,"PHASE2":1809,"PHASE3":1811,"PHASE4":1813,"NA":1819},{"trials":1806,"activeCount":101},[],{"trials":1808,"activeCount":101},[],{"trials":1810,"activeCount":101},[],{"trials":1812,"activeCount":101},[],{"trials":1814,"activeCount":101},[1815],{"nctId":1790,"briefTitle":1791,"status":107,"phases":1816,"primaryCompletion":1793,"completion":1794,"start":1795,"enrollment":1796,"conditions":1817,"interventions":1818},[92],[1798],[1777,1800],{"trials":1820,"activeCount":101},[],{"intervention":1822,"totalTrials":402,"cells":1823},"CKD-501 0.5mg",{"EARLY_PHASE1":1824,"PHASE1":1826,"PHASE2":1828,"PHASE3":1840,"PHASE4":1890,"NA":1892},{"trials":1825,"activeCount":101},[],{"trials":1827,"activeCount":101},[],{"trials":1829,"activeCount":101},[1830],{"nctId":1831,"briefTitle":1832,"status":107,"phases":1833,"primaryCompletion":957,"completion":957,"start":1834,"enrollment":1835,"conditions":1836,"interventions":1837},"NCT01030679","Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus",[90],"2007-07",214,[726],[1822,1838,1839],"CKD-501 1mg","CKD-501 2mg",{"trials":1841,"activeCount":101},[1842,1853,1863,1872,1883],{"nctId":1843,"briefTitle":1844,"status":126,"phases":1845,"primaryCompletion":1846,"completion":1847,"start":1848,"enrollment":1849,"conditions":1850,"interventions":1852},"NCT03641352","The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes",[91],"2021-04-30","2022-11-30","2018-05-02",240,[1851],"Type2 Diabetes",[1822],{"nctId":1854,"briefTitle":1855,"status":107,"phases":1856,"primaryCompletion":1857,"completion":1858,"start":1859,"enrollment":1860,"conditions":1861,"interventions":1862},"NCT03739125","Efficacy and Safety of CKD-501 Added to D150 Plus D745 10mg Therapy in Patients With Type 2 Diabetes",[91],"2020-05-25","2020-12-02","2017-11-07",226,[1851],[1822],{"nctId":1864,"briefTitle":1865,"status":126,"phases":1866,"primaryCompletion":1867,"completion":1868,"start":1869,"enrollment":1849,"conditions":1870,"interventions":1871},"NCT03627182","Efficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 Diabetes",[91],"2022-03-29","2023-02-10","2018-04-26",[1851],[1822],{"nctId":1873,"briefTitle":1874,"status":107,"phases":1875,"primaryCompletion":1876,"completion":1877,"start":1878,"enrollment":1879,"conditions":1880,"interventions":1881},"NCT01106131","Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin",[91],"2012-04","2012-11","2010-05",253,[23],[1822,1882],"Pioglitazone 15mg",{"nctId":1884,"briefTitle":1885,"status":107,"phases":1886,"primaryCompletion":1053,"completion":1053,"start":110,"enrollment":1887,"conditions":1888,"interventions":1889},"NCT01001611","An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus",[91],173,[726],[1822],{"trials":1891,"activeCount":101},[],{"trials":1893,"activeCount":101},[],{"intervention":1895,"totalTrials":402,"cells":1896},"D013, D326, D337",{"EARLY_PHASE1":1897,"PHASE1":1899,"PHASE2":1952,"PHASE3":1954,"PHASE4":1967,"NA":1969},{"trials":1898,"activeCount":101},[],{"trials":1900,"activeCount":101},[1901,1912,1923,1932,1942],{"nctId":1902,"briefTitle":1903,"status":107,"phases":1904,"primaryCompletion":1905,"completion":1906,"start":1907,"enrollment":485,"conditions":1908,"interventions":1909},"NCT05552495","Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions",[89],"2022-11-27","2022-12-12","2022-09-23",[21],[1910,1911,1895],"CKD-386(4) F1","CKD-386(4) F2",{"nctId":1913,"briefTitle":1914,"status":107,"phases":1915,"primaryCompletion":1916,"completion":1917,"start":1918,"enrollment":1919,"conditions":1920,"interventions":1921},"NCT05698043","A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80\u002F20\u002F10mg",[89],"2023-09-01","2023-09-26","2023-07-17",63,[21],[1922,1895],"CKD-386",{"nctId":1924,"briefTitle":1925,"status":107,"phases":1926,"primaryCompletion":1927,"completion":1928,"start":1929,"enrollment":675,"conditions":1930,"interventions":1931},"NCT04987970","A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80\u002F20\u002F10mg",[89],"2021-11-11","2021-11-27","2021-09-12",[21],[1922,1895],{"nctId":1933,"briefTitle":1934,"status":107,"phases":1935,"primaryCompletion":1936,"completion":1937,"start":1938,"enrollment":1939,"conditions":1940,"interventions":1941},"NCT04694989","A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2)",[89],"2021-04-07","2021-05-04","2021-02-20",62,[21],[1922,1895],{"nctId":1943,"briefTitle":1944,"status":107,"phases":1945,"primaryCompletion":1946,"completion":1947,"start":1948,"enrollment":1949,"conditions":1950,"interventions":1951},"NCT05245084","A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80\u002F20\u002F10mg",[89],"2022-06-06","2022-06-20","2022-03-15",64,[21],[1922,1895],{"trials":1953,"activeCount":101},[],{"trials":1955,"activeCount":101},[1956],{"nctId":1957,"briefTitle":1958,"status":107,"phases":1959,"primaryCompletion":1960,"completion":1960,"start":1961,"enrollment":1962,"conditions":1963,"interventions":1965},"NCT04312698","Clinical Trial to Evaluate the Efficacy and Safety of CKD-386",[91],"2021-06-18","2019-08-29",100,[1964],"Dyslipidemia Patients With Hypertension",[1895,1966],"D013, placebo of D326, placebo of D337",{"trials":1968,"activeCount":101},[],{"trials":1970,"activeCount":101},[],{"intervention":784,"totalTrials":402,"cells":1972},{"EARLY_PHASE1":1973,"PHASE1":1975,"PHASE2":2012,"PHASE3":2014,"PHASE4":2027,"NA":2029},{"trials":1974,"activeCount":101},[],{"trials":1976,"activeCount":101},[1977,1981,1991,2000,2004],{"nctId":775,"briefTitle":776,"status":107,"phases":1978,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":1979,"interventions":1980},[89],[15],[784,767,785],{"nctId":1982,"briefTitle":1983,"status":107,"phases":1984,"primaryCompletion":1985,"completion":1985,"start":1986,"enrollment":1987,"conditions":1988,"interventions":1989},"NCT01352689","CKD-828(80\u002F2.5mg) Pharmacokinetic Study_2nd",[89],"2011-05","2011-04",67,[15],[784,1990],"Combination Therapy",{"nctId":1992,"briefTitle":1993,"status":107,"phases":1994,"primaryCompletion":1995,"completion":1995,"start":1996,"enrollment":1997,"conditions":1998,"interventions":1999},"NCT01246193","CKD-828(80\u002F2.5mg) Pharmacokinetic Study",[89],"2010-12","2010-11",65,[15],[784,1990],{"nctId":787,"briefTitle":776,"status":107,"phases":2001,"primaryCompletion":789,"completion":789,"start":790,"enrollment":791,"conditions":2002,"interventions":2003},[89],[15],[784,767,785],{"nctId":2005,"briefTitle":2006,"status":107,"phases":2007,"primaryCompletion":800,"completion":1986,"start":2008,"enrollment":2009,"conditions":2010,"interventions":2011},"NCT01340131","CKD-828 (40\u002F5mg) Pharmacokinetic Study",[89],"2011-01",68,[15],[784,1990],{"trials":2013,"activeCount":101},[],{"trials":2015,"activeCount":101},[2016],{"nctId":2017,"briefTitle":2018,"status":126,"phases":2019,"primaryCompletion":2020,"completion":2020,"start":2021,"enrollment":131,"conditions":2022,"interventions":2023},"NCT04388215","Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet",[91],"2021-04","2019-10-23",[15,18],[784,784,2024,2024,2025,2025,2026,2026],"D326","D337","D013",{"trials":2028,"activeCount":101},[],{"trials":2030,"activeCount":101},[],{"intervention":2032,"totalTrials":2033,"cells":2034},"Amlodipine 5mg",4,{"EARLY_PHASE1":2035,"PHASE1":2037,"PHASE2":2050,"PHASE3":2061,"PHASE4":2086,"NA":2088},{"trials":2036,"activeCount":101},[],{"trials":2038,"activeCount":101},[2039],{"nctId":2040,"briefTitle":2041,"status":107,"phases":2042,"primaryCompletion":2043,"completion":2044,"start":2043,"enrollment":2045,"conditions":2046,"interventions":2047},"NCT02548286","Study to Compare the Safety and Pharmacokinetics of CKD-330 8\u002F5mg With Coadministration of the Two Separate Drugs",[89],"2015-08","2015-09",53,[15],[2048,2032,2049],"Candesartan 8mg","CKD-330 8\u002F5mg",{"trials":2051,"activeCount":101},[2052],{"nctId":2053,"briefTitle":2054,"status":126,"phases":2055,"primaryCompletion":852,"completion":779,"start":1063,"enrollment":2056,"conditions":2057,"interventions":2058},"NCT02206165","A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension",[90],456,[28],[2048,2059,2032,2060],"Candesartan 16mg","Amlodipine 10mg",{"trials":2062,"activeCount":101},[2063,2076],{"nctId":2064,"briefTitle":2065,"status":107,"phases":2066,"primaryCompletion":2067,"completion":2068,"start":2069,"enrollment":2070,"conditions":2071,"interventions":2072},"NCT02586311","CKD-330 Phase 3 Trial in Amlodipine Non-responder",[91],"2016-08","2016-09","2016-01",160,[15],[2073,2074,2075,2032],"CKD-330 16\u002F5mg","Amlodipine 5mg Placebo","CKD-330 16\u002F5mg Placebo",{"nctId":2077,"briefTitle":2078,"status":107,"phases":2079,"primaryCompletion":2080,"completion":2081,"start":2082,"enrollment":2083,"conditions":2084,"interventions":2085},"NCT02651870","Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy",[91],"2016-02-25","2016-02-29","2015-04-22",135,[15],[2059,2032,2060],{"trials":2087,"activeCount":101},[],{"trials":2089,"activeCount":101},[],{"intervention":2060,"totalTrials":97,"cells":2091},{"EARLY_PHASE1":2092,"PHASE1":2094,"PHASE2":2104,"PHASE3":2110,"PHASE4":2116,"NA":2118},{"trials":2093,"activeCount":101},[],{"trials":2095,"activeCount":101},[2096],{"nctId":2097,"briefTitle":2098,"status":107,"phases":2099,"primaryCompletion":2100,"completion":2100,"start":129,"enrollment":594,"conditions":2101,"interventions":2102},"NCT02064556","CKD-330 Drug-Drug Interaction Study (Amlodipine)",[89],"2014-07",[15],[2060,2103],"Amlodipine 10mg\u002FCandesartan 32mg",{"trials":2105,"activeCount":101},[2106],{"nctId":2053,"briefTitle":2054,"status":126,"phases":2107,"primaryCompletion":852,"completion":779,"start":1063,"enrollment":2056,"conditions":2108,"interventions":2109},[90],[28],[2048,2059,2032,2060],{"trials":2111,"activeCount":101},[2112],{"nctId":2077,"briefTitle":2078,"status":107,"phases":2113,"primaryCompletion":2080,"completion":2081,"start":2082,"enrollment":2083,"conditions":2114,"interventions":2115},[91],[15],[2059,2032,2060],{"trials":2117,"activeCount":101},[],{"trials":2119,"activeCount":101},[],{"intervention":2121,"totalTrials":97,"cells":2122},"D086",{"EARLY_PHASE1":2123,"PHASE1":2125,"PHASE2":2138,"PHASE3":2140,"PHASE4":2165,"NA":2167},{"trials":2124,"activeCount":101},[],{"trials":2126,"activeCount":101},[2127],{"nctId":2128,"briefTitle":2129,"status":107,"phases":2130,"primaryCompletion":1750,"completion":2131,"start":1749,"enrollment":2132,"conditions":2133,"interventions":2135},"NCT03017950","Pharmacokinetic Drug-drug Interaction of CKD-330 and D086",[89],"2017-05",83,[15,2134],"Hyperlipidemias",[2136,2121,2137],"CKD-330","CKD-330 + D086",{"trials":2139,"activeCount":101},[],{"trials":2141,"activeCount":101},[2142,2154],{"nctId":2143,"briefTitle":2144,"status":126,"phases":2145,"primaryCompletion":2146,"completion":2146,"start":2147,"enrollment":2148,"conditions":2149,"interventions":2151},"NCT05657574","A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia",[91],"2023-06","2022-11-24",228,[2150],"Primary Hypercholesterolemia",[2152,2153,2121],"D377","CKD-331",{"nctId":2155,"briefTitle":2156,"status":107,"phases":2157,"primaryCompletion":2158,"completion":2158,"start":2159,"enrollment":2160,"conditions":2161,"interventions":2163},"NCT03583905","Clinical Trial to Evaluate the Efficacy and Safety of CKD-333 Tablet",[91],"2019-07-17","2018-04-04",154,[2162],"Hypertensive Patients With Dyslipidemia",[2136,2121,2164],"D723",{"trials":2166,"activeCount":101},[],{"trials":2168,"activeCount":101},[],{"intervention":2170,"totalTrials":97,"cells":2171},"S-amlodipine 2.5mg",{"EARLY_PHASE1":2172,"PHASE1":2174,"PHASE2":2176,"PHASE3":2178,"PHASE4":2212,"NA":2214},{"trials":2173,"activeCount":101},[],{"trials":2175,"activeCount":101},[],{"trials":2177,"activeCount":101},[],{"trials":2179,"activeCount":101},[2180,2189,2201],{"nctId":2181,"briefTitle":2182,"status":126,"phases":2183,"primaryCompletion":1087,"completion":1087,"start":2184,"enrollment":233,"conditions":2185,"interventions":2186},"NCT01983735","Efficacy and Safety of TELMINUVO to Stage 2 Hypertension",[91],"2014-01",[15],[2187,2187,2170,2188],"TELMINUVO Tab.","S-amlodipine 5mg",{"nctId":2190,"briefTitle":2191,"status":107,"phases":2192,"primaryCompletion":2193,"completion":2193,"start":2194,"enrollment":2195,"conditions":2196,"interventions":2197},"NCT01634295","Efficacy and Safety of CKD-828 to Stage 2 Hypertension",[91],"2013-05","2012-07",103,[15],[2198,2199,2200,2170,2188],"CKD-828 2.5\u002F40mg","CKD-828 5\u002F40mg","CKD-828 5\u002F80mg",{"nctId":2202,"briefTitle":2203,"status":107,"phases":2204,"primaryCompletion":2205,"completion":2205,"start":2206,"enrollment":2207,"conditions":2208,"interventions":2209},"NCT01501253","CKD-828 S-Amlodipine Non-Responder Trial",[91],"2012-09","2011-08",187,[15],[2198,2210,2211],"CKD-828 2.5\u002F80mg","S-Amlodipine 2.5mg",{"trials":2213,"activeCount":101},[],{"trials":2215,"activeCount":101},[],{"intervention":2188,"totalTrials":97,"cells":2217},{"EARLY_PHASE1":2218,"PHASE1":2220,"PHASE2":2230,"PHASE3":2232,"PHASE4":2242,"NA":2244},{"trials":2219,"activeCount":101},[],{"trials":2221,"activeCount":101},[2222],{"nctId":2223,"briefTitle":2224,"status":107,"phases":2225,"primaryCompletion":2206,"completion":2206,"start":1985,"enrollment":594,"conditions":2226,"interventions":2228},"NCT01356043","CKD-828 Drug Interaction Study (S-amlodipine)",[89],[2227],"Healthy Male Volunteers",[2229,2188],"S-amlodipine 5mg,Telmisartan 80mg",{"trials":2231,"activeCount":101},[],{"trials":2233,"activeCount":101},[2234,2238],{"nctId":2181,"briefTitle":2182,"status":126,"phases":2235,"primaryCompletion":1087,"completion":1087,"start":2184,"enrollment":233,"conditions":2236,"interventions":2237},[91],[15],[2187,2187,2170,2188],{"nctId":2190,"briefTitle":2191,"status":107,"phases":2239,"primaryCompletion":2193,"completion":2193,"start":2194,"enrollment":2195,"conditions":2240,"interventions":2241},[91],[15],[2198,2199,2200,2170,2188],{"trials":2243,"activeCount":101},[],{"trials":2245,"activeCount":101},[],{"intervention":2059,"totalTrials":12,"cells":2247},{"EARLY_PHASE1":2248,"PHASE1":2250,"PHASE2":2252,"PHASE3":2258,"PHASE4":2264,"NA":2266},{"trials":2249,"activeCount":101},[],{"trials":2251,"activeCount":101},[],{"trials":2253,"activeCount":101},[2254],{"nctId":2053,"briefTitle":2054,"status":126,"phases":2255,"primaryCompletion":852,"completion":779,"start":1063,"enrollment":2056,"conditions":2256,"interventions":2257},[90],[28],[2048,2059,2032,2060],{"trials":2259,"activeCount":101},[2260],{"nctId":2077,"briefTitle":2078,"status":107,"phases":2261,"primaryCompletion":2080,"completion":2081,"start":2082,"enrollment":2083,"conditions":2262,"interventions":2263},[91],[15],[2059,2032,2060],{"trials":2265,"activeCount":101},[],{"trials":2267,"activeCount":101},[],{"intervention":2269,"totalTrials":12,"cells":2270},"CKD-390",{"EARLY_PHASE1":2271,"PHASE1":2273,"PHASE2":2284,"PHASE3":2286,"PHASE4":2296,"NA":2298},{"trials":2272,"activeCount":101},[],{"trials":2274,"activeCount":101},[2275],{"nctId":2276,"briefTitle":2277,"status":107,"phases":2278,"primaryCompletion":2279,"completion":2279,"start":1309,"enrollment":2280,"conditions":2281,"interventions":2282},"NCT02589457","Study to Compare the Safety and Pharmacokinetics of CKD-390 Tablet With Viread® Tablet",[89],"2015-12",40,[1221],[2269,2283],"Viread®",{"trials":2285,"activeCount":101},[],{"trials":2287,"activeCount":101},[2288],{"nctId":2289,"briefTitle":2290,"status":126,"phases":2291,"primaryCompletion":1019,"completion":1027,"start":2292,"enrollment":207,"conditions":2293,"interventions":2294},"NCT02805738","Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 Tablet",[91],"2016-04",[1221],[2269,2295],"viread",{"trials":2297,"activeCount":101},[],{"trials":2299,"activeCount":101},[],{"intervention":2153,"totalTrials":12,"cells":2301},{"EARLY_PHASE1":2302,"PHASE1":2304,"PHASE2":2317,"PHASE3":2319,"PHASE4":2325,"NA":2327},{"trials":2303,"activeCount":101},[],{"trials":2305,"activeCount":101},[2306],{"nctId":2307,"briefTitle":2308,"status":107,"phases":2309,"primaryCompletion":2310,"completion":2311,"start":2312,"enrollment":2313,"conditions":2314,"interventions":2315},"NCT05335044","Study to Evaluate the Safety and Pharmacokinetics of CKD-331",[89],"2022-06-23","2022-07-12","2022-05-31",47,[21],[2153,2316],"EX5619",{"trials":2318,"activeCount":101},[],{"trials":2320,"activeCount":101},[2321],{"nctId":2143,"briefTitle":2144,"status":126,"phases":2322,"primaryCompletion":2146,"completion":2146,"start":2147,"enrollment":2148,"conditions":2323,"interventions":2324},[91],[2150],[2152,2153,2121],{"trials":2326,"activeCount":101},[],{"trials":2328,"activeCount":101},[],{"intervention":2026,"totalTrials":12,"cells":2330},{"EARLY_PHASE1":2331,"PHASE1":2333,"PHASE2":2346,"PHASE3":2348,"PHASE4":2354,"NA":2356},{"trials":2332,"activeCount":101},[],{"trials":2334,"activeCount":101},[2335],{"nctId":2336,"briefTitle":2337,"status":107,"phases":2338,"primaryCompletion":2339,"completion":2340,"start":2341,"enrollment":791,"conditions":2342,"interventions":2343},"NCT03609606","A Study to Investigate Drug Interaction Between D326, D337, and D013 in Healthy Male Subjects",[89],"2018-09-14","2018-09-27","2018-08-09",[18,15],[2344,2026,2345],"D013, D326 and D337","D326 and D337",{"trials":2347,"activeCount":101},[],{"trials":2349,"activeCount":101},[2350],{"nctId":2017,"briefTitle":2018,"status":126,"phases":2351,"primaryCompletion":2020,"completion":2020,"start":2021,"enrollment":131,"conditions":2352,"interventions":2353},[91],[15,18],[784,784,2024,2024,2025,2025,2026,2026],{"trials":2355,"activeCount":101},[],{"trials":2357,"activeCount":101},[],{"intervention":2359,"totalTrials":12,"cells":2360},"Telmisartan 80mg",{"EARLY_PHASE1":2361,"PHASE1":2363,"PHASE2":2374,"PHASE3":2376,"PHASE4":2388,"NA":2390},{"trials":2362,"activeCount":101},[],{"trials":2364,"activeCount":101},[2365],{"nctId":2366,"briefTitle":2367,"status":107,"phases":2368,"primaryCompletion":2369,"completion":2369,"start":2370,"enrollment":451,"conditions":2371,"interventions":2372},"NCT01356017","CKD-828 Drug Interaction Study (Telmisartan)",[89],"2011-09","2011-06",[2227],[2373,2359],"Telmisartan 80mg, S-amlodipine 5mg",{"trials":2375,"activeCount":101},[],{"trials":2377,"activeCount":101},[2378],{"nctId":2379,"briefTitle":2380,"status":107,"phases":2381,"primaryCompletion":2382,"completion":1689,"start":2206,"enrollment":2383,"conditions":2384,"interventions":2385},"NCT01426100","CKD-828 Telmisartan Non-Responder Trial",[91],"2012-05",183,[15],[2386,2387,2359],"CKD-828 40\u002F2.5mg","CKD-828 40\u002F5mg",{"trials":2389,"activeCount":101},[],{"trials":2391,"activeCount":101},[],{"intervention":2393,"totalTrials":12,"cells":2394},"CKD-495 75mg",{"EARLY_PHASE1":2395,"PHASE1":2397,"PHASE2":2399,"PHASE3":2413,"PHASE4":2424,"NA":2426},{"trials":2396,"activeCount":101},[],{"trials":2398,"activeCount":101},[],{"trials":2400,"activeCount":101},[2401],{"nctId":2402,"briefTitle":2403,"status":107,"phases":2404,"primaryCompletion":2405,"completion":2405,"start":2406,"enrollment":1354,"conditions":2407,"interventions":2409},"NCT03437785","Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 Tablet",[90],"2018-10-12","2018-01-16",[2408],"Gastritis",[2393,2410,2411,2412],"CKD-495 150mg","Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg","Rebamipide 100mg",{"trials":2414,"activeCount":101},[2415],{"nctId":2416,"briefTitle":2417,"status":107,"phases":2418,"primaryCompletion":437,"completion":437,"start":2419,"enrollment":2420,"conditions":2421,"interventions":2422},"NCT04255589","A Clinical Trial to Evaluate the Efficacy and Safety of CKD-495",[91],"2020-01-06",242,[2408],[2393,2423],"Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg",{"trials":2425,"activeCount":101},[],{"trials":2427,"activeCount":101},[],{"intervention":2429,"totalTrials":12,"cells":2430},"CKD-11101",{"EARLY_PHASE1":2431,"PHASE1":2433,"PHASE2":2435,"PHASE3":2437,"PHASE4":2455,"NA":2457},{"trials":2432,"activeCount":101},[],{"trials":2434,"activeCount":101},[],{"trials":2436,"activeCount":101},[],{"trials":2438,"activeCount":101},[2439,2448],{"nctId":2440,"briefTitle":2441,"status":107,"phases":2442,"primaryCompletion":864,"completion":2443,"start":778,"enrollment":1752,"conditions":2444,"interventions":2446},"NCT03431623","CKD-11101 Phase 3 SC Study",[91],"2017-08",[2445],"Anemia of Chronic Kidney Disease",[2429,2447],"NESP",{"nctId":2449,"briefTitle":2450,"status":107,"phases":2451,"primaryCompletion":1308,"completion":1308,"start":779,"enrollment":2452,"conditions":2453,"interventions":2454},"NCT03428594","CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis",[91],403,[2445],[2429,2447],{"trials":2456,"activeCount":101},[],{"trials":2458,"activeCount":101},[],{"intervention":2447,"totalTrials":12,"cells":2460},{"EARLY_PHASE1":2461,"PHASE1":2463,"PHASE2":2465,"PHASE3":2467,"PHASE4":2477,"NA":2479},{"trials":2462,"activeCount":101},[],{"trials":2464,"activeCount":101},[],{"trials":2466,"activeCount":101},[],{"trials":2468,"activeCount":101},[2469,2473],{"nctId":2440,"briefTitle":2441,"status":107,"phases":2470,"primaryCompletion":864,"completion":2443,"start":778,"enrollment":1752,"conditions":2471,"interventions":2472},[91],[2445],[2429,2447],{"nctId":2449,"briefTitle":2450,"status":107,"phases":2474,"primaryCompletion":1308,"completion":1308,"start":779,"enrollment":2452,"conditions":2475,"interventions":2476},[91],[2445],[2429,2447],{"trials":2478,"activeCount":101},[],{"trials":2480,"activeCount":101},[],{"intervention":2482,"totalTrials":12,"cells":2483},"CKD-351",{"EARLY_PHASE1":2484,"PHASE1":2486,"PHASE2":2488,"PHASE3":2501,"PHASE4":2515,"NA":2517},{"trials":2485,"activeCount":101},[],{"trials":2487,"activeCount":101},[],{"trials":2489,"activeCount":101},[2490],{"nctId":2491,"briefTitle":2492,"status":126,"phases":2493,"primaryCompletion":2494,"completion":2494,"start":2495,"enrollment":1962,"conditions":2496,"interventions":2499},"NCT04448223","A Clinical Study to Evaluate the Efficacy and Safety of CKD-351",[90],"2022-12-05","2020-06-11",[2497,2498],"Primary Open Angle Glaucoma","Ocular Hypertension",[2482,2500],"Latanoprost+Dorzolmamide",{"trials":2502,"activeCount":101},[2503],{"nctId":2504,"briefTitle":2492,"status":126,"phases":2505,"primaryCompletion":2506,"completion":2507,"start":2508,"enrollment":2509,"conditions":2510,"interventions":2512},"NCT03762369",[91],"2022-02-28","2022-05-30","2018-12-07",384,[2511,2498],"Primary Open-angle Glaucoma",[2482,2513,2514],"Latanoprost","D930",{"trials":2516,"activeCount":101},[],{"trials":2518,"activeCount":101},[],{"intervention":2520,"totalTrials":12,"cells":2521},"Atorvastatin 20mg",{"EARLY_PHASE1":2522,"PHASE1":2524,"PHASE2":2526,"PHASE3":2542,"PHASE4":2554,"NA":2556},{"trials":2523,"activeCount":101},[],{"trials":2525,"activeCount":101},[],{"trials":2527,"activeCount":101},[2528],{"nctId":2529,"briefTitle":2530,"status":107,"phases":2531,"primaryCompletion":2532,"completion":2533,"start":2534,"enrollment":1939,"conditions":2535,"interventions":2536},"NCT02977065","To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors",[90],"2017-12-30","2018-01-30","2017-03-23",[18],[2520,2537,2538,2539,2540,2541],"Atorvastatin 20 mg + CKD-519 50 mg","Atorvastatin 20 mg + CKD-519 100 mg","Atorvastatin 20 mg + CKD-519 200 mg","Rosuvastatin 10 mg","Rosuvastatin 10 mg + CKD-519 100 mg",{"trials":2543,"activeCount":101},[2544],{"nctId":2545,"briefTitle":2546,"status":126,"phases":2547,"primaryCompletion":2067,"completion":2067,"start":2548,"enrollment":2549,"conditions":2550,"interventions":2552},"NCT01956201","Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin",[91],"2013-12",476,[2551],"Mixed Hyperlipidemia",[2520,2553],"Fenofibrate 160mg",{"trials":2555,"activeCount":101},[],{"trials":2557,"activeCount":101},[],{"intervention":2514,"totalTrials":12,"cells":2559},{"EARLY_PHASE1":2560,"PHASE1":2562,"PHASE2":2575,"PHASE3":2577,"PHASE4":2583,"NA":2585},{"trials":2561,"activeCount":101},[],{"trials":2563,"activeCount":101},[2564],{"nctId":2565,"briefTitle":2566,"status":107,"phases":2567,"primaryCompletion":2568,"completion":2569,"start":2570,"enrollment":451,"conditions":2571,"interventions":2573},"NCT05207761","Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930",[89],"2022-10-18","2022-11-02","2022-01-19",[2572],"Glaucoma",[2574,2514],"D565",{"trials":2576,"activeCount":101},[],{"trials":2578,"activeCount":101},[2579],{"nctId":2504,"briefTitle":2492,"status":126,"phases":2580,"primaryCompletion":2506,"completion":2507,"start":2508,"enrollment":2509,"conditions":2581,"interventions":2582},[91],[2511,2498],[2482,2513,2514],{"trials":2584,"activeCount":101},[],{"trials":2586,"activeCount":101},[],{"intervention":2198,"totalTrials":12,"cells":2588},{"EARLY_PHASE1":2589,"PHASE1":2591,"PHASE2":2593,"PHASE3":2595,"PHASE4":2605,"NA":2607},{"trials":2590,"activeCount":101},[],{"trials":2592,"activeCount":101},[],{"trials":2594,"activeCount":101},[],{"trials":2596,"activeCount":101},[2597,2601],{"nctId":2190,"briefTitle":2191,"status":107,"phases":2598,"primaryCompletion":2193,"completion":2193,"start":2194,"enrollment":2195,"conditions":2599,"interventions":2600},[91],[15],[2198,2199,2200,2170,2188],{"nctId":2202,"briefTitle":2203,"status":107,"phases":2602,"primaryCompletion":2205,"completion":2205,"start":2206,"enrollment":2207,"conditions":2603,"interventions":2604},[91],[15],[2198,2210,2211],{"trials":2606,"activeCount":101},[],{"trials":2608,"activeCount":101},[],{"intervention":2136,"totalTrials":12,"cells":2610},{"EARLY_PHASE1":2611,"PHASE1":2613,"PHASE2":2619,"PHASE3":2621,"PHASE4":2627,"NA":2629},{"trials":2612,"activeCount":101},[],{"trials":2614,"activeCount":101},[2615],{"nctId":2128,"briefTitle":2129,"status":107,"phases":2616,"primaryCompletion":1750,"completion":2131,"start":1749,"enrollment":2132,"conditions":2617,"interventions":2618},[89],[15,2134],[2136,2121,2137],{"trials":2620,"activeCount":101},[],{"trials":2622,"activeCount":101},[2623],{"nctId":2155,"briefTitle":2156,"status":107,"phases":2624,"primaryCompletion":2158,"completion":2158,"start":2159,"enrollment":2160,"conditions":2625,"interventions":2626},[91],[2162],[2136,2121,2164],{"trials":2628,"activeCount":101},[],{"trials":2630,"activeCount":101},[],{"intervention":2632,"totalTrials":144,"cells":2633},"Xenobella",{"EARLY_PHASE1":2634,"PHASE1":2636,"PHASE2":2638,"PHASE3":2640,"PHASE4":2653,"NA":2655},{"trials":2635,"activeCount":101},[],{"trials":2637,"activeCount":101},[],{"trials":2639,"activeCount":101},[],{"trials":2641,"activeCount":101},[2642],{"nctId":2643,"briefTitle":2644,"status":126,"phases":2645,"primaryCompletion":2646,"completion":2068,"start":2647,"enrollment":2648,"conditions":2649,"interventions":2651},"NCT02777723","Study to Evaluate the Efficacy and Safety of CKD-350",[91],"2016-07","2016-05",138,[2650],"Dry Eye Syndrome",[2632,2652],"Isotonic 0.3% Sodium Hyaluronate",{"trials":2654,"activeCount":101},[],{"trials":2656,"activeCount":101},[],{"intervention":2652,"totalTrials":144,"cells":2658},{"EARLY_PHASE1":2659,"PHASE1":2661,"PHASE2":2663,"PHASE3":2665,"PHASE4":2671,"NA":2673},{"trials":2660,"activeCount":101},[],{"trials":2662,"activeCount":101},[],{"trials":2664,"activeCount":101},[],{"trials":2666,"activeCount":101},[2667],{"nctId":2643,"briefTitle":2644,"status":126,"phases":2668,"primaryCompletion":2646,"completion":2068,"start":2647,"enrollment":2648,"conditions":2669,"interventions":2670},[91],[2650],[2632,2652],{"trials":2672,"activeCount":101},[],{"trials":2674,"activeCount":101},[],{"intervention":2295,"totalTrials":144,"cells":2676},{"EARLY_PHASE1":2677,"PHASE1":2679,"PHASE2":2681,"PHASE3":2683,"PHASE4":2689,"NA":2691},{"trials":2678,"activeCount":101},[],{"trials":2680,"activeCount":101},[],{"trials":2682,"activeCount":101},[],{"trials":2684,"activeCount":101},[2685],{"nctId":2289,"briefTitle":2290,"status":126,"phases":2686,"primaryCompletion":1019,"completion":1027,"start":2292,"enrollment":207,"conditions":2687,"interventions":2688},[91],[1221],[2269,2295],{"trials":2690,"activeCount":101},[],{"trials":2692,"activeCount":101},[],{"intervention":2024,"totalTrials":144,"cells":2694},{"EARLY_PHASE1":2695,"PHASE1":2697,"PHASE2":2699,"PHASE3":2701,"PHASE4":2707,"NA":2709},{"trials":2696,"activeCount":101},[],{"trials":2698,"activeCount":101},[],{"trials":2700,"activeCount":101},[],{"trials":2702,"activeCount":101},[2703],{"nctId":2017,"briefTitle":2018,"status":126,"phases":2704,"primaryCompletion":2020,"completion":2020,"start":2021,"enrollment":131,"conditions":2705,"interventions":2706},[91],[15,18],[784,784,2024,2024,2025,2025,2026,2026],{"trials":2708,"activeCount":101},[],{"trials":2710,"activeCount":101},[],{"intervention":2025,"totalTrials":144,"cells":2712},{"EARLY_PHASE1":2713,"PHASE1":2715,"PHASE2":2717,"PHASE3":2719,"PHASE4":2725,"NA":2727},{"trials":2714,"activeCount":101},[],{"trials":2716,"activeCount":101},[],{"trials":2718,"activeCount":101},[],{"trials":2720,"activeCount":101},[2721],{"nctId":2017,"briefTitle":2018,"status":126,"phases":2722,"primaryCompletion":2020,"completion":2020,"start":2021,"enrollment":131,"conditions":2723,"interventions":2724},[91],[15,18],[784,784,2024,2024,2025,2025,2026,2026],{"trials":2726,"activeCount":101},[],{"trials":2728,"activeCount":101},[],{"intervention":2730,"totalTrials":144,"cells":2731},"D064 and D702, QD",{"EARLY_PHASE1":2732,"PHASE1":2734,"PHASE2":2736,"PHASE3":2738,"PHASE4":2751,"NA":2753},{"trials":2733,"activeCount":101},[],{"trials":2735,"activeCount":101},[],{"trials":2737,"activeCount":101},[],{"trials":2739,"activeCount":101},[2740],{"nctId":2741,"briefTitle":2742,"status":107,"phases":2743,"primaryCompletion":2744,"completion":2745,"start":2746,"enrollment":2747,"conditions":2748,"interventions":2749},"NCT06121518","Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy",[91],"2024-03-22","2024-03-26","2023-07-31",235,[28],[2730,2750],"D064 and Placebo of D702, QD",{"trials":2752,"activeCount":101},[],{"trials":2754,"activeCount":101},[],{"intervention":2750,"totalTrials":144,"cells":2756},{"EARLY_PHASE1":2757,"PHASE1":2759,"PHASE2":2761,"PHASE3":2763,"PHASE4":2769,"NA":2771},{"trials":2758,"activeCount":101},[],{"trials":2760,"activeCount":101},[],{"trials":2762,"activeCount":101},[],{"trials":2764,"activeCount":101},[2765],{"nctId":2741,"briefTitle":2742,"status":107,"phases":2766,"primaryCompletion":2744,"completion":2745,"start":2746,"enrollment":2747,"conditions":2767,"interventions":2768},[91],[28],[2730,2750],{"trials":2770,"activeCount":101},[],{"trials":2772,"activeCount":101},[],{"intervention":1966,"totalTrials":144,"cells":2774},{"EARLY_PHASE1":2775,"PHASE1":2777,"PHASE2":2779,"PHASE3":2781,"PHASE4":2787,"NA":2789},{"trials":2776,"activeCount":101},[],{"trials":2778,"activeCount":101},[],{"trials":2780,"activeCount":101},[],{"trials":2782,"activeCount":101},[2783],{"nctId":1957,"briefTitle":1958,"status":107,"phases":2784,"primaryCompletion":1960,"completion":1960,"start":1961,"enrollment":1962,"conditions":2785,"interventions":2786},[91],[1964],[1895,1966],{"trials":2788,"activeCount":101},[],{"trials":2790,"activeCount":101},[],{"intervention":2792,"totalTrials":144,"cells":2793},"CKD-352",{"EARLY_PHASE1":2794,"PHASE1":2796,"PHASE2":2798,"PHASE3":2800,"PHASE4":2813,"NA":2815},{"trials":2795,"activeCount":101},[],{"trials":2797,"activeCount":101},[],{"trials":2799,"activeCount":101},[],{"trials":2801,"activeCount":101},[2802],{"nctId":2803,"briefTitle":2804,"status":107,"phases":2805,"primaryCompletion":2806,"completion":2806,"start":2807,"enrollment":2808,"conditions":2809,"interventions":2811},"NCT04548427","Study to Evaluate the Efficacy and Safety of CKD-352",[91],"2021-05-07","2020-09-22",283,[2810],"Dry Eye Disease",[2792,2812],"Diquafosol Sodium 3%",{"trials":2814,"activeCount":101},[],{"trials":2816,"activeCount":101},[],{"intervention":2812,"totalTrials":144,"cells":2818},{"EARLY_PHASE1":2819,"PHASE1":2821,"PHASE2":2823,"PHASE3":2825,"PHASE4":2831,"NA":2833},{"trials":2820,"activeCount":101},[],{"trials":2822,"activeCount":101},[],{"trials":2824,"activeCount":101},[],{"trials":2826,"activeCount":101},[2827],{"nctId":2803,"briefTitle":2804,"status":107,"phases":2828,"primaryCompletion":2806,"completion":2806,"start":2807,"enrollment":2808,"conditions":2829,"interventions":2830},[91],[2810],[2792,2812],{"trials":2832,"activeCount":101},[],{"trials":2834,"activeCount":101},[],{"intervention":2423,"totalTrials":144,"cells":2836},{"EARLY_PHASE1":2837,"PHASE1":2839,"PHASE2":2841,"PHASE3":2843,"PHASE4":2849,"NA":2851},{"trials":2838,"activeCount":101},[],{"trials":2840,"activeCount":101},[],{"trials":2842,"activeCount":101},[],{"trials":2844,"activeCount":101},[2845],{"nctId":2416,"briefTitle":2417,"status":107,"phases":2846,"primaryCompletion":437,"completion":437,"start":2419,"enrollment":2420,"conditions":2847,"interventions":2848},[91],[2408],[2393,2423],{"trials":2850,"activeCount":101},[],{"trials":2852,"activeCount":101},[],{"intervention":2073,"totalTrials":144,"cells":2854},{"EARLY_PHASE1":2855,"PHASE1":2857,"PHASE2":2859,"PHASE3":2861,"PHASE4":2867,"NA":2869},{"trials":2856,"activeCount":101},[],{"trials":2858,"activeCount":101},[],{"trials":2860,"activeCount":101},[],{"trials":2862,"activeCount":101},[2863],{"nctId":2064,"briefTitle":2065,"status":107,"phases":2864,"primaryCompletion":2067,"completion":2068,"start":2069,"enrollment":2070,"conditions":2865,"interventions":2866},[91],[15],[2073,2074,2075,2032],{"trials":2868,"activeCount":101},[],{"trials":2870,"activeCount":101},[],{"intervention":2074,"totalTrials":144,"cells":2872},{"EARLY_PHASE1":2873,"PHASE1":2875,"PHASE2":2877,"PHASE3":2879,"PHASE4":2885,"NA":2887},{"trials":2874,"activeCount":101},[],{"trials":2876,"activeCount":101},[],{"trials":2878,"activeCount":101},[],{"trials":2880,"activeCount":101},[2881],{"nctId":2064,"briefTitle":2065,"status":107,"phases":2882,"primaryCompletion":2067,"completion":2068,"start":2069,"enrollment":2070,"conditions":2883,"interventions":2884},[91],[15],[2073,2074,2075,2032],{"trials":2886,"activeCount":101},[],{"trials":2888,"activeCount":101},[],{"intervention":2075,"totalTrials":144,"cells":2890},{"EARLY_PHASE1":2891,"PHASE1":2893,"PHASE2":2895,"PHASE3":2897,"PHASE4":2903,"NA":2905},{"trials":2892,"activeCount":101},[],{"trials":2894,"activeCount":101},[],{"trials":2896,"activeCount":101},[],{"trials":2898,"activeCount":101},[2899],{"nctId":2064,"briefTitle":2065,"status":107,"phases":2900,"primaryCompletion":2067,"completion":2068,"start":2069,"enrollment":2070,"conditions":2901,"interventions":2902},[91],[15],[2073,2074,2075,2032],{"trials":2904,"activeCount":101},[],{"trials":2906,"activeCount":101},[],{"intervention":2908,"totalTrials":144,"cells":2909},"CKD-342",{"EARLY_PHASE1":2910,"PHASE1":2912,"PHASE2":2914,"PHASE3":2916,"PHASE4":2929,"NA":2931},{"trials":2911,"activeCount":101},[],{"trials":2913,"activeCount":101},[],{"trials":2915,"activeCount":101},[],{"trials":2917,"activeCount":101},[2918],{"nctId":2919,"briefTitle":2920,"status":107,"phases":2921,"primaryCompletion":2922,"completion":2647,"start":778,"enrollment":2923,"conditions":2924,"interventions":2926},"NCT02498509","Clinical Trial to Evaluate the Efficacy and Safety of CKD-342",[91],"2016-03",459,[2925],"Rhinitis, Allergic, Perennial",[2908,2927,2928],"Mometasone furoate","Levocabastine HCL",{"trials":2930,"activeCount":101},[],{"trials":2932,"activeCount":101},[],{"intervention":2927,"totalTrials":144,"cells":2934},{"EARLY_PHASE1":2935,"PHASE1":2937,"PHASE2":2939,"PHASE3":2941,"PHASE4":2947,"NA":2949},{"trials":2936,"activeCount":101},[],{"trials":2938,"activeCount":101},[],{"trials":2940,"activeCount":101},[],{"trials":2942,"activeCount":101},[2943],{"nctId":2919,"briefTitle":2920,"status":107,"phases":2944,"primaryCompletion":2922,"completion":2647,"start":778,"enrollment":2923,"conditions":2945,"interventions":2946},[91],[2925],[2908,2927,2928],{"trials":2948,"activeCount":101},[],{"trials":2950,"activeCount":101},[],{"intervention":2928,"totalTrials":144,"cells":2952},{"EARLY_PHASE1":2953,"PHASE1":2955,"PHASE2":2957,"PHASE3":2959,"PHASE4":2965,"NA":2967},{"trials":2954,"activeCount":101},[],{"trials":2956,"activeCount":101},[],{"trials":2958,"activeCount":101},[],{"trials":2960,"activeCount":101},[2961],{"nctId":2919,"briefTitle":2920,"status":107,"phases":2962,"primaryCompletion":2922,"completion":2647,"start":778,"enrollment":2923,"conditions":2963,"interventions":2964},[91],[2925],[2908,2927,2928],{"trials":2966,"activeCount":101},[],{"trials":2968,"activeCount":101},[],{"intervention":1882,"totalTrials":144,"cells":2970},{"EARLY_PHASE1":2971,"PHASE1":2973,"PHASE2":2975,"PHASE3":2977,"PHASE4":2983,"NA":2985},{"trials":2972,"activeCount":101},[],{"trials":2974,"activeCount":101},[],{"trials":2976,"activeCount":101},[],{"trials":2978,"activeCount":101},[2979],{"nctId":1873,"briefTitle":1874,"status":107,"phases":2980,"primaryCompletion":1876,"completion":1877,"start":1878,"enrollment":1879,"conditions":2981,"interventions":2982},[91],[23],[1822,1882],{"trials":2984,"activeCount":101},[],{"trials":2986,"activeCount":101},[],{"intervention":2152,"totalTrials":144,"cells":2988},{"EARLY_PHASE1":2989,"PHASE1":2991,"PHASE2":2993,"PHASE3":2995,"PHASE4":3001,"NA":3003},{"trials":2990,"activeCount":101},[],{"trials":2992,"activeCount":101},[],{"trials":2994,"activeCount":101},[],{"trials":2996,"activeCount":101},[2997],{"nctId":2143,"briefTitle":2144,"status":126,"phases":2998,"primaryCompletion":2146,"completion":2146,"start":2147,"enrollment":2148,"conditions":2999,"interventions":3000},[91],[2150],[2152,2153,2121],{"trials":3002,"activeCount":101},[],{"trials":3004,"activeCount":101},[],{"intervention":3006,"totalTrials":144,"cells":3007},"CKD-825",{"EARLY_PHASE1":3008,"PHASE1":3010,"PHASE2":3012,"PHASE3":3014,"PHASE4":3026,"NA":3028},{"trials":3009,"activeCount":101},[],{"trials":3011,"activeCount":101},[],{"trials":3013,"activeCount":101},[],{"trials":3015,"activeCount":101},[3016],{"nctId":3017,"briefTitle":3018,"status":126,"phases":3019,"primaryCompletion":1193,"completion":3020,"start":3021,"enrollment":3022,"conditions":3023,"interventions":3025},"NCT03950843","A Clinical Trial to Evaluate the Efficacy and Safety of CKD-825 in Patients With Atrial Fibrillation",[91],"2021-12","2019-04-23",162,[3024],"Atrial Fibrillation",[3006],{"trials":3027,"activeCount":101},[],{"trials":3029,"activeCount":101},[],{"intervention":3031,"totalTrials":144,"cells":3032},"D745 formulation I",{"EARLY_PHASE1":3033,"PHASE1":3035,"PHASE2":3037,"PHASE3":3039,"PHASE4":3053,"NA":3055},{"trials":3034,"activeCount":101},[],{"trials":3036,"activeCount":101},[],{"trials":3038,"activeCount":101},[],{"trials":3040,"activeCount":101},[3041],{"nctId":3042,"briefTitle":3043,"status":107,"phases":3044,"primaryCompletion":3045,"completion":3046,"start":3047,"enrollment":3048,"conditions":3049,"interventions":3050},"NCT05566028","The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients with Type 2 Diabetes",[91],"2024-01-10","2024-07-23","2022-10-12",172,[31],[3031,3051,3052],"D745 formulation II","D745 Placebo",{"trials":3054,"activeCount":101},[],{"trials":3056,"activeCount":101},[],{"intervention":3051,"totalTrials":144,"cells":3058},{"EARLY_PHASE1":3059,"PHASE1":3061,"PHASE2":3063,"PHASE3":3065,"PHASE4":3071,"NA":3073},{"trials":3060,"activeCount":101},[],{"trials":3062,"activeCount":101},[],{"trials":3064,"activeCount":101},[],{"trials":3066,"activeCount":101},[3067],{"nctId":3042,"briefTitle":3043,"status":107,"phases":3068,"primaryCompletion":3045,"completion":3046,"start":3047,"enrollment":3048,"conditions":3069,"interventions":3070},[91],[31],[3031,3051,3052],{"trials":3072,"activeCount":101},[],{"trials":3074,"activeCount":101},[],{"intervention":3052,"totalTrials":144,"cells":3076},{"EARLY_PHASE1":3077,"PHASE1":3079,"PHASE2":3081,"PHASE3":3083,"PHASE4":3089,"NA":3091},{"trials":3078,"activeCount":101},[],{"trials":3080,"activeCount":101},[],{"trials":3082,"activeCount":101},[],{"trials":3084,"activeCount":101},[3085],{"nctId":3042,"briefTitle":3043,"status":107,"phases":3086,"primaryCompletion":3045,"completion":3046,"start":3047,"enrollment":3048,"conditions":3087,"interventions":3088},[91],[31],[3031,3051,3052],{"trials":3090,"activeCount":101},[],{"trials":3092,"activeCount":101},[],{"intervention":3094,"totalTrials":144,"cells":3095},"D064, D702, placebo of D660",{"EARLY_PHASE1":3096,"PHASE1":3098,"PHASE2":3100,"PHASE3":3102,"PHASE4":3114,"NA":3116},{"trials":3097,"activeCount":101},[],{"trials":3099,"activeCount":101},[],{"trials":3101,"activeCount":101},[],{"trials":3103,"activeCount":101},[3104],{"nctId":3105,"briefTitle":3106,"status":107,"phases":3107,"primaryCompletion":3108,"completion":3108,"start":3109,"enrollment":3110,"conditions":3111,"interventions":3112},"NCT05931224","Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy",[91],"2024-05-13","2023-06-28",346,[28],[3094,3113],"D660, placebo of D064, placebo of D702",{"trials":3115,"activeCount":101},[],{"trials":3117,"activeCount":101},[],{"intervention":3113,"totalTrials":144,"cells":3119},{"EARLY_PHASE1":3120,"PHASE1":3122,"PHASE2":3124,"PHASE3":3126,"PHASE4":3132,"NA":3134},{"trials":3121,"activeCount":101},[],{"trials":3123,"activeCount":101},[],{"trials":3125,"activeCount":101},[],{"trials":3127,"activeCount":101},[3128],{"nctId":3105,"briefTitle":3106,"status":107,"phases":3129,"primaryCompletion":3108,"completion":3108,"start":3109,"enrollment":3110,"conditions":3130,"interventions":3131},[91],[28],[3094,3113],{"trials":3133,"activeCount":101},[],{"trials":3135,"activeCount":101},[],{"intervention":3137,"totalTrials":144,"cells":3138},"Atorvastatin10mg, Ezetimibe10mg",{"EARLY_PHASE1":3139,"PHASE1":3141,"PHASE2":3143,"PHASE3":3145,"PHASE4":3161,"NA":3163},{"trials":3140,"activeCount":101},[],{"trials":3142,"activeCount":101},[],{"trials":3144,"activeCount":101},[],{"trials":3146,"activeCount":101},[3147],{"nctId":3148,"briefTitle":3149,"status":107,"phases":3150,"primaryCompletion":1309,"completion":2069,"start":3151,"enrollment":3152,"conditions":3153,"interventions":3155},"NCT02451098","Clinical Trial to Evaluate the Efficacy and Safety of CKD-391",[91],"2015-03",385,[3154],"Hyperlipidemia",[3137,3156,3157,3158,3159,3160],"Atorvastatin10mg, Ezetimibe placebo","Atorvastatin20mg, Ezetimibe10mg","Atorvastatin20mg, Ezetimibe placebo","Atorvastatin40mg, Ezetimibe10mg","Atorvastatin40mg, Ezetimibe placebo",{"trials":3162,"activeCount":101},[],{"trials":3164,"activeCount":101},[],{"intervention":3156,"totalTrials":144,"cells":3166},{"EARLY_PHASE1":3167,"PHASE1":3169,"PHASE2":3171,"PHASE3":3173,"PHASE4":3179,"NA":3181},{"trials":3168,"activeCount":101},[],{"trials":3170,"activeCount":101},[],{"trials":3172,"activeCount":101},[],{"trials":3174,"activeCount":101},[3175],{"nctId":3148,"briefTitle":3149,"status":107,"phases":3176,"primaryCompletion":1309,"completion":2069,"start":3151,"enrollment":3152,"conditions":3177,"interventions":3178},[91],[3154],[3137,3156,3157,3158,3159,3160],{"trials":3180,"activeCount":101},[],{"trials":3182,"activeCount":101},[],{"intervention":3157,"totalTrials":144,"cells":3184},{"EARLY_PHASE1":3185,"PHASE1":3187,"PHASE2":3189,"PHASE3":3191,"PHASE4":3197,"NA":3199},{"trials":3186,"activeCount":101},[],{"trials":3188,"activeCount":101},[],{"trials":3190,"activeCount":101},[],{"trials":3192,"activeCount":101},[3193],{"nctId":3148,"briefTitle":3149,"status":107,"phases":3194,"primaryCompletion":1309,"completion":2069,"start":3151,"enrollment":3152,"conditions":3195,"interventions":3196},[91],[3154],[3137,3156,3157,3158,3159,3160],{"trials":3198,"activeCount":101},[],{"trials":3200,"activeCount":101},[],{"intervention":3158,"totalTrials":144,"cells":3202},{"EARLY_PHASE1":3203,"PHASE1":3205,"PHASE2":3207,"PHASE3":3209,"PHASE4":3215,"NA":3217},{"trials":3204,"activeCount":101},[],{"trials":3206,"activeCount":101},[],{"trials":3208,"activeCount":101},[],{"trials":3210,"activeCount":101},[3211],{"nctId":3148,"briefTitle":3149,"status":107,"phases":3212,"primaryCompletion":1309,"completion":2069,"start":3151,"enrollment":3152,"conditions":3213,"interventions":3214},[91],[3154],[3137,3156,3157,3158,3159,3160],{"trials":3216,"activeCount":101},[],{"trials":3218,"activeCount":101},[],{"intervention":3159,"totalTrials":144,"cells":3220},{"EARLY_PHASE1":3221,"PHASE1":3223,"PHASE2":3225,"PHASE3":3227,"PHASE4":3233,"NA":3235},{"trials":3222,"activeCount":101},[],{"trials":3224,"activeCount":101},[],{"trials":3226,"activeCount":101},[],{"trials":3228,"activeCount":101},[3229],{"nctId":3148,"briefTitle":3149,"status":107,"phases":3230,"primaryCompletion":1309,"completion":2069,"start":3151,"enrollment":3152,"conditions":3231,"interventions":3232},[91],[3154],[3137,3156,3157,3158,3159,3160],{"trials":3234,"activeCount":101},[],{"trials":3236,"activeCount":101},[],{"intervention":3160,"totalTrials":144,"cells":3238},{"EARLY_PHASE1":3239,"PHASE1":3241,"PHASE2":3243,"PHASE3":3245,"PHASE4":3251,"NA":3253},{"trials":3240,"activeCount":101},[],{"trials":3242,"activeCount":101},[],{"trials":3244,"activeCount":101},[],{"trials":3246,"activeCount":101},[3247],{"nctId":3148,"briefTitle":3149,"status":107,"phases":3248,"primaryCompletion":1309,"completion":2069,"start":3151,"enrollment":3152,"conditions":3249,"interventions":3250},[91],[3154],[3137,3156,3157,3158,3159,3160],{"trials":3252,"activeCount":101},[],{"trials":3254,"activeCount":101},[],{"intervention":2513,"totalTrials":144,"cells":3256},{"EARLY_PHASE1":3257,"PHASE1":3259,"PHASE2":3261,"PHASE3":3263,"PHASE4":3269,"NA":3271},{"trials":3258,"activeCount":101},[],{"trials":3260,"activeCount":101},[],{"trials":3262,"activeCount":101},[],{"trials":3264,"activeCount":101},[3265],{"nctId":2504,"briefTitle":2492,"status":126,"phases":3266,"primaryCompletion":2506,"completion":2507,"start":2508,"enrollment":2509,"conditions":3267,"interventions":3268},[91],[2511,2498],[2482,2513,2514],{"trials":3270,"activeCount":101},[],{"trials":3272,"activeCount":101},[],{"intervention":3274,"totalTrials":144,"cells":3275},"Tamsulosin 0.2mg",{"EARLY_PHASE1":3276,"PHASE1":3278,"PHASE2":3280,"PHASE3":3282,"PHASE4":3293,"NA":3295},{"trials":3277,"activeCount":101},[],{"trials":3279,"activeCount":101},[],{"trials":3281,"activeCount":101},[],{"trials":3283,"activeCount":101},[3284],{"nctId":3285,"briefTitle":3286,"status":107,"phases":3287,"primaryCompletion":2292,"completion":2647,"start":2044,"enrollment":3288,"conditions":3289,"interventions":3291},"NCT03246880","Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients",[91],455,[3290],"Benign Prostatic Hyperplasia",[3274,3292],"Tadalafil 5mg",{"trials":3294,"activeCount":101},[],{"trials":3296,"activeCount":101},[],{"intervention":3292,"totalTrials":144,"cells":3298},{"EARLY_PHASE1":3299,"PHASE1":3301,"PHASE2":3303,"PHASE3":3305,"PHASE4":3311,"NA":3313},{"trials":3300,"activeCount":101},[],{"trials":3302,"activeCount":101},[],{"trials":3304,"activeCount":101},[],{"trials":3306,"activeCount":101},[3307],{"nctId":3285,"briefTitle":3286,"status":107,"phases":3308,"primaryCompletion":2292,"completion":2647,"start":2044,"enrollment":3288,"conditions":3309,"interventions":3310},[91],[3290],[3274,3292],{"trials":3312,"activeCount":101},[],{"trials":3314,"activeCount":101},[],{"intervention":2386,"totalTrials":144,"cells":3316},{"EARLY_PHASE1":3317,"PHASE1":3319,"PHASE2":3321,"PHASE3":3323,"PHASE4":3329,"NA":3331},{"trials":3318,"activeCount":101},[],{"trials":3320,"activeCount":101},[],{"trials":3322,"activeCount":101},[],{"trials":3324,"activeCount":101},[3325],{"nctId":2379,"briefTitle":2380,"status":107,"phases":3326,"primaryCompletion":2382,"completion":1689,"start":2206,"enrollment":2383,"conditions":3327,"interventions":3328},[91],[15],[2386,2387,2359],{"trials":3330,"activeCount":101},[],{"trials":3332,"activeCount":101},[],{"intervention":2387,"totalTrials":144,"cells":3334},{"EARLY_PHASE1":3335,"PHASE1":3337,"PHASE2":3339,"PHASE3":3341,"PHASE4":3347,"NA":3349},{"trials":3336,"activeCount":101},[],{"trials":3338,"activeCount":101},[],{"trials":3340,"activeCount":101},[],{"trials":3342,"activeCount":101},[3343],{"nctId":2379,"briefTitle":2380,"status":107,"phases":3344,"primaryCompletion":2382,"completion":1689,"start":2206,"enrollment":2383,"conditions":3345,"interventions":3346},[91],[15],[2386,2387,2359],{"trials":3348,"activeCount":101},[],{"trials":3350,"activeCount":101},[],{"intervention":3352,"totalTrials":144,"cells":3353},"D064, D701, placebo of D012",{"EARLY_PHASE1":3354,"PHASE1":3356,"PHASE2":3358,"PHASE3":3360,"PHASE4":3372,"NA":3374},{"trials":3355,"activeCount":101},[],{"trials":3357,"activeCount":101},[],{"trials":3359,"activeCount":101},[],{"trials":3361,"activeCount":101},[3362],{"nctId":3363,"briefTitle":3364,"status":126,"phases":3365,"primaryCompletion":3366,"completion":3366,"start":3367,"enrollment":3368,"conditions":3369,"interventions":3370},"NCT05526703","Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy",[91],"2023-10","2022-09-28",108,[28],[3352,3371],"D012, placebo of D064, placebo of D701",{"trials":3373,"activeCount":101},[],{"trials":3375,"activeCount":101},[],{"intervention":3371,"totalTrials":144,"cells":3377},{"EARLY_PHASE1":3378,"PHASE1":3380,"PHASE2":3382,"PHASE3":3384,"PHASE4":3390,"NA":3392},{"trials":3379,"activeCount":101},[],{"trials":3381,"activeCount":101},[],{"trials":3383,"activeCount":101},[],{"trials":3385,"activeCount":101},[3386],{"nctId":3363,"briefTitle":3364,"status":126,"phases":3387,"primaryCompletion":3366,"completion":3366,"start":3367,"enrollment":3368,"conditions":3388,"interventions":3389},[91],[28],[3352,3371],{"trials":3391,"activeCount":101},[],{"trials":3393,"activeCount":101},[],{"intervention":2553,"totalTrials":144,"cells":3395},{"EARLY_PHASE1":3396,"PHASE1":3398,"PHASE2":3400,"PHASE3":3402,"PHASE4":3408,"NA":3410},{"trials":3397,"activeCount":101},[],{"trials":3399,"activeCount":101},[],{"trials":3401,"activeCount":101},[],{"trials":3403,"activeCount":101},[3404],{"nctId":2545,"briefTitle":2546,"status":126,"phases":3405,"primaryCompletion":2067,"completion":2067,"start":2548,"enrollment":2549,"conditions":3406,"interventions":3407},[91],[2551],[2520,2553],{"trials":3409,"activeCount":101},[],{"trials":3411,"activeCount":101},[],{"intervention":2187,"totalTrials":144,"cells":3413},{"EARLY_PHASE1":3414,"PHASE1":3416,"PHASE2":3418,"PHASE3":3420,"PHASE4":3426,"NA":3428},{"trials":3415,"activeCount":101},[],{"trials":3417,"activeCount":101},[],{"trials":3419,"activeCount":101},[],{"trials":3421,"activeCount":101},[3422],{"nctId":2181,"briefTitle":2182,"status":126,"phases":3423,"primaryCompletion":1087,"completion":1087,"start":2184,"enrollment":233,"conditions":3424,"interventions":3425},[91],[15],[2187,2187,2170,2188],{"trials":3427,"activeCount":101},[],{"trials":3429,"activeCount":101},[],{"intervention":3431,"totalTrials":144,"cells":3432},"Carvedilol SR 32mg, QD",{"EARLY_PHASE1":3433,"PHASE1":3435,"PHASE2":3437,"PHASE3":3439,"PHASE4":3452,"NA":3454},{"trials":3434,"activeCount":101},[],{"trials":3436,"activeCount":101},[],{"trials":3438,"activeCount":101},[],{"trials":3440,"activeCount":101},[3441],{"nctId":3442,"briefTitle":3443,"status":107,"phases":3444,"primaryCompletion":3445,"completion":3445,"start":853,"enrollment":3446,"conditions":3447,"interventions":3448},"NCT01756430","Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension",[91],"2013-09",238,[15],[3431,3449,3450,3451],"Carvedilol SR 64mg, QD","Carvedilol IR 25mg, QD","Carvedilol IR 25mg, BID",{"trials":3453,"activeCount":101},[],{"trials":3455,"activeCount":101},[],{"intervention":3449,"totalTrials":144,"cells":3457},{"EARLY_PHASE1":3458,"PHASE1":3460,"PHASE2":3462,"PHASE3":3464,"PHASE4":3470,"NA":3472},{"trials":3459,"activeCount":101},[],{"trials":3461,"activeCount":101},[],{"trials":3463,"activeCount":101},[],{"trials":3465,"activeCount":101},[3466],{"nctId":3442,"briefTitle":3443,"status":107,"phases":3467,"primaryCompletion":3445,"completion":3445,"start":853,"enrollment":3446,"conditions":3468,"interventions":3469},[91],[15],[3431,3449,3450,3451],{"trials":3471,"activeCount":101},[],{"trials":3473,"activeCount":101},[],{"intervention":3450,"totalTrials":144,"cells":3475},{"EARLY_PHASE1":3476,"PHASE1":3478,"PHASE2":3480,"PHASE3":3482,"PHASE4":3488,"NA":3490},{"trials":3477,"activeCount":101},[],{"trials":3479,"activeCount":101},[],{"trials":3481,"activeCount":101},[],{"trials":3483,"activeCount":101},[3484],{"nctId":3442,"briefTitle":3443,"status":107,"phases":3485,"primaryCompletion":3445,"completion":3445,"start":853,"enrollment":3446,"conditions":3486,"interventions":3487},[91],[15],[3431,3449,3450,3451],{"trials":3489,"activeCount":101},[],{"trials":3491,"activeCount":101},[],{"intervention":3451,"totalTrials":144,"cells":3493},{"EARLY_PHASE1":3494,"PHASE1":3496,"PHASE2":3498,"PHASE3":3500,"PHASE4":3506,"NA":3508},{"trials":3495,"activeCount":101},[],{"trials":3497,"activeCount":101},[],{"trials":3499,"activeCount":101},[],{"trials":3501,"activeCount":101},[3502],{"nctId":3442,"briefTitle":3443,"status":107,"phases":3503,"primaryCompletion":3445,"completion":3445,"start":853,"enrollment":3446,"conditions":3504,"interventions":3505},[91],[15],[3431,3449,3450,3451],{"trials":3507,"activeCount":101},[],{"trials":3509,"activeCount":101},[],{"intervention":3511,"totalTrials":144,"cells":3512},"CKD-314+SOC",{"EARLY_PHASE1":3513,"PHASE1":3515,"PHASE2":3517,"PHASE3":3519,"PHASE4":3533,"NA":3535},{"trials":3514,"activeCount":101},[],{"trials":3516,"activeCount":101},[],{"trials":3518,"activeCount":101},[],{"trials":3520,"activeCount":101},[3521],{"nctId":3522,"briefTitle":3523,"status":126,"phases":3524,"primaryCompletion":3525,"completion":3526,"start":3527,"enrollment":3528,"conditions":3529,"interventions":3531},"NCT04871646","Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314",[91],"2022-03","2022-08","2021-06-30",586,[3530],"COVID-19 Pneumonia",[3511,3532],"CKD-314 Placebo+SOC",{"trials":3534,"activeCount":101},[],{"trials":3536,"activeCount":101},[],{"intervention":3532,"totalTrials":144,"cells":3538},{"EARLY_PHASE1":3539,"PHASE1":3541,"PHASE2":3543,"PHASE3":3545,"PHASE4":3551,"NA":3553},{"trials":3540,"activeCount":101},[],{"trials":3542,"activeCount":101},[],{"trials":3544,"activeCount":101},[],{"trials":3546,"activeCount":101},[3547],{"nctId":3522,"briefTitle":3523,"status":126,"phases":3548,"primaryCompletion":3525,"completion":3526,"start":3527,"enrollment":3528,"conditions":3549,"interventions":3550},[91],[3530],[3511,3532],{"trials":3552,"activeCount":101},[],{"trials":3554,"activeCount":101},[],{"intervention":2199,"totalTrials":144,"cells":3556},{"EARLY_PHASE1":3557,"PHASE1":3559,"PHASE2":3561,"PHASE3":3563,"PHASE4":3569,"NA":3571},{"trials":3558,"activeCount":101},[],{"trials":3560,"activeCount":101},[],{"trials":3562,"activeCount":101},[],{"trials":3564,"activeCount":101},[3565],{"nctId":2190,"briefTitle":2191,"status":107,"phases":3566,"primaryCompletion":2193,"completion":2193,"start":2194,"enrollment":2195,"conditions":3567,"interventions":3568},[91],[15],[2198,2199,2200,2170,2188],{"trials":3570,"activeCount":101},[],{"trials":3572,"activeCount":101},[],{"intervention":2200,"totalTrials":144,"cells":3574},{"EARLY_PHASE1":3575,"PHASE1":3577,"PHASE2":3579,"PHASE3":3581,"PHASE4":3587,"NA":3589},{"trials":3576,"activeCount":101},[],{"trials":3578,"activeCount":101},[],{"trials":3580,"activeCount":101},[],{"trials":3582,"activeCount":101},[3583],{"nctId":2190,"briefTitle":2191,"status":107,"phases":3584,"primaryCompletion":2193,"completion":2193,"start":2194,"enrollment":2195,"conditions":3585,"interventions":3586},[91],[15],[2198,2199,2200,2170,2188],{"trials":3588,"activeCount":101},[],{"trials":3590,"activeCount":101},[],{"intervention":3592,"totalTrials":144,"cells":3593},"CKD-701",{"EARLY_PHASE1":3594,"PHASE1":3596,"PHASE2":3598,"PHASE3":3600,"PHASE4":3613,"NA":3615},{"trials":3595,"activeCount":101},[],{"trials":3597,"activeCount":101},[],{"trials":3599,"activeCount":101},[],{"trials":3601,"activeCount":101},[3602],{"nctId":3603,"briefTitle":3604,"status":107,"phases":3605,"primaryCompletion":3606,"completion":3606,"start":3607,"enrollment":3608,"conditions":3609,"interventions":3611},"NCT04857177","A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration",[91],"2021-03-17","2018-10-19",312,[3610],"Neovascular(Wet) Age Related Macular Degeneration",[3592,3612],"Lucentis®",{"trials":3614,"activeCount":101},[],{"trials":3616,"activeCount":101},[],{"intervention":3612,"totalTrials":144,"cells":3618},{"EARLY_PHASE1":3619,"PHASE1":3621,"PHASE2":3623,"PHASE3":3625,"PHASE4":3631,"NA":3633},{"trials":3620,"activeCount":101},[],{"trials":3622,"activeCount":101},[],{"trials":3624,"activeCount":101},[],{"trials":3626,"activeCount":101},[3627],{"nctId":3603,"briefTitle":3604,"status":107,"phases":3628,"primaryCompletion":3606,"completion":3606,"start":3607,"enrollment":3608,"conditions":3629,"interventions":3630},[91],[3610],[3592,3612],{"trials":3632,"activeCount":101},[],{"trials":3634,"activeCount":101},[],{"intervention":2210,"totalTrials":144,"cells":3636},{"EARLY_PHASE1":3637,"PHASE1":3639,"PHASE2":3641,"PHASE3":3643,"PHASE4":3649,"NA":3651},{"trials":3638,"activeCount":101},[],{"trials":3640,"activeCount":101},[],{"trials":3642,"activeCount":101},[],{"trials":3644,"activeCount":101},[3645],{"nctId":2202,"briefTitle":2203,"status":107,"phases":3646,"primaryCompletion":2205,"completion":2205,"start":2206,"enrollment":2207,"conditions":3647,"interventions":3648},[91],[15],[2198,2210,2211],{"trials":3650,"activeCount":101},[],{"trials":3652,"activeCount":101},[],{"intervention":2164,"totalTrials":144,"cells":3654},{"EARLY_PHASE1":3655,"PHASE1":3657,"PHASE2":3659,"PHASE3":3661,"PHASE4":3667,"NA":3669},{"trials":3656,"activeCount":101},[],{"trials":3658,"activeCount":101},[],{"trials":3660,"activeCount":101},[],{"trials":3662,"activeCount":101},[3663],{"nctId":2155,"briefTitle":2156,"status":107,"phases":3664,"primaryCompletion":2158,"completion":2158,"start":2159,"enrollment":2160,"conditions":3665,"interventions":3666},[91],[2162],[2136,2121,2164],{"trials":3668,"activeCount":101},[],{"trials":3670,"activeCount":101},[],{"intervention":3672,"totalTrials":3673,"cells":3674},"Reference drug",7,{"EARLY_PHASE1":3675,"PHASE1":3677,"PHASE2":3736,"PHASE3":3748,"PHASE4":3750,"NA":3752},{"trials":3676,"activeCount":101},[],{"trials":3678,"activeCount":101},[3679,3691,3701,3709,3719,3729],{"nctId":3680,"briefTitle":3681,"status":107,"phases":3682,"primaryCompletion":3683,"completion":3684,"start":3685,"enrollment":3686,"conditions":3687,"interventions":3689},"NCT04075643","Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-385 in Healthy Volunteers",[89],"2019-09-30","2019-10-30","2019-09-19",52,[3688],"Cardiovascular Diseases",[3672,3690],"Test drug",{"nctId":3692,"briefTitle":3693,"status":126,"phases":3694,"primaryCompletion":3695,"completion":3695,"start":3696,"enrollment":594,"conditions":3697,"interventions":3698},"NCT04651881","Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fed Conditions",[89],"2020-12-09","2020-10-27",[3688],[3672,3699,3700],"Test drug 1","Test drug 2",{"nctId":3702,"briefTitle":3703,"status":126,"phases":3704,"primaryCompletion":3705,"completion":3705,"start":3706,"enrollment":594,"conditions":3707,"interventions":3708},"NCT04678388","Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fasting Conditions",[89],"2020-12-12","2020-10-29",[3688],[3672,3699,3700],{"nctId":3710,"briefTitle":3711,"status":107,"phases":3712,"primaryCompletion":3713,"completion":3714,"start":3715,"enrollment":3716,"conditions":3717,"interventions":3718},"NCT04083872","Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)",[89],"2019-10-21","2019-11-01","2019-09-06",16,[3688],[3672,3690],{"nctId":3720,"briefTitle":3721,"status":126,"phases":3722,"primaryCompletion":3723,"completion":3724,"start":3725,"enrollment":3726,"conditions":3727,"interventions":3728},"NCT04322032","Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-389",[89],"2020-05-12","2020-05-18","2020-04-06",34,[31],[3672,3690],{"nctId":3730,"briefTitle":3731,"status":107,"phases":3732,"primaryCompletion":3713,"completion":3733,"start":3715,"enrollment":594,"conditions":3734,"interventions":3735},"NCT04083846","Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)",[89],"2019-10-25",[3688],[3672,3699,3700],{"trials":3737,"activeCount":101},[3738],{"nctId":3739,"briefTitle":3740,"status":107,"phases":3741,"primaryCompletion":3742,"completion":3742,"start":3743,"enrollment":1962,"conditions":3744,"interventions":3746},"NCT06954766","Initial Pilot Study to Evaluate the Safety and Temporary Symptom Improvement Efficacy of CKD-981",[90],"2025-10-28","2025-04-28",[3745],"Knee Osteoarthritis",[3747],"Reference Drug",{"trials":3749,"activeCount":101},[],{"trials":3751,"activeCount":101},[],{"trials":3753,"activeCount":101},[],{"intervention":785,"totalTrials":97,"cells":3755},{"EARLY_PHASE1":3756,"PHASE1":3758,"PHASE2":3768,"PHASE3":3774,"PHASE4":3776,"NA":3778},{"trials":3757,"activeCount":101},[],{"trials":3759,"activeCount":101},[3760,3764],{"nctId":775,"briefTitle":776,"status":107,"phases":3761,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":3762,"interventions":3763},[89],[15],[784,767,785],{"nctId":787,"briefTitle":776,"status":107,"phases":3765,"primaryCompletion":789,"completion":789,"start":790,"enrollment":791,"conditions":3766,"interventions":3767},[89],[15],[784,767,785],{"trials":3769,"activeCount":101},[3770],{"nctId":797,"briefTitle":798,"status":107,"phases":3771,"primaryCompletion":800,"completion":800,"start":801,"enrollment":802,"conditions":3772,"interventions":3773},[90],[15],[805,806,767],{"trials":3775,"activeCount":101},[],{"trials":3777,"activeCount":101},[],{"trials":3779,"activeCount":101},[],{"intervention":3781,"totalTrials":97,"cells":3782},"Belotecan",{"EARLY_PHASE1":3783,"PHASE1":3785,"PHASE2":3787,"PHASE3":3817,"PHASE4":3819,"NA":3821},{"trials":3784,"activeCount":101},[],{"trials":3786,"activeCount":101},[],{"trials":3788,"activeCount":101},[3789,3797,3807],{"nctId":3790,"briefTitle":3791,"status":107,"phases":3792,"primaryCompletion":1028,"completion":1028,"start":2008,"enrollment":913,"conditions":3793,"interventions":3795},"NCT01630018","Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial",[90],[3794],"Epithelial Ovarian Cancer",[3796,3781],"Topotecan",{"nctId":3798,"briefTitle":3799,"status":107,"phases":3800,"primaryCompletion":3801,"completion":3802,"start":3803,"enrollment":3686,"conditions":3804,"interventions":3806},"NCT01022671","Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy",[90],"2010-02","2010-03","2009-09",[3805],"Carcinoma, Non-Small-Cell Lung",[3781],{"nctId":3808,"briefTitle":3809,"status":107,"phases":3810,"primaryCompletion":3811,"completion":1027,"start":3812,"enrollment":3813,"conditions":3814,"interventions":3816},"NCT01497873","A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer",[90],"2017-12","2010-09",164,[3815],"Small Cell Lung Cancer",[3796,3781],{"trials":3818,"activeCount":101},[],{"trials":3820,"activeCount":101},[],{"trials":3822,"activeCount":101},[],{"intervention":2048,"totalTrials":12,"cells":3824},{"EARLY_PHASE1":3825,"PHASE1":3827,"PHASE2":3833,"PHASE3":3839,"PHASE4":3841,"NA":3843},{"trials":3826,"activeCount":101},[],{"trials":3828,"activeCount":101},[3829],{"nctId":2040,"briefTitle":2041,"status":107,"phases":3830,"primaryCompletion":2043,"completion":2044,"start":2043,"enrollment":2045,"conditions":3831,"interventions":3832},[89],[15],[2048,2032,2049],{"trials":3834,"activeCount":101},[3835],{"nctId":2053,"briefTitle":2054,"status":126,"phases":3836,"primaryCompletion":852,"completion":779,"start":1063,"enrollment":2056,"conditions":3837,"interventions":3838},[90],[28],[2048,2059,2032,2060],{"trials":3840,"activeCount":101},[],{"trials":3842,"activeCount":101},[],{"trials":3844,"activeCount":101},[],{"intervention":1838,"totalTrials":12,"cells":3846},{"EARLY_PHASE1":3847,"PHASE1":3849,"PHASE2":3859,"PHASE3":3865,"PHASE4":3867,"NA":3869},{"trials":3848,"activeCount":101},[],{"trials":3850,"activeCount":101},[3851],{"nctId":3852,"briefTitle":3853,"status":107,"phases":3854,"primaryCompletion":3855,"completion":3856,"start":3802,"enrollment":594,"conditions":3857,"interventions":3858},"NCT01071720","The Effect of Food on the Pharmacokinetic Characteristics of CKD-501",[89],"2010-06","2010-08",[25],[1838],{"trials":3860,"activeCount":101},[3861],{"nctId":1831,"briefTitle":1832,"status":107,"phases":3862,"primaryCompletion":957,"completion":957,"start":1834,"enrollment":1835,"conditions":3863,"interventions":3864},[90],[726],[1822,1838,1839],{"trials":3866,"activeCount":101},[],{"trials":3868,"activeCount":101},[],{"trials":3870,"activeCount":101},[],{"intervention":3872,"totalTrials":12,"cells":3873},"CKD-506",{"EARLY_PHASE1":3874,"PHASE1":3876,"PHASE2":3888,"PHASE3":3899,"PHASE4":3901,"NA":3903},{"trials":3875,"activeCount":101},[],{"trials":3877,"activeCount":101},[3878],{"nctId":3879,"briefTitle":3880,"status":107,"phases":3881,"primaryCompletion":3882,"completion":3882,"start":2506,"enrollment":3883,"conditions":3884,"interventions":3886},"NCT05238948","CKD-506 Drug-Drug Interaction Study in Healthy Male Subjects",[89],"2022-04-29",17,[3885],"Drug Drug Interaction",[3887,3872],"Midazolam",{"trials":3889,"activeCount":101},[3890],{"nctId":3891,"briefTitle":3892,"status":107,"phases":3893,"primaryCompletion":3683,"completion":3894,"start":3895,"enrollment":3896,"conditions":3897,"interventions":3898},"NCT04204603","A Study Evaluating the Efficacy and Safety of CKD-506 in Adult Subjects With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate",[90],"2019-10-29","2018-11-30",122,[1692],[3872],{"trials":3900,"activeCount":101},[],{"trials":3902,"activeCount":101},[],{"trials":3904,"activeCount":101},[],{"intervention":2574,"totalTrials":12,"cells":3906},{"EARLY_PHASE1":3907,"PHASE1":3909,"PHASE2":3915,"PHASE3":3928,"PHASE4":3930,"NA":3932},{"trials":3908,"activeCount":101},[],{"trials":3910,"activeCount":101},[3911],{"nctId":2565,"briefTitle":2566,"status":107,"phases":3912,"primaryCompletion":2568,"completion":2569,"start":2570,"enrollment":451,"conditions":3913,"interventions":3914},[89],[2572],[2574,2514],{"trials":3916,"activeCount":101},[3917],{"nctId":3918,"briefTitle":3919,"status":126,"phases":3920,"primaryCompletion":3921,"completion":3922,"start":3923,"enrollment":817,"conditions":3924,"interventions":3926},"NCT03067415","Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily",[90],"2017-09-10","2017-09-30","2017-03-30",[3925,2498],"Glaucoma, Primary Open Angle",[3927,2574],"D565H",{"trials":3929,"activeCount":101},[],{"trials":3931,"activeCount":101},[],{"trials":3933,"activeCount":101},[],{"intervention":3935,"totalTrials":12,"cells":3936},"Nafamostat Mesilate",{"EARLY_PHASE1":3937,"PHASE1":3939,"PHASE2":3941,"PHASE3":3960,"PHASE4":3962,"NA":3964},{"trials":3938,"activeCount":101},[],{"trials":3940,"activeCount":101},[],{"trials":3942,"activeCount":101},[3943,3952],{"nctId":3944,"briefTitle":3945,"status":107,"phases":3946,"primaryCompletion":3947,"completion":3947,"start":3948,"enrollment":8,"conditions":3949,"interventions":3951},"NCT04628143","A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia",[90],"2021-04-05","2020-12-21",[3950],"COVID-19",[3935],{"nctId":3953,"briefTitle":3954,"status":107,"phases":3955,"primaryCompletion":3705,"completion":3705,"start":3956,"enrollment":3957,"conditions":3958,"interventions":3959},"NCT04623021","A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia",[90],"2020-09-25",104,[3950],[3935],{"trials":3961,"activeCount":101},[],{"trials":3963,"activeCount":101},[],{"trials":3965,"activeCount":101},[],{"intervention":3796,"totalTrials":12,"cells":3967},{"EARLY_PHASE1":3968,"PHASE1":3970,"PHASE2":3972,"PHASE3":3982,"PHASE4":3984,"NA":3986},{"trials":3969,"activeCount":101},[],{"trials":3971,"activeCount":101},[],{"trials":3973,"activeCount":101},[3974,3978],{"nctId":3790,"briefTitle":3791,"status":107,"phases":3975,"primaryCompletion":1028,"completion":1028,"start":2008,"enrollment":913,"conditions":3976,"interventions":3977},[90],[3794],[3796,3781],{"nctId":3808,"briefTitle":3809,"status":107,"phases":3979,"primaryCompletion":3811,"completion":1027,"start":3812,"enrollment":3813,"conditions":3980,"interventions":3981},[90],[3815],[3796,3781],{"trials":3983,"activeCount":101},[],{"trials":3985,"activeCount":101},[],{"trials":3987,"activeCount":101},[],{"intervention":3989,"totalTrials":144,"cells":3990},"CKD-516",{"EARLY_PHASE1":3991,"PHASE1":3993,"PHASE2":3995,"PHASE3":4006,"PHASE4":4008,"NA":4010},{"trials":3992,"activeCount":101},[],{"trials":3994,"activeCount":101},[],{"trials":3996,"activeCount":101},[3997],{"nctId":3998,"briefTitle":3999,"status":126,"phases":4000,"primaryCompletion":4001,"completion":4002,"start":1749,"enrollment":594,"conditions":4003,"interventions":4005},"NCT03076957","A Phase 1\u002F2a Study to Assess the Safety and Efficacy of CKD-516 Tab. in Combination With Irinotecan Inj.",[89,90],"2018-06","2019-06",[4004],"Colorectal Cancer",[3989],{"trials":4007,"activeCount":101},[],{"trials":4009,"activeCount":101},[],{"trials":4011,"activeCount":101},[],{"intervention":2410,"totalTrials":144,"cells":4013},{"EARLY_PHASE1":4014,"PHASE1":4016,"PHASE2":4018,"PHASE3":4024,"PHASE4":4026,"NA":4028},{"trials":4015,"activeCount":101},[],{"trials":4017,"activeCount":101},[],{"trials":4019,"activeCount":101},[4020],{"nctId":2402,"briefTitle":2403,"status":107,"phases":4021,"primaryCompletion":2405,"completion":2405,"start":2406,"enrollment":1354,"conditions":4022,"interventions":4023},[90],[2408],[2393,2410,2411,2412],{"trials":4025,"activeCount":101},[],{"trials":4027,"activeCount":101},[],{"trials":4029,"activeCount":101},[],{"intervention":2411,"totalTrials":144,"cells":4031},{"EARLY_PHASE1":4032,"PHASE1":4034,"PHASE2":4036,"PHASE3":4042,"PHASE4":4044,"NA":4046},{"trials":4033,"activeCount":101},[],{"trials":4035,"activeCount":101},[],{"trials":4037,"activeCount":101},[4038],{"nctId":2402,"briefTitle":2403,"status":107,"phases":4039,"primaryCompletion":2405,"completion":2405,"start":2406,"enrollment":1354,"conditions":4040,"interventions":4041},[90],[2408],[2393,2410,2411,2412],{"trials":4043,"activeCount":101},[],{"trials":4045,"activeCount":101},[],{"trials":4047,"activeCount":101},[],{"intervention":2412,"totalTrials":144,"cells":4049},{"EARLY_PHASE1":4050,"PHASE1":4052,"PHASE2":4054,"PHASE3":4060,"PHASE4":4062,"NA":4064},{"trials":4051,"activeCount":101},[],{"trials":4053,"activeCount":101},[],{"trials":4055,"activeCount":101},[4056],{"nctId":2402,"briefTitle":2403,"status":107,"phases":4057,"primaryCompletion":2405,"completion":2405,"start":2406,"enrollment":1354,"conditions":4058,"interventions":4059},[90],[2408],[2393,2410,2411,2412],{"trials":4061,"activeCount":101},[],{"trials":4063,"activeCount":101},[],{"trials":4065,"activeCount":101},[],{"intervention":805,"totalTrials":144,"cells":4067},{"EARLY_PHASE1":4068,"PHASE1":4070,"PHASE2":4072,"PHASE3":4078,"PHASE4":4080,"NA":4082},{"trials":4069,"activeCount":101},[],{"trials":4071,"activeCount":101},[],{"trials":4073,"activeCount":101},[4074],{"nctId":797,"briefTitle":798,"status":107,"phases":4075,"primaryCompletion":800,"completion":800,"start":801,"enrollment":802,"conditions":4076,"interventions":4077},[90],[15],[805,806,767],{"trials":4079,"activeCount":101},[],{"trials":4081,"activeCount":101},[],{"trials":4083,"activeCount":101},[],{"intervention":2500,"totalTrials":144,"cells":4085},{"EARLY_PHASE1":4086,"PHASE1":4088,"PHASE2":4090,"PHASE3":4096,"PHASE4":4098,"NA":4100},{"trials":4087,"activeCount":101},[],{"trials":4089,"activeCount":101},[],{"trials":4091,"activeCount":101},[4092],{"nctId":2491,"briefTitle":2492,"status":126,"phases":4093,"primaryCompletion":2494,"completion":2494,"start":2495,"enrollment":1962,"conditions":4094,"interventions":4095},[90],[2497,2498],[2482,2500],{"trials":4097,"activeCount":101},[],{"trials":4099,"activeCount":101},[],{"trials":4101,"activeCount":101},[],{"intervention":2537,"totalTrials":144,"cells":4103},{"EARLY_PHASE1":4104,"PHASE1":4106,"PHASE2":4108,"PHASE3":4114,"PHASE4":4116,"NA":4118},{"trials":4105,"activeCount":101},[],{"trials":4107,"activeCount":101},[],{"trials":4109,"activeCount":101},[4110],{"nctId":2529,"briefTitle":2530,"status":107,"phases":4111,"primaryCompletion":2532,"completion":2533,"start":2534,"enrollment":1939,"conditions":4112,"interventions":4113},[90],[18],[2520,2537,2538,2539,2540,2541],{"trials":4115,"activeCount":101},[],{"trials":4117,"activeCount":101},[],{"trials":4119,"activeCount":101},[],{"intervention":2538,"totalTrials":144,"cells":4121},{"EARLY_PHASE1":4122,"PHASE1":4124,"PHASE2":4126,"PHASE3":4132,"PHASE4":4134,"NA":4136},{"trials":4123,"activeCount":101},[],{"trials":4125,"activeCount":101},[],{"trials":4127,"activeCount":101},[4128],{"nctId":2529,"briefTitle":2530,"status":107,"phases":4129,"primaryCompletion":2532,"completion":2533,"start":2534,"enrollment":1939,"conditions":4130,"interventions":4131},[90],[18],[2520,2537,2538,2539,2540,2541],{"trials":4133,"activeCount":101},[],{"trials":4135,"activeCount":101},[],{"trials":4137,"activeCount":101},[],{"intervention":2539,"totalTrials":144,"cells":4139},{"EARLY_PHASE1":4140,"PHASE1":4142,"PHASE2":4144,"PHASE3":4150,"PHASE4":4152,"NA":4154},{"trials":4141,"activeCount":101},[],{"trials":4143,"activeCount":101},[],{"trials":4145,"activeCount":101},[4146],{"nctId":2529,"briefTitle":2530,"status":107,"phases":4147,"primaryCompletion":2532,"completion":2533,"start":2534,"enrollment":1939,"conditions":4148,"interventions":4149},[90],[18],[2520,2537,2538,2539,2540,2541],{"trials":4151,"activeCount":101},[],{"trials":4153,"activeCount":101},[],{"trials":4155,"activeCount":101},[],{"intervention":2540,"totalTrials":144,"cells":4157},{"EARLY_PHASE1":4158,"PHASE1":4160,"PHASE2":4162,"PHASE3":4168,"PHASE4":4170,"NA":4172},{"trials":4159,"activeCount":101},[],{"trials":4161,"activeCount":101},[],{"trials":4163,"activeCount":101},[4164],{"nctId":2529,"briefTitle":2530,"status":107,"phases":4165,"primaryCompletion":2532,"completion":2533,"start":2534,"enrollment":1939,"conditions":4166,"interventions":4167},[90],[18],[2520,2537,2538,2539,2540,2541],{"trials":4169,"activeCount":101},[],{"trials":4171,"activeCount":101},[],{"trials":4173,"activeCount":101},[],{"intervention":2541,"totalTrials":144,"cells":4175},{"EARLY_PHASE1":4176,"PHASE1":4178,"PHASE2":4180,"PHASE3":4186,"PHASE4":4188,"NA":4190},{"trials":4177,"activeCount":101},[],{"trials":4179,"activeCount":101},[],{"trials":4181,"activeCount":101},[4182],{"nctId":2529,"briefTitle":2530,"status":107,"phases":4183,"primaryCompletion":2532,"completion":2533,"start":2534,"enrollment":1939,"conditions":4184,"interventions":4185},[90],[18],[2520,2537,2538,2539,2540,2541],{"trials":4187,"activeCount":101},[],{"trials":4189,"activeCount":101},[],{"trials":4191,"activeCount":101},[],{"intervention":3927,"totalTrials":144,"cells":4193},{"EARLY_PHASE1":4194,"PHASE1":4196,"PHASE2":4198,"PHASE3":4204,"PHASE4":4206,"NA":4208},{"trials":4195,"activeCount":101},[],{"trials":4197,"activeCount":101},[],{"trials":4199,"activeCount":101},[4200],{"nctId":3918,"briefTitle":3919,"status":126,"phases":4201,"primaryCompletion":3921,"completion":3922,"start":3923,"enrollment":817,"conditions":4202,"interventions":4203},[90],[3925,2498],[3927,2574],{"trials":4205,"activeCount":101},[],{"trials":4207,"activeCount":101},[],{"trials":4209,"activeCount":101},[],{"intervention":1839,"totalTrials":144,"cells":4211},{"EARLY_PHASE1":4212,"PHASE1":4214,"PHASE2":4216,"PHASE3":4222,"PHASE4":4224,"NA":4226},{"trials":4213,"activeCount":101},[],{"trials":4215,"activeCount":101},[],{"trials":4217,"activeCount":101},[4218],{"nctId":1831,"briefTitle":1832,"status":107,"phases":4219,"primaryCompletion":957,"completion":957,"start":1834,"enrollment":1835,"conditions":4220,"interventions":4221},[90],[726],[1822,1838,1839],{"trials":4223,"activeCount":101},[],{"trials":4225,"activeCount":101},[],{"trials":4227,"activeCount":101},[],{"intervention":4229,"totalTrials":144,"cells":4230},"CKD-498 dose#1",{"EARLY_PHASE1":4231,"PHASE1":4233,"PHASE2":4235,"PHASE3":4248,"PHASE4":4250,"NA":4252},{"trials":4232,"activeCount":101},[],{"trials":4234,"activeCount":101},[],{"trials":4236,"activeCount":101},[4237],{"nctId":4238,"briefTitle":4239,"status":107,"phases":4240,"primaryCompletion":4241,"completion":4241,"start":4242,"enrollment":4243,"conditions":4244,"interventions":4245},"NCT05677438","A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia",[90],"2023-12-15","2022-12-20",121,[332],[4229,4246,4247],"CKD-498 dose#2","CKD-498 dose#3",{"trials":4249,"activeCount":101},[],{"trials":4251,"activeCount":101},[],{"trials":4253,"activeCount":101},[],{"intervention":4246,"totalTrials":144,"cells":4255},{"EARLY_PHASE1":4256,"PHASE1":4258,"PHASE2":4260,"PHASE3":4266,"PHASE4":4268,"NA":4270},{"trials":4257,"activeCount":101},[],{"trials":4259,"activeCount":101},[],{"trials":4261,"activeCount":101},[4262],{"nctId":4238,"briefTitle":4239,"status":107,"phases":4263,"primaryCompletion":4241,"completion":4241,"start":4242,"enrollment":4243,"conditions":4264,"interventions":4265},[90],[332],[4229,4246,4247],{"trials":4267,"activeCount":101},[],{"trials":4269,"activeCount":101},[],{"trials":4271,"activeCount":101},[],{"intervention":4247,"totalTrials":144,"cells":4273},{"EARLY_PHASE1":4274,"PHASE1":4276,"PHASE2":4278,"PHASE3":4284,"PHASE4":4286,"NA":4288},{"trials":4275,"activeCount":101},[],{"trials":4277,"activeCount":101},[],{"trials":4279,"activeCount":101},[4280],{"nctId":4238,"briefTitle":4239,"status":107,"phases":4281,"primaryCompletion":4241,"completion":4241,"start":4242,"enrollment":4243,"conditions":4282,"interventions":4283},[90],[332],[4229,4246,4247],{"trials":4285,"activeCount":101},[],{"trials":4287,"activeCount":101},[],{"trials":4289,"activeCount":101},[],{"intervention":4291,"totalTrials":144,"cells":4292},"CKD-497 200mg",{"EARLY_PHASE1":4293,"PHASE1":4295,"PHASE2":4297,"PHASE3":4313,"PHASE4":4315,"NA":4317},{"trials":4294,"activeCount":101},[],{"trials":4296,"activeCount":101},[],{"trials":4298,"activeCount":101},[4299],{"nctId":4300,"briefTitle":4301,"status":107,"phases":4302,"primaryCompletion":4303,"completion":4303,"start":4304,"enrollment":4305,"conditions":4306,"interventions":4308},"NCT03726853","The Clinical Trial to Evaluate the Efficacy and Safety of CKD-497",[90],"2019-03-21","2018-05-29",220,[4307],"Respiratory Infection",[4291,4309,4310,4311,4312],"CKD-497 300mg","CKD-497 placebo","Comparator","Comparator placebo",{"trials":4314,"activeCount":101},[],{"trials":4316,"activeCount":101},[],{"trials":4318,"activeCount":101},[],{"intervention":4309,"totalTrials":144,"cells":4320},{"EARLY_PHASE1":4321,"PHASE1":4323,"PHASE2":4325,"PHASE3":4331,"PHASE4":4333,"NA":4335},{"trials":4322,"activeCount":101},[],{"trials":4324,"activeCount":101},[],{"trials":4326,"activeCount":101},[4327],{"nctId":4300,"briefTitle":4301,"status":107,"phases":4328,"primaryCompletion":4303,"completion":4303,"start":4304,"enrollment":4305,"conditions":4329,"interventions":4330},[90],[4307],[4291,4309,4310,4311,4312],{"trials":4332,"activeCount":101},[],{"trials":4334,"activeCount":101},[],{"trials":4336,"activeCount":101},[],{"intervention":4310,"totalTrials":144,"cells":4338},{"EARLY_PHASE1":4339,"PHASE1":4341,"PHASE2":4343,"PHASE3":4349,"PHASE4":4351,"NA":4353},{"trials":4340,"activeCount":101},[],{"trials":4342,"activeCount":101},[],{"trials":4344,"activeCount":101},[4345],{"nctId":4300,"briefTitle":4301,"status":107,"phases":4346,"primaryCompletion":4303,"completion":4303,"start":4304,"enrollment":4305,"conditions":4347,"interventions":4348},[90],[4307],[4291,4309,4310,4311,4312],{"trials":4350,"activeCount":101},[],{"trials":4352,"activeCount":101},[],{"trials":4354,"activeCount":101},[],{"intervention":4311,"totalTrials":144,"cells":4356},{"EARLY_PHASE1":4357,"PHASE1":4359,"PHASE2":4361,"PHASE3":4367,"PHASE4":4369,"NA":4371},{"trials":4358,"activeCount":101},[],{"trials":4360,"activeCount":101},[],{"trials":4362,"activeCount":101},[4363],{"nctId":4300,"briefTitle":4301,"status":107,"phases":4364,"primaryCompletion":4303,"completion":4303,"start":4304,"enrollment":4305,"conditions":4365,"interventions":4366},[90],[4307],[4291,4309,4310,4311,4312],{"trials":4368,"activeCount":101},[],{"trials":4370,"activeCount":101},[],{"trials":4372,"activeCount":101},[],{"intervention":4312,"totalTrials":144,"cells":4374},{"EARLY_PHASE1":4375,"PHASE1":4377,"PHASE2":4379,"PHASE3":4385,"PHASE4":4387,"NA":4389},{"trials":4376,"activeCount":101},[],{"trials":4378,"activeCount":101},[],{"trials":4380,"activeCount":101},[4381],{"nctId":4300,"briefTitle":4301,"status":107,"phases":4382,"primaryCompletion":4303,"completion":4303,"start":4304,"enrollment":4305,"conditions":4383,"interventions":4384},[90],[4307],[4291,4309,4310,4311,4312],{"trials":4386,"activeCount":101},[],{"trials":4388,"activeCount":101},[],{"trials":4390,"activeCount":101},[],{"intervention":4392,"totalTrials":144,"cells":4393},"Bredinin tablet 150mg",{"EARLY_PHASE1":4394,"PHASE1":4396,"PHASE2":4398,"PHASE3":4409,"PHASE4":4411,"NA":4413},{"trials":4395,"activeCount":101},[],{"trials":4397,"activeCount":101},[],{"trials":4399,"activeCount":101},[4400],{"nctId":4401,"briefTitle":4402,"status":126,"phases":4403,"primaryCompletion":4404,"completion":863,"start":4405,"enrollment":675,"conditions":4406,"interventions":4407},"NCT02005757","Efficacy and Safety Study of Mizoribine in Active Rheumatoid (AMOLED)",[90],"2016-06","2013-11",[1692],[4392,4408],"Bredinin tablet 50mg",{"trials":4410,"activeCount":101},[],{"trials":4412,"activeCount":101},[],{"trials":4414,"activeCount":101},[],{"intervention":4408,"totalTrials":144,"cells":4416},{"EARLY_PHASE1":4417,"PHASE1":4419,"PHASE2":4421,"PHASE3":4427,"PHASE4":4429,"NA":4431},{"trials":4418,"activeCount":101},[],{"trials":4420,"activeCount":101},[],{"trials":4422,"activeCount":101},[4423],{"nctId":4401,"briefTitle":4402,"status":126,"phases":4424,"primaryCompletion":4404,"completion":863,"start":4405,"enrollment":675,"conditions":4425,"interventions":4426},[90],[1692],[4392,4408],{"trials":4428,"activeCount":101},[],{"trials":4430,"activeCount":101},[],{"trials":4432,"activeCount":101},[],{"intervention":4434,"totalTrials":35,"cells":4435},"CKD-828, D097, D337",{"EARLY_PHASE1":4436,"PHASE1":4438,"PHASE2":4517,"PHASE3":4519,"PHASE4":4521,"NA":4523},{"trials":4437,"activeCount":101},[],{"trials":4439,"activeCount":101},[4440,4451,4460,4469,4480,4489,4498,4508],{"nctId":4441,"briefTitle":4442,"status":107,"phases":4443,"primaryCompletion":4444,"completion":4445,"start":4446,"enrollment":4447,"conditions":4448,"interventions":4449},"NCT04660370","A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348",[89],"2021-02-24","2021-04-15","2021-01-09",70,[21],[4450,4434],"CKD-348",{"nctId":4452,"briefTitle":4453,"status":107,"phases":4454,"primaryCompletion":4455,"completion":4456,"start":4457,"enrollment":1939,"conditions":4458,"interventions":4459},"NCT04883658","A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(2)",[89],"2021-07-20","2021-08-19","2021-06-04",[21],[4450,4434],{"nctId":4461,"briefTitle":4462,"status":107,"phases":4463,"primaryCompletion":4464,"completion":4465,"start":4466,"enrollment":1919,"conditions":4467,"interventions":4468},"NCT05192356","A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3)",[89],"2022-05-08","2022-06-08","2022-02-23",[21],[4450,4434],{"nctId":4470,"briefTitle":4471,"status":107,"phases":4472,"primaryCompletion":4473,"completion":4474,"start":4475,"enrollment":415,"conditions":4476,"interventions":4477},"NCT04258865","A Clinical Trial to Compare the Pharmacokinetics and Tolerability of CKD-348",[89],"2020-04-26","2020-05-13","2020-03-25",[15,18],[4478,4479,4434],"CKD-348 F1","CKD-348 F2",{"nctId":4481,"briefTitle":4482,"status":107,"phases":4483,"primaryCompletion":4484,"completion":4485,"start":4486,"enrollment":1919,"conditions":4487,"interventions":4488},"NCT06112678","A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(6)",[89],"2024-02-19","2024-03-18","2024-01-04",[15,18],[4450,4434],{"nctId":4490,"briefTitle":4491,"status":107,"phases":4492,"primaryCompletion":4493,"completion":4494,"start":4495,"enrollment":1939,"conditions":4496,"interventions":4497},"NCT04587206","A Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-348",[89],"2020-12-30","2021-01-15","2020-10-15",[21],[4450,4434],{"nctId":4499,"briefTitle":4500,"status":107,"phases":4501,"primaryCompletion":1847,"completion":4502,"start":4503,"enrollment":451,"conditions":4504,"interventions":4505},"NCT05549401","Clinical Trial to Evaluate the Tolerability and the Pharmacokinetics of CKD-348",[89],"2022-12-09","2022-09-29",[21],[4506,4507,4434],"CKD-348(4) F1","CKD-348(4) F2",{"nctId":4509,"briefTitle":4510,"status":107,"phases":4511,"primaryCompletion":4512,"completion":4513,"start":4514,"enrollment":1997,"conditions":4515,"interventions":4516},"NCT05749861","A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5)",[89],"2023-06-07","2023-07-18","2023-04-22",[21],[4450,4434],{"trials":4518,"activeCount":101},[],{"trials":4520,"activeCount":101},[],{"trials":4522,"activeCount":101},[],{"trials":4524,"activeCount":101},[],{"intervention":4526,"totalTrials":3673,"cells":4527},"CKD-387",{"EARLY_PHASE1":4528,"PHASE1":4530,"PHASE2":4600,"PHASE3":4602,"PHASE4":4604,"NA":4606},{"trials":4529,"activeCount":101},[],{"trials":4531,"activeCount":101},[4532,4542,4552,4563,4572,4582,4592],{"nctId":4533,"briefTitle":4534,"status":126,"phases":4535,"primaryCompletion":4536,"completion":2339,"start":4537,"enrollment":9,"conditions":4538,"interventions":4540},"NCT03646799","Pharmacokinetics and Safety\u002FTolerability After Oral Administration of CKD-387 and D484 in Healthy Adults",[89],"2018-09-09","2018-08-30",[4539],"Type II Diabetes",[4526,4541],"D484",{"nctId":4543,"briefTitle":4544,"status":126,"phases":4545,"primaryCompletion":4546,"completion":4547,"start":4548,"enrollment":9,"conditions":4549,"interventions":4550},"NCT03849261","Pharmacokinetics and Safety\u002FTolerability After Oral Administration of CKD-387 and D635 in Healthy Adults",[89],"2019-02-01","2019-02-22","2019-01-14",[441],[4526,4551],"D635",{"nctId":4553,"briefTitle":4554,"status":107,"phases":4555,"primaryCompletion":4556,"completion":4557,"start":4558,"enrollment":4559,"conditions":4560,"interventions":4562},"NCT06399055","Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fasting Conditions",[89],"2022-09-26","2022-10-09","2022-09-16",37,[4561],"Endocrine, Nutritional and Metabolic Diseases",[4526,4541],{"nctId":4564,"briefTitle":4565,"status":107,"phases":4566,"primaryCompletion":4567,"completion":4568,"start":4569,"enrollment":2280,"conditions":4570,"interventions":4571},"NCT05673369","Clinical Study to Evaluate Pharmacokinetic Profiles and Safety of CKD-387 Under Fasting Condition",[89],"2023-02-11","2023-02-27","2023-02-01",[4561],[4526,4541],{"nctId":4573,"briefTitle":4574,"status":126,"phases":4575,"primaryCompletion":4576,"completion":4577,"start":4578,"enrollment":4579,"conditions":4580,"interventions":4581},"NCT03849339","Pharmacokinetics and Safety\u002FTolerability After Oral Administration of CKD-387 and D635 Under Fed Condition",[89],"2019-02-21","2019-02-28","2019-01-28",20,[23],[4526,4551],{"nctId":4583,"briefTitle":4584,"status":107,"phases":4585,"primaryCompletion":4586,"completion":4587,"start":4588,"enrollment":4589,"conditions":4590,"interventions":4591},"NCT03738449","The Clinical Trial to Investigate the Pharmacokinetics and Safety\u002FTolerability of CKD-387 Under Fed Condition",[89],"2019-01-18","2019-01-24","2019-01-08",23,[23],[4526,4541],{"nctId":4593,"briefTitle":4594,"status":107,"phases":4595,"primaryCompletion":4503,"completion":4596,"start":4597,"enrollment":485,"conditions":4598,"interventions":4599},"NCT06399068","Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fed Conditions",[89],"2022-10-05","2022-09-19",[4561],[4526,4541],{"trials":4601,"activeCount":101},[],{"trials":4603,"activeCount":101},[],{"trials":4605,"activeCount":101},[],{"trials":4607,"activeCount":101},[],{"intervention":4450,"totalTrials":402,"cells":4609},{"EARLY_PHASE1":4610,"PHASE1":4612,"PHASE2":4638,"PHASE3":4640,"PHASE4":4642,"NA":4644},{"trials":4611,"activeCount":101},[],{"trials":4613,"activeCount":101},[4614,4618,4622,4626,4630,4634],{"nctId":4441,"briefTitle":4442,"status":107,"phases":4615,"primaryCompletion":4444,"completion":4445,"start":4446,"enrollment":4447,"conditions":4616,"interventions":4617},[89],[21],[4450,4434],{"nctId":4452,"briefTitle":4453,"status":107,"phases":4619,"primaryCompletion":4455,"completion":4456,"start":4457,"enrollment":1939,"conditions":4620,"interventions":4621},[89],[21],[4450,4434],{"nctId":4461,"briefTitle":4462,"status":107,"phases":4623,"primaryCompletion":4464,"completion":4465,"start":4466,"enrollment":1919,"conditions":4624,"interventions":4625},[89],[21],[4450,4434],{"nctId":4481,"briefTitle":4482,"status":107,"phases":4627,"primaryCompletion":4484,"completion":4485,"start":4486,"enrollment":1919,"conditions":4628,"interventions":4629},[89],[15,18],[4450,4434],{"nctId":4490,"briefTitle":4491,"status":107,"phases":4631,"primaryCompletion":4493,"completion":4494,"start":4495,"enrollment":1939,"conditions":4632,"interventions":4633},[89],[21],[4450,4434],{"nctId":4509,"briefTitle":4510,"status":107,"phases":4635,"primaryCompletion":4512,"completion":4513,"start":4514,"enrollment":1997,"conditions":4636,"interventions":4637},[89],[21],[4450,4434],{"trials":4639,"activeCount":101},[],{"trials":4641,"activeCount":101},[],{"trials":4643,"activeCount":101},[],{"trials":4645,"activeCount":101},[],{"intervention":4647,"totalTrials":768,"cells":4648},"CKD-501",{"EARLY_PHASE1":4649,"PHASE1":4651,"PHASE2":4695,"PHASE3":4697,"PHASE4":4699,"NA":4701},{"trials":4650,"activeCount":101},[],{"trials":4652,"activeCount":101},[4653,4661,4670,4679,4686],{"nctId":4654,"briefTitle":4655,"status":107,"phases":4656,"primaryCompletion":4657,"completion":3801,"start":110,"enrollment":594,"conditions":4658,"interventions":4659},"NCT01005160","Drug Interaction Between CKD-501 and Metformin",[89],"2009-12",[2227],[4660,4647],"Metformin",{"nctId":4662,"briefTitle":4663,"status":107,"phases":4664,"primaryCompletion":4665,"completion":4665,"start":1063,"enrollment":4666,"conditions":4667,"interventions":4669},"NCT02005744","A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function",[89],"2016-02",26,[4668],"Liver Dysfunction",[4647],{"nctId":4671,"briefTitle":4672,"status":107,"phases":4673,"primaryCompletion":2206,"completion":2206,"start":1986,"enrollment":4674,"conditions":4675,"interventions":4676},"NCT01341392","Drug-drug Interaction Study(CKD-501, Amlodipine)",[89],25,[23],[4647,4677,4678],"amlodiopine","CKD-501 amlodipine",{"nctId":4680,"briefTitle":4681,"status":107,"phases":4682,"primaryCompletion":852,"completion":852,"start":128,"enrollment":112,"conditions":4683,"interventions":4685},"NCT02007941","Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function Subjects",[89],[4684,25],"Renal Impairment",[4647],{"nctId":4687,"briefTitle":4688,"status":107,"phases":4689,"primaryCompletion":4690,"completion":4690,"start":4691,"enrollment":781,"conditions":4692,"interventions":4693},"NCT04334213","A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150",[89],"2020-08-05","2020-05-07",[31],[4647,4694,443],"D745, D150",{"trials":4696,"activeCount":101},[],{"trials":4698,"activeCount":101},[],{"trials":4700,"activeCount":101},[],{"trials":4702,"activeCount":101},[],{"intervention":1922,"totalTrials":768,"cells":4704},{"EARLY_PHASE1":4705,"PHASE1":4707,"PHASE2":4736,"PHASE3":4738,"PHASE4":4740,"NA":4742},{"trials":4706,"activeCount":101},[],{"trials":4708,"activeCount":101},[4709,4720,4724,4728,4732],{"nctId":4710,"briefTitle":4711,"status":107,"phases":4712,"primaryCompletion":4713,"completion":4714,"start":4715,"enrollment":4716,"conditions":4717,"interventions":4718},"NCT04673864","A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386",[89],"2021-03-04","2021-03-30","2021-01-17",66,[21],[1922,4719],"D012, D326, D337",{"nctId":1913,"briefTitle":1914,"status":107,"phases":4721,"primaryCompletion":1916,"completion":1917,"start":1918,"enrollment":1919,"conditions":4722,"interventions":4723},[89],[21],[1922,1895],{"nctId":1924,"briefTitle":1925,"status":107,"phases":4725,"primaryCompletion":1927,"completion":1928,"start":1929,"enrollment":675,"conditions":4726,"interventions":4727},[89],[21],[1922,1895],{"nctId":1933,"briefTitle":1934,"status":107,"phases":4729,"primaryCompletion":1936,"completion":1937,"start":1938,"enrollment":1939,"conditions":4730,"interventions":4731},[89],[21],[1922,1895],{"nctId":1943,"briefTitle":1944,"status":107,"phases":4733,"primaryCompletion":1946,"completion":1947,"start":1948,"enrollment":1949,"conditions":4734,"interventions":4735},[89],[21],[1922,1895],{"trials":4737,"activeCount":101},[],{"trials":4739,"activeCount":101},[],{"trials":4741,"activeCount":101},[],{"trials":4743,"activeCount":101},[],{"intervention":4541,"totalTrials":768,"cells":4745},{"EARLY_PHASE1":4746,"PHASE1":4748,"PHASE2":4770,"PHASE3":4772,"PHASE4":4774,"NA":4776},{"trials":4747,"activeCount":101},[],{"trials":4749,"activeCount":101},[4750,4754,4758,4762,4766],{"nctId":4533,"briefTitle":4534,"status":126,"phases":4751,"primaryCompletion":4536,"completion":2339,"start":4537,"enrollment":9,"conditions":4752,"interventions":4753},[89],[4539],[4526,4541],{"nctId":4553,"briefTitle":4554,"status":107,"phases":4755,"primaryCompletion":4556,"completion":4557,"start":4558,"enrollment":4559,"conditions":4756,"interventions":4757},[89],[4561],[4526,4541],{"nctId":4564,"briefTitle":4565,"status":107,"phases":4759,"primaryCompletion":4567,"completion":4568,"start":4569,"enrollment":2280,"conditions":4760,"interventions":4761},[89],[4561],[4526,4541],{"nctId":4583,"briefTitle":4584,"status":107,"phases":4763,"primaryCompletion":4586,"completion":4587,"start":4588,"enrollment":4589,"conditions":4764,"interventions":4765},[89],[23],[4526,4541],{"nctId":4593,"briefTitle":4594,"status":107,"phases":4767,"primaryCompletion":4503,"completion":4596,"start":4597,"enrollment":485,"conditions":4768,"interventions":4769},[89],[4561],[4526,4541],{"trials":4771,"activeCount":101},[],{"trials":4773,"activeCount":101},[],{"trials":4775,"activeCount":101},[],{"trials":4777,"activeCount":101},[],{"intervention":4779,"totalTrials":2033,"cells":4780},"CKD-381",{"EARLY_PHASE1":4781,"PHASE1":4783,"PHASE2":4822,"PHASE3":4824,"PHASE4":4826,"NA":4828},{"trials":4782,"activeCount":101},[],{"trials":4784,"activeCount":101},[4785,4796,4804,4813],{"nctId":4786,"briefTitle":4787,"status":107,"phases":4788,"primaryCompletion":4789,"completion":4789,"start":4790,"enrollment":4791,"conditions":4792,"interventions":4794},"NCT03211143","A Study to Compare PK, PD and Safety of CKD-381 in Healthy Subjects",[89],"2017-08-28","2017-06-20",41,[4793],"GERD",[4779,4795],"Nexium",{"nctId":4797,"briefTitle":4798,"status":107,"phases":4799,"primaryCompletion":2339,"completion":2339,"start":4800,"enrollment":4791,"conditions":4801,"interventions":4802},"NCT03558425","A Study to Compare PK, PD and Safety of CKD-381 and D026 in Healthy Subjects",[89],"2018-06-27",[4793],[4779,4803],"D026",{"nctId":4805,"briefTitle":4806,"status":107,"phases":4807,"primaryCompletion":4808,"completion":4808,"start":4809,"enrollment":4810,"conditions":4811,"interventions":4812},"NCT03444402","A Study to Compare PK and Safety of CKD-381 and D026 in Healthy Male Subjects",[89],"2018-05-04","2018-03-02",18,[4793],[4779,4779,4803],{"nctId":4814,"briefTitle":4815,"status":107,"phases":4816,"primaryCompletion":4817,"completion":4818,"start":4819,"enrollment":112,"conditions":4820,"interventions":4821},"NCT04830930","A Study to Investigate the Effect of Food on the PK, PD of CKD-381 in Healthy Volunteers",[89],"2021-06-17","2021-07-26","2021-04-21",[4793],[4779],{"trials":4823,"activeCount":101},[],{"trials":4825,"activeCount":101},[],{"trials":4827,"activeCount":101},[],{"trials":4829,"activeCount":101},[],{"intervention":3690,"totalTrials":2033,"cells":4831},{"EARLY_PHASE1":4832,"PHASE1":4834,"PHASE2":4858,"PHASE3":4860,"PHASE4":4862,"NA":4864},{"trials":4833,"activeCount":101},[],{"trials":4835,"activeCount":101},[4836,4840,4844,4848],{"nctId":3680,"briefTitle":3681,"status":107,"phases":4837,"primaryCompletion":3683,"completion":3684,"start":3685,"enrollment":3686,"conditions":4838,"interventions":4839},[89],[3688],[3672,3690],{"nctId":3710,"briefTitle":3711,"status":107,"phases":4841,"primaryCompletion":3713,"completion":3714,"start":3715,"enrollment":3716,"conditions":4842,"interventions":4843},[89],[3688],[3672,3690],{"nctId":3720,"briefTitle":3721,"status":126,"phases":4845,"primaryCompletion":3723,"completion":3724,"start":3725,"enrollment":3726,"conditions":4846,"interventions":4847},[89],[31],[3672,3690],{"nctId":4849,"briefTitle":4850,"status":107,"phases":4851,"primaryCompletion":4852,"completion":4853,"start":4854,"enrollment":675,"conditions":4855,"interventions":4856},"NCT03346187","A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337",[89],"2017-05-31","2017-06-13","2017-05-19",[18],[4857,3690],"Active Comparator",{"trials":4859,"activeCount":101},[],{"trials":4861,"activeCount":101},[],{"trials":4863,"activeCount":101},[],{"trials":4865,"activeCount":101},[],{"intervention":443,"totalTrials":2033,"cells":4867},{"EARLY_PHASE1":4868,"PHASE1":4870,"PHASE2":4900,"PHASE3":4902,"PHASE4":4904,"NA":4906},{"trials":4869,"activeCount":101},[],{"trials":4871,"activeCount":101},[4872,4876,4886,4896],{"nctId":434,"briefTitle":435,"status":107,"phases":4873,"primaryCompletion":437,"completion":438,"start":439,"enrollment":11,"conditions":4874,"interventions":4875},[89],[441],[443,41],{"nctId":4877,"briefTitle":4878,"status":107,"phases":4879,"primaryCompletion":4880,"completion":4881,"start":4882,"enrollment":415,"conditions":4883,"interventions":4884},"NCT07304726","Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25\u002F12.5\u002F1000mg in Healthy Volunteers",[89],"2025-11-09","2025-11-23","2025-10-30",[31],[4885,443],"CKD-383 0.25\u002F12.5\u002F1000mg",{"nctId":4887,"briefTitle":4888,"status":107,"phases":4889,"primaryCompletion":4890,"completion":4891,"start":4892,"enrollment":485,"conditions":4893,"interventions":4894},"NCT07304687","Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5\u002F25\u002F1000mg in Healthy Volunteers",[89],"2025-11-03","2025-11-22","2025-10-24",[31],[4895,443],"CKD-383 0.5\u002F25\u002F1000mg",{"nctId":4687,"briefTitle":4688,"status":107,"phases":4897,"primaryCompletion":4690,"completion":4690,"start":4691,"enrollment":781,"conditions":4898,"interventions":4899},[89],[31],[4647,4694,443],{"trials":4901,"activeCount":101},[],{"trials":4903,"activeCount":101},[],{"trials":4905,"activeCount":101},[],{"trials":4907,"activeCount":101},[],{"intervention":4909,"totalTrials":97,"cells":4910},"CKD-391",{"EARLY_PHASE1":4911,"PHASE1":4913,"PHASE2":4940,"PHASE3":4942,"PHASE4":4944,"NA":4946},{"trials":4912,"activeCount":101},[],{"trials":4914,"activeCount":101},[4915,4923,4930],{"nctId":4916,"briefTitle":4917,"status":107,"phases":4918,"primaryCompletion":2279,"completion":2279,"start":2043,"enrollment":4919,"conditions":4920,"interventions":4921},"NCT02501200","CKD-391 Pharmacokinetic Study Phase I",[89],46,[25],[4909,4922],"Atrovastatin and Ezetimibe combination therapy",{"nctId":4924,"briefTitle":4925,"status":107,"phases":4926,"primaryCompletion":1309,"completion":1309,"start":4927,"enrollment":3686,"conditions":4928,"interventions":4929},"NCT02461004","CKD-391 Pharmacokinetic Study",[89],"2015-07",[25],[4909,4922],{"nctId":4931,"briefTitle":4932,"status":107,"phases":4933,"primaryCompletion":4934,"completion":4935,"start":4936,"enrollment":4716,"conditions":4937,"interventions":4938},"NCT06088017","A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391(2)",[89],"2024-01-07","2024-01-22","2023-10-23",[18],[4909,4939],"CKD-331, D337",{"trials":4941,"activeCount":101},[],{"trials":4943,"activeCount":101},[],{"trials":4945,"activeCount":101},[],{"trials":4947,"activeCount":101},[],{"intervention":4949,"totalTrials":97,"cells":4950},"CKD-379",{"EARLY_PHASE1":4951,"PHASE1":4953,"PHASE2":4984,"PHASE3":4986,"PHASE4":4988,"NA":4990},{"trials":4952,"activeCount":101},[],{"trials":4954,"activeCount":101},[4955,4966,4975],{"nctId":4956,"briefTitle":4957,"status":126,"phases":4958,"primaryCompletion":4959,"completion":4960,"start":4961,"enrollment":451,"conditions":4962,"interventions":4964},"NCT05952219","Study to Evaluate the Safety and Pharmacokinetics of CKD-379",[89],"2023-06-19","2023-10-30","2023-06-02",[4963],"Type II Diabetes Mellitus",[4949,4965],"D759+D745+D029+D150",{"nctId":4967,"briefTitle":4968,"status":107,"phases":4969,"primaryCompletion":4970,"completion":4971,"start":4972,"enrollment":415,"conditions":4973,"interventions":4974},"NCT06652971","A Clinical Trial to Evaluate the Food Effect of CKD-379",[89],"2024-12-04","2024-12-17","2024-11-05",[4963],[4949],{"nctId":4976,"briefTitle":4977,"status":107,"phases":4978,"primaryCompletion":4979,"completion":4980,"start":4568,"enrollment":451,"conditions":4981,"interventions":4982},"NCT05719155","Pharmacokinetics and Safety\u002FTolerability of CKD-379",[89],"2023-03-23","2023-04-10",[4963],[4949,4983],"D759+D745+D150",{"trials":4985,"activeCount":101},[],{"trials":4987,"activeCount":101},[],{"trials":4989,"activeCount":101},[],{"trials":4991,"activeCount":101},[],{"intervention":4993,"totalTrials":97,"cells":4994},"CKD-508",{"EARLY_PHASE1":4995,"PHASE1":4997,"PHASE2":5026,"PHASE3":5028,"PHASE4":5030,"NA":5032},{"trials":4996,"activeCount":101},[],{"trials":4998,"activeCount":101},[4999,5008,5018],{"nctId":5000,"briefTitle":5001,"status":107,"phases":5002,"primaryCompletion":5003,"completion":5003,"start":5004,"enrollment":594,"conditions":5005,"interventions":5006},"NCT06979973","A Drug-drug Interaction Study to Investigate the Pharmacokinetic Interactions Between CKD-508, Midazolam, and Rosuvastatin in Healthy Adult Male Participants",[89],"2025-08-17","2025-05-14",[25],[3887,5007,4993],"Rosuvastatin",{"nctId":5009,"briefTitle":5010,"status":107,"phases":5011,"primaryCompletion":5012,"completion":5012,"start":5013,"enrollment":5014,"conditions":5015,"interventions":5017},"NCT04488900","Evaluation of the Safety and Tolerability of CKD-508 in Healthy Subjects",[89],"2023-07-02","2020-07-06",88,[5016],"Healthy Subjects",[4993,4993],{"nctId":5019,"briefTitle":5020,"status":107,"phases":5021,"primaryCompletion":5022,"completion":5022,"start":5023,"enrollment":16,"conditions":5024,"interventions":5025},"NCT06727396","A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants",[89],"2025-06-05","2024-11-14",[5016],[4993],{"trials":5027,"activeCount":101},[],{"trials":5029,"activeCount":101},[],{"trials":5031,"activeCount":101},[],{"trials":5033,"activeCount":101},[],{"intervention":3699,"totalTrials":97,"cells":5035},{"EARLY_PHASE1":5036,"PHASE1":5038,"PHASE2":5052,"PHASE3":5054,"PHASE4":5056,"NA":5058},{"trials":5037,"activeCount":101},[],{"trials":5039,"activeCount":101},[5040,5044,5048],{"nctId":3692,"briefTitle":3693,"status":126,"phases":5041,"primaryCompletion":3695,"completion":3695,"start":3696,"enrollment":594,"conditions":5042,"interventions":5043},[89],[3688],[3672,3699,3700],{"nctId":3702,"briefTitle":3703,"status":126,"phases":5045,"primaryCompletion":3705,"completion":3705,"start":3706,"enrollment":594,"conditions":5046,"interventions":5047},[89],[3688],[3672,3699,3700],{"nctId":3730,"briefTitle":3731,"status":107,"phases":5049,"primaryCompletion":3713,"completion":3733,"start":3715,"enrollment":594,"conditions":5050,"interventions":5051},[89],[3688],[3672,3699,3700],{"trials":5053,"activeCount":101},[],{"trials":5055,"activeCount":101},[],{"trials":5057,"activeCount":101},[],{"trials":5059,"activeCount":101},[],{"intervention":3700,"totalTrials":97,"cells":5061},{"EARLY_PHASE1":5062,"PHASE1":5064,"PHASE2":5078,"PHASE3":5080,"PHASE4":5082,"NA":5084},{"trials":5063,"activeCount":101},[],{"trials":5065,"activeCount":101},[5066,5070,5074],{"nctId":3692,"briefTitle":3693,"status":126,"phases":5067,"primaryCompletion":3695,"completion":3695,"start":3696,"enrollment":594,"conditions":5068,"interventions":5069},[89],[3688],[3672,3699,3700],{"nctId":3702,"briefTitle":3703,"status":126,"phases":5071,"primaryCompletion":3705,"completion":3705,"start":3706,"enrollment":594,"conditions":5072,"interventions":5073},[89],[3688],[3672,3699,3700],{"nctId":3730,"briefTitle":3731,"status":107,"phases":5075,"primaryCompletion":3713,"completion":3733,"start":3715,"enrollment":594,"conditions":5076,"interventions":5077},[89],[3688],[3672,3699,3700],{"trials":5079,"activeCount":101},[],{"trials":5081,"activeCount":101},[],{"trials":5083,"activeCount":101},[],{"trials":5085,"activeCount":101},[],{"intervention":1990,"totalTrials":97,"cells":5087},{"EARLY_PHASE1":5088,"PHASE1":5090,"PHASE2":5104,"PHASE3":5106,"PHASE4":5108,"NA":5110},{"trials":5089,"activeCount":101},[],{"trials":5091,"activeCount":101},[5092,5096,5100],{"nctId":1982,"briefTitle":1983,"status":107,"phases":5093,"primaryCompletion":1985,"completion":1985,"start":1986,"enrollment":1987,"conditions":5094,"interventions":5095},[89],[15],[784,1990],{"nctId":1992,"briefTitle":1993,"status":107,"phases":5097,"primaryCompletion":1995,"completion":1995,"start":1996,"enrollment":1997,"conditions":5098,"interventions":5099},[89],[15],[784,1990],{"nctId":2005,"briefTitle":2006,"status":107,"phases":5101,"primaryCompletion":800,"completion":1986,"start":2008,"enrollment":2009,"conditions":5102,"interventions":5103},[89],[15],[784,1990],{"trials":5105,"activeCount":101},[],{"trials":5107,"activeCount":101},[],{"trials":5109,"activeCount":101},[],{"trials":5111,"activeCount":101},[],{"intervention":4803,"totalTrials":97,"cells":5113},{"EARLY_PHASE1":5114,"PHASE1":5116,"PHASE2":5133,"PHASE3":5135,"PHASE4":5137,"NA":5139},{"trials":5115,"activeCount":101},[],{"trials":5117,"activeCount":101},[5118,5122,5129],{"nctId":4797,"briefTitle":4798,"status":107,"phases":5119,"primaryCompletion":2339,"completion":2339,"start":4800,"enrollment":4791,"conditions":5120,"interventions":5121},[89],[4793],[4779,4803],{"nctId":5123,"briefTitle":5124,"status":126,"phases":5125,"primaryCompletion":1193,"completion":1193,"start":3956,"enrollment":781,"conditions":5126,"interventions":5127},"NCT04703374","A Study to Compare PK, PD and Safety of CKD-382 in Healthy Subjects",[89],[4793],[5128,5128,4803],"CKD-382",{"nctId":4805,"briefTitle":4806,"status":107,"phases":5130,"primaryCompletion":4808,"completion":4808,"start":4809,"enrollment":4810,"conditions":5131,"interventions":5132},[89],[4793],[4779,4779,4803],{"trials":5134,"activeCount":101},[],{"trials":5136,"activeCount":101},[],{"trials":5138,"activeCount":101},[],{"trials":5140,"activeCount":101},[],{"intervention":5142,"totalTrials":97,"cells":5143},"CKD-393",{"EARLY_PHASE1":5144,"PHASE1":5146,"PHASE2":5179,"PHASE3":5181,"PHASE4":5183,"NA":5185},{"trials":5145,"activeCount":101},[],{"trials":5147,"activeCount":101},[5148,5159,5168],{"nctId":5149,"briefTitle":5150,"status":107,"phases":5151,"primaryCompletion":5152,"completion":5153,"start":5154,"enrollment":485,"conditions":5155,"interventions":5157},"NCT05347576","A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions",[89],"2022-05-02","2022-05-09","2022-04-21",[5156],"Type2Diabetes",[5142,5158],"CKD-501, D759, D150, D029",{"nctId":5160,"briefTitle":5161,"status":107,"phases":5162,"primaryCompletion":5163,"completion":5164,"start":5165,"enrollment":112,"conditions":5166,"interventions":5167},"NCT05274880","Study to Evaluate the Food Effect on Pharmacokinetics Profile and Safety of CKD-393",[89],"2022-07-15","2022-07-26","2022-06-21",[4963],[5142],{"nctId":5169,"briefTitle":5170,"status":107,"phases":5171,"primaryCompletion":5172,"completion":5173,"start":5174,"enrollment":5175,"conditions":5176,"interventions":5177},"NCT05113693","Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393",[89],"2021-12-06","2021-12-10","2021-11-25",33,[31],[5142,5178],"CKD-501, D759, H053",{"trials":5180,"activeCount":101},[],{"trials":5182,"activeCount":101},[],{"trials":5184,"activeCount":101},[],{"trials":5186,"activeCount":101},[],{"intervention":5188,"totalTrials":97,"cells":5189},"CKD-519",{"EARLY_PHASE1":5190,"PHASE1":5192,"PHASE2":5212,"PHASE3":5214,"PHASE4":5216,"NA":5218},{"trials":5191,"activeCount":101},[],{"trials":5193,"activeCount":101},[5194,5202,5207],{"nctId":5195,"briefTitle":5196,"status":107,"phases":5197,"primaryCompletion":5198,"completion":5198,"start":5199,"enrollment":4810,"conditions":5200,"interventions":5201},"NCT03210649","Study to Investigate the Safety\u002FTolerability and Pharmacokinetics\u002FPharmacodynamics of CKD-519",[89],"2017-04-24","2017-03-07",[34],[5188],{"nctId":5203,"briefTitle":5196,"status":107,"phases":5204,"primaryCompletion":1052,"completion":2043,"start":1028,"enrollment":4791,"conditions":5205,"interventions":5206},"NCT02156544",[89],[34],[5188],{"nctId":5208,"briefTitle":5196,"status":107,"phases":5209,"primaryCompletion":2646,"completion":2646,"start":2292,"enrollment":594,"conditions":5210,"interventions":5211},"NCT02753504",[89],[34],[5188],{"trials":5213,"activeCount":101},[],{"trials":5215,"activeCount":101},[],{"trials":5217,"activeCount":101},[],{"trials":5219,"activeCount":101},[],{"intervention":4922,"totalTrials":12,"cells":5221},{"EARLY_PHASE1":5222,"PHASE1":5224,"PHASE2":5234,"PHASE3":5236,"PHASE4":5238,"NA":5240},{"trials":5223,"activeCount":101},[],{"trials":5225,"activeCount":101},[5226,5230],{"nctId":4916,"briefTitle":4917,"status":107,"phases":5227,"primaryCompletion":2279,"completion":2279,"start":2043,"enrollment":4919,"conditions":5228,"interventions":5229},[89],[25],[4909,4922],{"nctId":4924,"briefTitle":4925,"status":107,"phases":5231,"primaryCompletion":1309,"completion":1309,"start":4927,"enrollment":3686,"conditions":5232,"interventions":5233},[89],[25],[4909,4922],{"trials":5235,"activeCount":101},[],{"trials":5237,"activeCount":101},[],{"trials":5239,"activeCount":101},[],{"trials":5241,"activeCount":101},[],{"intervention":5243,"totalTrials":12,"cells":5244},"CKD-581",{"EARLY_PHASE1":5245,"PHASE1":5247,"PHASE2":5266,"PHASE3":5268,"PHASE4":5270,"NA":5272},{"trials":5246,"activeCount":101},[],{"trials":5248,"activeCount":101},[5249,5258],{"nctId":5250,"briefTitle":5251,"status":126,"phases":5252,"primaryCompletion":2020,"completion":5253,"start":5254,"enrollment":4810,"conditions":5255,"interventions":5257},"NCT03051841","CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma",[89],"2022-11","2017-01",[5256],"Myeloma, Multiple",[5243],{"nctId":5259,"briefTitle":5260,"status":107,"phases":5261,"primaryCompletion":2922,"completion":4404,"start":2382,"enrollment":1569,"conditions":5262,"interventions":5265},"NCT01580371","Safety and Pharmacokinetic Profile of CKD-581",[89],[5263,5264],"Lymphoma","Multiple Myeloma",[5243],{"trials":5267,"activeCount":101},[],{"trials":5269,"activeCount":101},[],{"trials":5271,"activeCount":101},[],{"trials":5273,"activeCount":101},[],{"intervention":3887,"totalTrials":12,"cells":5275},{"EARLY_PHASE1":5276,"PHASE1":5278,"PHASE2":5288,"PHASE3":5290,"PHASE4":5292,"NA":5294},{"trials":5277,"activeCount":101},[],{"trials":5279,"activeCount":101},[5280,5284],{"nctId":5000,"briefTitle":5001,"status":107,"phases":5281,"primaryCompletion":5003,"completion":5003,"start":5004,"enrollment":594,"conditions":5282,"interventions":5283},[89],[25],[3887,5007,4993],{"nctId":3879,"briefTitle":3880,"status":107,"phases":5285,"primaryCompletion":3882,"completion":3882,"start":2506,"enrollment":3883,"conditions":5286,"interventions":5287},[89],[3885],[3887,3872],{"trials":5289,"activeCount":101},[],{"trials":5291,"activeCount":101},[],{"trials":5293,"activeCount":101},[],{"trials":5295,"activeCount":101},[],{"intervention":5007,"totalTrials":12,"cells":5297},{"EARLY_PHASE1":5298,"PHASE1":5300,"PHASE2":5315,"PHASE3":5317,"PHASE4":5319,"NA":5321},{"trials":5299,"activeCount":101},[],{"trials":5301,"activeCount":101},[5302,5306],{"nctId":5000,"briefTitle":5001,"status":107,"phases":5303,"primaryCompletion":5003,"completion":5003,"start":5004,"enrollment":594,"conditions":5304,"interventions":5305},[89],[25],[3887,5007,4993],{"nctId":5307,"briefTitle":5308,"status":107,"phases":5309,"primaryCompletion":1063,"completion":1063,"start":5310,"enrollment":1949,"conditions":5311,"interventions":5312},"NCT02047175","CKD-346 DDI Study(Telmisartan\u002FS-Amlodipine, Rosuvastatin)",[89],"2014-02",[15,3154],[5313,5007,5314,5314],"Telmisartan\u002FS-Amlodipine","Telmisartan\u002FS-Amlodipine + Rosuvastatin",{"trials":5316,"activeCount":101},[],{"trials":5318,"activeCount":101},[],{"trials":5320,"activeCount":101},[],{"trials":5322,"activeCount":101},[],{"intervention":5324,"totalTrials":12,"cells":5325},"CKD-375",{"EARLY_PHASE1":5326,"PHASE1":5328,"PHASE2":5350,"PHASE3":5352,"PHASE4":5354,"NA":5356},{"trials":5327,"activeCount":101},[],{"trials":5329,"activeCount":101},[5330,5340],{"nctId":5331,"briefTitle":5332,"status":126,"phases":5333,"primaryCompletion":5334,"completion":5335,"start":5336,"enrollment":112,"conditions":5337,"interventions":5338},"NCT03848637","The Clinical Trial to Investigate the Pharmacokinetics and Safety\u002FTolerability of CKD-375",[89],"2019-04-24","2019-05-01","2019-04-14",[23],[5324,5339],"D387",{"nctId":5341,"briefTitle":5342,"status":126,"phases":5343,"primaryCompletion":5344,"completion":5345,"start":5346,"enrollment":4666,"conditions":5347,"interventions":5348},"NCT04221360","A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-375",[89],"2020-03-06","2020-06-08","2020-01-29",[441],[5324,5349],"D390",{"trials":5351,"activeCount":101},[],{"trials":5353,"activeCount":101},[],{"trials":5355,"activeCount":101},[],{"trials":5357,"activeCount":101},[],{"intervention":5359,"totalTrials":12,"cells":5360},"CKD-386 Formulation 1",{"EARLY_PHASE1":5361,"PHASE1":5363,"PHASE2":5387,"PHASE3":5389,"PHASE4":5391,"NA":5393},{"trials":5362,"activeCount":101},[],{"trials":5364,"activeCount":101},[5365,5376],{"nctId":5366,"briefTitle":5367,"status":126,"phases":5368,"primaryCompletion":5369,"completion":5370,"start":5371,"enrollment":415,"conditions":5372,"interventions":5373},"NCT04223895","A Clinical Trial to Investigate the Pharmacokinetics and Safety\u002FTolerability of CKD-386 in Healthy Adult Volunteers",[89],"2020-03-04","2020-06-15","2020-02-01",[441],[5359,5374,5375],"CKD-386 Formulation 2","D012, D326 and D337",{"nctId":5377,"briefTitle":5378,"status":126,"phases":5379,"primaryCompletion":5380,"completion":5380,"start":5381,"enrollment":415,"conditions":5382,"interventions":5383},"NCT03920579","A Clinical Trial to Investigate the Pharmacokinetics and Safety\u002FTolerability of CKD-386 in Healthy Male Volunteers",[89],"2019-05","2019-04-01",[15,18],[5384,5385,5386],"CKD-386 formulation 1","CKD-386 formulation 2","D326, D337 and D013",{"trials":5388,"activeCount":101},[],{"trials":5390,"activeCount":101},[],{"trials":5392,"activeCount":101},[],{"trials":5394,"activeCount":101},[],{"intervention":5374,"totalTrials":12,"cells":5396},{"EARLY_PHASE1":5397,"PHASE1":5399,"PHASE2":5409,"PHASE3":5411,"PHASE4":5413,"NA":5415},{"trials":5398,"activeCount":101},[],{"trials":5400,"activeCount":101},[5401,5405],{"nctId":5366,"briefTitle":5367,"status":126,"phases":5402,"primaryCompletion":5369,"completion":5370,"start":5371,"enrollment":415,"conditions":5403,"interventions":5404},[89],[441],[5359,5374,5375],{"nctId":5377,"briefTitle":5378,"status":126,"phases":5406,"primaryCompletion":5380,"completion":5380,"start":5381,"enrollment":415,"conditions":5407,"interventions":5408},[89],[15,18],[5384,5385,5386],{"trials":5410,"activeCount":101},[],{"trials":5412,"activeCount":101},[],{"trials":5414,"activeCount":101},[],{"trials":5416,"activeCount":101},[],{"intervention":5418,"totalTrials":12,"cells":5419},"NESP 60μg",{"EARLY_PHASE1":5420,"PHASE1":5422,"PHASE2":5444,"PHASE3":5446,"PHASE4":5448,"NA":5450},{"trials":5421,"activeCount":101},[],{"trials":5423,"activeCount":101},[5424,5435],{"nctId":5425,"briefTitle":5426,"status":107,"phases":5427,"primaryCompletion":5428,"completion":5429,"start":5430,"enrollment":3726,"conditions":5431,"interventions":5433},"NCT01685671","Pharmacokinetics Study of CKD-11101 and NESP After SC Administration in Health Male Volunteers",[89],"2012-12-25","2013-01-15","2012-10-26",[5432],"Anemia",[5418,5434],"CKD-11101 60μg",{"nctId":5436,"briefTitle":5437,"status":107,"phases":5438,"primaryCompletion":5439,"completion":5440,"start":5441,"enrollment":485,"conditions":5442,"interventions":5443},"NCT01684605","Pharmacokinetics Study of CKD-11101 and NESP After IV Administration in Health Male Volunteers",[89],"2012-11-13","2013-01-03","2012-10-12",[5432],[5418,5434],{"trials":5445,"activeCount":101},[],{"trials":5447,"activeCount":101},[],{"trials":5449,"activeCount":101},[],{"trials":5451,"activeCount":101},[],{"intervention":5434,"totalTrials":12,"cells":5453},{"EARLY_PHASE1":5454,"PHASE1":5456,"PHASE2":5466,"PHASE3":5468,"PHASE4":5470,"NA":5472},{"trials":5455,"activeCount":101},[],{"trials":5457,"activeCount":101},[5458,5462],{"nctId":5425,"briefTitle":5426,"status":107,"phases":5459,"primaryCompletion":5428,"completion":5429,"start":5430,"enrollment":3726,"conditions":5460,"interventions":5461},[89],[5432],[5418,5434],{"nctId":5436,"briefTitle":5437,"status":107,"phases":5463,"primaryCompletion":5439,"completion":5440,"start":5441,"enrollment":485,"conditions":5464,"interventions":5465},[89],[5432],[5418,5434],{"trials":5467,"activeCount":101},[],{"trials":5469,"activeCount":101},[],{"trials":5471,"activeCount":101},[],{"trials":5473,"activeCount":101},[],{"intervention":5475,"totalTrials":12,"cells":5476},"CKD-501, D759, D150",{"EARLY_PHASE1":5477,"PHASE1":5479,"PHASE2":5501,"PHASE3":5503,"PHASE4":5505,"NA":5507},{"trials":5478,"activeCount":101},[],{"trials":5480,"activeCount":101},[5481,5491],{"nctId":5482,"briefTitle":5483,"status":107,"phases":5484,"primaryCompletion":5485,"completion":5486,"start":5370,"enrollment":781,"conditions":5487,"interventions":5488},"NCT04431687","A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)",[89],"2020-07-24","2020-10-26",[23],[5489,5490,5475],"CKD 501","D759, D150",{"nctId":5492,"briefTitle":5493,"status":126,"phases":5494,"primaryCompletion":5495,"completion":3947,"start":5496,"enrollment":4666,"conditions":5497,"interventions":5499},"NCT04706286","Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393",[89],"2021-03-29","2021-02-18",[5498],"T2DM (Type 2 Diabetes Mellitus)",[5475,5500],"CKD-393 0.5\u002F100\u002F1000 mg",{"trials":5502,"activeCount":101},[],{"trials":5504,"activeCount":101},[],{"trials":5506,"activeCount":101},[],{"trials":5508,"activeCount":101},[],{"intervention":5510,"totalTrials":12,"cells":5511},"D418 Tab.",{"EARLY_PHASE1":5512,"PHASE1":5514,"PHASE2":5537,"PHASE3":5539,"PHASE4":5541,"NA":5543},{"trials":5513,"activeCount":101},[],{"trials":5515,"activeCount":101},[5516,5527],{"nctId":5517,"briefTitle":5518,"status":107,"phases":5519,"primaryCompletion":5520,"completion":5521,"start":5522,"enrollment":1997,"conditions":5523,"interventions":5525},"NCT05189288","Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388(2) in Healthy Subjects",[89],"2022-03-12","2022-04-15","2022-01-14",[5524],"Chronic Hepatitis b",[5510,5526],"CKD-388 Tab.",{"nctId":5528,"briefTitle":5529,"status":126,"phases":5530,"primaryCompletion":5531,"completion":5532,"start":5533,"enrollment":5534,"conditions":5535,"interventions":5536},"NCT04676893","Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388 in Healthy Subjects",[89],"2021-05-11","2021-05-18","2021-02-26",56,[5524],[5510,5526],{"trials":5538,"activeCount":101},[],{"trials":5540,"activeCount":101},[],{"trials":5542,"activeCount":101},[],{"trials":5544,"activeCount":101},[],{"intervention":5526,"totalTrials":12,"cells":5546},{"EARLY_PHASE1":5547,"PHASE1":5549,"PHASE2":5559,"PHASE3":5561,"PHASE4":5563,"NA":5565},{"trials":5548,"activeCount":101},[],{"trials":5550,"activeCount":101},[5551,5555],{"nctId":5517,"briefTitle":5518,"status":107,"phases":5552,"primaryCompletion":5520,"completion":5521,"start":5522,"enrollment":1997,"conditions":5553,"interventions":5554},[89],[5524],[5510,5526],{"nctId":5528,"briefTitle":5529,"status":126,"phases":5556,"primaryCompletion":5531,"completion":5532,"start":5533,"enrollment":5534,"conditions":5557,"interventions":5558},[89],[5524],[5510,5526],{"trials":5560,"activeCount":101},[],{"trials":5562,"activeCount":101},[],{"trials":5564,"activeCount":101},[],{"trials":5566,"activeCount":101},[],{"intervention":2049,"totalTrials":12,"cells":5568},{"EARLY_PHASE1":5569,"PHASE1":5571,"PHASE2":5585,"PHASE3":5587,"PHASE4":5589,"NA":5591},{"trials":5570,"activeCount":101},[],{"trials":5572,"activeCount":101},[5573,5581],{"nctId":5574,"briefTitle":5575,"status":107,"phases":5576,"primaryCompletion":1087,"completion":5577,"start":2100,"enrollment":451,"conditions":5578,"interventions":5579},"NCT02186496","Bioequivalence Study (Candesartan 8 mg and Amlodipine 5 mg)",[89],"2014-11",[15],[2049,5580],"Candesartan 8mg and Amlodipine 5mg",{"nctId":2040,"briefTitle":2041,"status":107,"phases":5582,"primaryCompletion":2043,"completion":2044,"start":2043,"enrollment":2045,"conditions":5583,"interventions":5584},[89],[15],[2048,2032,2049],{"trials":5586,"activeCount":101},[],{"trials":5588,"activeCount":101},[],{"trials":5590,"activeCount":101},[],{"trials":5592,"activeCount":101},[],{"intervention":5594,"totalTrials":12,"cells":5595},"Cialis Tab. 5mg",{"EARLY_PHASE1":5596,"PHASE1":5598,"PHASE2":5615,"PHASE3":5617,"PHASE4":5619,"NA":5621},{"trials":5597,"activeCount":101},[],{"trials":5599,"activeCount":101},[5600,5607],{"nctId":5601,"briefTitle":5602,"status":107,"phases":5603,"primaryCompletion":1052,"completion":789,"start":790,"enrollment":3716,"conditions":5604,"interventions":5605},"NCT02247518","CKD-397 Drug-drug Interaction Study (A)",[89],[25],[5594,5606],"Harnal-D Cap. 0.2mg",{"nctId":5608,"briefTitle":5609,"status":107,"phases":5610,"primaryCompletion":1052,"completion":789,"start":790,"enrollment":5611,"conditions":5612,"interventions":5614},"NCT02247505","CKD-397 Drug-drug Interaction Study (B)",[89],29,[5613],"Healty Male Volunteers",[5606,5594],{"trials":5616,"activeCount":101},[],{"trials":5618,"activeCount":101},[],{"trials":5620,"activeCount":101},[],{"trials":5622,"activeCount":101},[],{"intervention":5606,"totalTrials":12,"cells":5624},{"EARLY_PHASE1":5625,"PHASE1":5627,"PHASE2":5637,"PHASE3":5639,"PHASE4":5641,"NA":5643},{"trials":5626,"activeCount":101},[],{"trials":5628,"activeCount":101},[5629,5633],{"nctId":5601,"briefTitle":5602,"status":107,"phases":5630,"primaryCompletion":1052,"completion":789,"start":790,"enrollment":3716,"conditions":5631,"interventions":5632},[89],[25],[5594,5606],{"nctId":5608,"briefTitle":5609,"status":107,"phases":5634,"primaryCompletion":1052,"completion":789,"start":790,"enrollment":5611,"conditions":5635,"interventions":5636},[89],[5613],[5606,5594],{"trials":5638,"activeCount":101},[],{"trials":5640,"activeCount":101},[],{"trials":5642,"activeCount":101},[],{"trials":5644,"activeCount":101},[],{"intervention":5646,"totalTrials":12,"cells":5647},"Fixed dose combination of clopidogrel\u002FAspirin",{"EARLY_PHASE1":5648,"PHASE1":5650,"PHASE2":5669,"PHASE3":5671,"PHASE4":5673,"NA":5675},{"trials":5649,"activeCount":101},[],{"trials":5651,"activeCount":101},[5652,5661],{"nctId":5653,"briefTitle":5654,"status":107,"phases":5655,"primaryCompletion":2008,"completion":2369,"start":1995,"enrollment":675,"conditions":5656,"interventions":5658},"NCT01663038","Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination",[89],[5657],"Coronary Artery Disease",[5659,5646,5660],"Clopidogrel","Aspirin",{"nctId":5662,"briefTitle":5663,"status":107,"phases":5664,"primaryCompletion":2369,"completion":2369,"start":2206,"enrollment":675,"conditions":5665,"interventions":5666},"NCT01496261","Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination-2nd Trial",[89],[5657],[5667,5668],"Clopidogrel and Aspirin","Fixed dose combination of clopidogrel\u002Faspirin",{"trials":5670,"activeCount":101},[],{"trials":5672,"activeCount":101},[],{"trials":5674,"activeCount":101},[],{"trials":5676,"activeCount":101},[],{"intervention":5678,"totalTrials":12,"cells":5679},"Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg",{"EARLY_PHASE1":5680,"PHASE1":5682,"PHASE2":5699,"PHASE3":5701,"PHASE4":5703,"NA":5705},{"trials":5681,"activeCount":101},[],{"trials":5683,"activeCount":101},[5684,5692],{"nctId":5685,"briefTitle":5686,"status":107,"phases":5687,"primaryCompletion":2193,"completion":5688,"start":1568,"enrollment":594,"conditions":5689,"interventions":5690},"NCT01842230","Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan\u002FS-amlodipine",[89],"2013-07",[28,3154],[5678,5691],"Telmisartan 80mg and S-amlodipine 5mg",{"nctId":5693,"briefTitle":5694,"status":107,"phases":5695,"primaryCompletion":2193,"completion":5688,"start":1568,"enrollment":594,"conditions":5696,"interventions":5697},"NCT01842256","Study to Investigate the Effect of Telmisartan\u002FS-amlodipine on the Pharmacokinetic Properties of Atorvastatin.",[89],[28,3154],[5678,5698],"atorvastatin 40mg",{"trials":5700,"activeCount":101},[],{"trials":5702,"activeCount":101},[],{"trials":5704,"activeCount":101},[],{"trials":5706,"activeCount":101},[],{"intervention":5708,"totalTrials":12,"cells":5709},"CKD-397",{"EARLY_PHASE1":5710,"PHASE1":5712,"PHASE2":5729,"PHASE3":5731,"PHASE4":5733,"NA":5735},{"trials":5711,"activeCount":101},[],{"trials":5713,"activeCount":101},[5714,5722],{"nctId":5715,"briefTitle":5716,"status":107,"phases":5717,"primaryCompletion":2279,"completion":2279,"start":5718,"enrollment":9,"conditions":5719,"interventions":5720},"NCT02645890","Study to Compare the Safety and Pharmacokinetics of CKD-397",[89],"2015-11",[3290],[5708,5721],"TD+TM",{"nctId":5723,"briefTitle":5724,"status":107,"phases":5725,"primaryCompletion":2292,"completion":2647,"start":2279,"enrollment":3716,"conditions":5726,"interventions":5728},"NCT02615782","A Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 in Healthy Male Subjects",[89],[5727],"Benign Prostatic Hypertrophy (BPH)",[5708],{"trials":5730,"activeCount":101},[],{"trials":5732,"activeCount":101},[],{"trials":5734,"activeCount":101},[],{"trials":5736,"activeCount":101},[],{"intervention":4983,"totalTrials":12,"cells":5738},{"EARLY_PHASE1":5739,"PHASE1":5741,"PHASE2":5757,"PHASE3":5759,"PHASE4":5761,"NA":5763},{"trials":5740,"activeCount":101},[],{"trials":5742,"activeCount":101},[5743,5753],{"nctId":5744,"briefTitle":5745,"status":107,"phases":5746,"primaryCompletion":5747,"completion":5748,"start":5164,"enrollment":594,"conditions":5749,"interventions":5750},"NCT05452525","Pharmacokinetics and Safety\u002FTolerability Profile of CKD-379",[89],"2022-08-27","2022-09-21",[4963],[5751,5752,4983],"CKD-379 I","CKD-379 II",{"nctId":4976,"briefTitle":4977,"status":107,"phases":5754,"primaryCompletion":4979,"completion":4980,"start":4568,"enrollment":451,"conditions":5755,"interventions":5756},[89],[4963],[4949,4983],{"trials":5758,"activeCount":101},[],{"trials":5760,"activeCount":101},[],{"trials":5762,"activeCount":101},[],{"trials":5764,"activeCount":101},[],{"intervention":4551,"totalTrials":12,"cells":5766},{"EARLY_PHASE1":5767,"PHASE1":5769,"PHASE2":5779,"PHASE3":5781,"PHASE4":5783,"NA":5785},{"trials":5768,"activeCount":101},[],{"trials":5770,"activeCount":101},[5771,5775],{"nctId":4543,"briefTitle":4544,"status":126,"phases":5772,"primaryCompletion":4546,"completion":4547,"start":4548,"enrollment":9,"conditions":5773,"interventions":5774},[89],[441],[4526,4551],{"nctId":4573,"briefTitle":4574,"status":126,"phases":5776,"primaryCompletion":4576,"completion":4577,"start":4578,"enrollment":4579,"conditions":5777,"interventions":5778},[89],[23],[4526,4551],{"trials":5780,"activeCount":101},[],{"trials":5782,"activeCount":101},[],{"trials":5784,"activeCount":101},[],{"trials":5786,"activeCount":101},[],{"intervention":5788,"totalTrials":12,"cells":5789},"CKD-843-R",{"EARLY_PHASE1":5790,"PHASE1":5792,"PHASE2":5815,"PHASE3":5817,"PHASE4":5819,"NA":5821},{"trials":5791,"activeCount":101},[],{"trials":5793,"activeCount":101},[5794,5804],{"nctId":5795,"briefTitle":5796,"status":107,"phases":5797,"primaryCompletion":5798,"completion":5798,"start":1846,"enrollment":2280,"conditions":5799,"interventions":5801},"NCT04805606","A Clinical Traial to Assess Pharmacokinetic\u002FPharmacodynamic Profiles and Safety of CKD-843",[89],"2021-12-24",[5800],"Alopecia",[5802,5803,5788],"CKD-843 A","CKD-843 B",{"nctId":5805,"briefTitle":5806,"status":107,"phases":5807,"primaryCompletion":5808,"completion":5809,"start":5810,"enrollment":4791,"conditions":5811,"interventions":5812},"NCT05587699","The Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A",[89],"2023-09-15","2023-10-17","2022-11-15",[5800],[5813,5813,5814,5814,5788],"CKD-843 A 45mg","CKD-843 A 55mg",{"trials":5816,"activeCount":101},[],{"trials":5818,"activeCount":101},[],{"trials":5820,"activeCount":101},[],{"trials":5822,"activeCount":101},[],{"intervention":5824,"totalTrials":12,"cells":5825},"CKD-333 Tab.",{"EARLY_PHASE1":5826,"PHASE1":5828,"PHASE2":5852,"PHASE3":5854,"PHASE4":5856,"NA":5858},{"trials":5827,"activeCount":101},[],{"trials":5829,"activeCount":101},[5830,5842],{"nctId":5831,"briefTitle":5832,"status":126,"phases":5833,"primaryCompletion":5834,"completion":5835,"start":5836,"enrollment":5837,"conditions":5838,"interventions":5840},"NCT04478097","Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers",[89],"2020-11-05","2021-01-01","2020-07-14",51,[5839],"Cardiovascular Disease",[5841,5824],"CKD-330 Tab. and D086 Tab.",{"nctId":5843,"briefTitle":5844,"status":126,"phases":5845,"primaryCompletion":5846,"completion":5847,"start":5848,"enrollment":5837,"conditions":5849,"interventions":5850},"NCT04611932","Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-333 Low Dose in Healthy Volunteers",[89],"2021-03-10","2021-04-27","2020-11-11",[5839],[5851,5824],"CKD-330 Tab. and D090 Tab.",{"trials":5853,"activeCount":101},[],{"trials":5855,"activeCount":101},[],{"trials":5857,"activeCount":101},[],{"trials":5859,"activeCount":101},[],{"intervention":5861,"totalTrials":12,"cells":5862},"CKD-385",{"EARLY_PHASE1":5863,"PHASE1":5865,"PHASE2":5882,"PHASE3":5884,"PHASE4":5886,"NA":5888},{"trials":5864,"activeCount":101},[],{"trials":5866,"activeCount":101},[5867,5875],{"nctId":5868,"briefTitle":3693,"status":126,"phases":5869,"primaryCompletion":5870,"completion":5871,"start":4457,"enrollment":3686,"conditions":5872,"interventions":5873},"NCT04906785",[89],"2021-07-30","2021-08-06",[3688],[5861,5874],"D744",{"nctId":5876,"briefTitle":3703,"status":126,"phases":5877,"primaryCompletion":5878,"completion":5879,"start":4457,"enrollment":3686,"conditions":5880,"interventions":5881},"NCT04906798",[89],"2021-07-16","2021-07-23",[3688],[5861,5874],{"trials":5883,"activeCount":101},[],{"trials":5885,"activeCount":101},[],{"trials":5887,"activeCount":101},[],{"trials":5889,"activeCount":101},[],{"intervention":5874,"totalTrials":12,"cells":5891},{"EARLY_PHASE1":5892,"PHASE1":5894,"PHASE2":5904,"PHASE3":5906,"PHASE4":5908,"NA":5910},{"trials":5893,"activeCount":101},[],{"trials":5895,"activeCount":101},[5896,5900],{"nctId":5868,"briefTitle":3693,"status":126,"phases":5897,"primaryCompletion":5870,"completion":5871,"start":4457,"enrollment":3686,"conditions":5898,"interventions":5899},[89],[3688],[5861,5874],{"nctId":5876,"briefTitle":3703,"status":126,"phases":5901,"primaryCompletion":5878,"completion":5879,"start":4457,"enrollment":3686,"conditions":5902,"interventions":5903},[89],[3688],[5861,5874],{"trials":5905,"activeCount":101},[],{"trials":5907,"activeCount":101},[],{"trials":5909,"activeCount":101},[],{"trials":5911,"activeCount":101},[],{"intervention":454,"totalTrials":12,"cells":5913},{"EARLY_PHASE1":5914,"PHASE1":5916,"PHASE2":5931,"PHASE3":5933,"PHASE4":5935,"NA":5937},{"trials":5915,"activeCount":101},[],{"trials":5917,"activeCount":101},[5918,5922],{"nctId":445,"briefTitle":446,"status":107,"phases":5919,"primaryCompletion":448,"completion":449,"start":450,"enrollment":451,"conditions":5920,"interventions":5921},[89],[31],[41,454],{"nctId":5923,"briefTitle":5924,"status":107,"phases":5925,"primaryCompletion":5926,"completion":5927,"start":3742,"enrollment":415,"conditions":5928,"interventions":5929},"NCT07304700","Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5\u002F10\u002F1000mg in Healthy Volunteers",[89],"2025-11-07","2025-11-12",[31],[5930,454],"CKD-383 0.5\u002F10\u002F1000mg",{"trials":5932,"activeCount":101},[],{"trials":5934,"activeCount":101},[],{"trials":5936,"activeCount":101},[],{"trials":5938,"activeCount":101},[],{"intervention":5940,"totalTrials":12,"cells":5941},"Harnal-D Tab.",{"EARLY_PHASE1":5942,"PHASE1":5944,"PHASE2":5962,"PHASE3":5964,"PHASE4":5966,"NA":5968},{"trials":5943,"activeCount":101},[],{"trials":5945,"activeCount":101},[5946,5956],{"nctId":5947,"briefTitle":5948,"status":107,"phases":5949,"primaryCompletion":5950,"completion":5951,"start":5952,"enrollment":415,"conditions":5953,"interventions":5954},"NCT03887858","Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. \"Harnal-D\" in Healthy Volunteers",[89],"2019-03-22","2019-05-07","2019-03-11",[3290],[5940,5955],"Chong Kun Dang Tamsulosin HCl Tab.",{"nctId":5957,"briefTitle":5958,"status":107,"phases":5959,"primaryCompletion":5950,"completion":3021,"start":5952,"enrollment":415,"conditions":5960,"interventions":5961},"NCT03887871","Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. \"Harnal-D\" in Healthy Volunteers After Meal",[89],[3290],[5940,5955],{"trials":5963,"activeCount":101},[],{"trials":5965,"activeCount":101},[],{"trials":5967,"activeCount":101},[],{"trials":5969,"activeCount":101},[],{"intervention":5955,"totalTrials":12,"cells":5971},{"EARLY_PHASE1":5972,"PHASE1":5974,"PHASE2":5984,"PHASE3":5986,"PHASE4":5988,"NA":5990},{"trials":5973,"activeCount":101},[],{"trials":5975,"activeCount":101},[5976,5980],{"nctId":5947,"briefTitle":5948,"status":107,"phases":5977,"primaryCompletion":5950,"completion":5951,"start":5952,"enrollment":415,"conditions":5978,"interventions":5979},[89],[3290],[5940,5955],{"nctId":5957,"briefTitle":5958,"status":107,"phases":5981,"primaryCompletion":5950,"completion":3021,"start":5952,"enrollment":415,"conditions":5982,"interventions":5983},[89],[3290],[5940,5955],{"trials":5985,"activeCount":101},[],{"trials":5987,"activeCount":101},[],{"trials":5989,"activeCount":101},[],{"trials":5991,"activeCount":101},[],{"intervention":5993,"totalTrials":12,"cells":5994},"CKD-337",{"EARLY_PHASE1":5995,"PHASE1":5997,"PHASE2":6013,"PHASE3":6015,"PHASE4":6017,"NA":6019},{"trials":5996,"activeCount":101},[],{"trials":5998,"activeCount":101},[5999,6005],{"nctId":6000,"briefTitle":4850,"status":107,"phases":6001,"primaryCompletion":2922,"completion":2647,"start":2069,"enrollment":781,"conditions":6002,"interventions":6003},"NCT02651753",[89],[34],[6004,5993],"Lipitor + Lipidil supra",{"nctId":6006,"briefTitle":6007,"status":107,"phases":6008,"primaryCompletion":6009,"completion":1859,"start":6010,"enrollment":3716,"conditions":6011,"interventions":6012},"NCT03382756","A Clinical Trial to Assess the Effects of Food on the Bioavailability of CKD-337",[89],"2017-11-02","2017-10-12",[18],[5993],{"trials":6014,"activeCount":101},[],{"trials":6016,"activeCount":101},[],{"trials":6018,"activeCount":101},[],{"trials":6020,"activeCount":101},[],{"intervention":6022,"totalTrials":12,"cells":6023},"Candesartan 16mg and Amlodipine 5mg",{"EARLY_PHASE1":6024,"PHASE1":6026,"PHASE2":6042,"PHASE3":6044,"PHASE4":6046,"NA":6048},{"trials":6025,"activeCount":101},[],{"trials":6027,"activeCount":101},[6028,6035],{"nctId":6029,"briefTitle":6030,"status":107,"phases":6031,"primaryCompletion":778,"completion":2043,"start":852,"enrollment":451,"conditions":6032,"interventions":6033},"NCT02811731","Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - B",[89],[15],[6034,6022],"CKD-330 16\u002F5mg - B",{"nctId":6036,"briefTitle":6037,"status":107,"phases":6038,"primaryCompletion":778,"completion":2043,"start":852,"enrollment":451,"conditions":6039,"interventions":6040},"NCT02801526","Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - A",[89],[15],[6041,6022],"CKD-330 16\u002F5mg - A",{"trials":6043,"activeCount":101},[],{"trials":6045,"activeCount":101},[],{"trials":6047,"activeCount":101},[],{"trials":6049,"activeCount":101},[],{"intervention":6051,"totalTrials":12,"cells":6052},"Lixiana",{"EARLY_PHASE1":6053,"PHASE1":6055,"PHASE2":6077,"PHASE3":6079,"PHASE4":6081,"NA":6083},{"trials":6054,"activeCount":101},[],{"trials":6056,"activeCount":101},[6057,6067],{"nctId":6058,"briefTitle":6059,"status":126,"phases":6060,"primaryCompletion":6061,"completion":6062,"start":5847,"enrollment":675,"conditions":6063,"interventions":6065},"NCT04867200","A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Volunteers",[89],"2021-05-25","2021-06-01",[6064],"Anticoagulant",[6051,6066],"CKD-344",{"nctId":6068,"briefTitle":6069,"status":126,"phases":6070,"primaryCompletion":6071,"completion":6072,"start":6073,"enrollment":6074,"conditions":6075,"interventions":6076},"NCT04673695","A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344",[89],"2020-12-26","2021-01-02","2020-11-13",50,[6064],[6051,6066],{"trials":6078,"activeCount":101},[],{"trials":6080,"activeCount":101},[],{"trials":6082,"activeCount":101},[],{"trials":6084,"activeCount":101},[],{"intervention":6066,"totalTrials":12,"cells":6086},{"EARLY_PHASE1":6087,"PHASE1":6089,"PHASE2":6099,"PHASE3":6101,"PHASE4":6103,"NA":6105},{"trials":6088,"activeCount":101},[],{"trials":6090,"activeCount":101},[6091,6095],{"nctId":6058,"briefTitle":6059,"status":126,"phases":6092,"primaryCompletion":6061,"completion":6062,"start":5847,"enrollment":675,"conditions":6093,"interventions":6094},[89],[6064],[6051,6066],{"nctId":6068,"briefTitle":6069,"status":126,"phases":6096,"primaryCompletion":6071,"completion":6072,"start":6073,"enrollment":6074,"conditions":6097,"interventions":6098},[89],[6064],[6051,6066],{"trials":6100,"activeCount":101},[],{"trials":6102,"activeCount":101},[],{"trials":6104,"activeCount":101},[],{"trials":6106,"activeCount":101},[],{"intervention":6108,"totalTrials":12,"cells":6109},"CKD-519 200mg",{"EARLY_PHASE1":6110,"PHASE1":6112,"PHASE2":6129,"PHASE3":6131,"PHASE4":6133,"NA":6135},{"trials":6111,"activeCount":101},[],{"trials":6113,"activeCount":101},[6114,6121],{"nctId":6115,"briefTitle":6116,"status":107,"phases":6117,"primaryCompletion":863,"completion":5254,"start":2067,"enrollment":451,"conditions":6118,"interventions":6120},"NCT02916901","Study to Investigate the Influence of CKD-519 on 24-h Ambulatory Blood Pressure in Healthy Adult Volunteers",[89],[6119],"Healthy Volunteers",[6108],{"nctId":6122,"briefTitle":6123,"status":107,"phases":6124,"primaryCompletion":6125,"completion":5254,"start":2067,"enrollment":781,"conditions":6126,"interventions":6127},"NCT02894541","Study to Investigate the Effects of Food on the Pharmacokinetics\u002FPharmacodynamics of CKD-519",[89],"2016-11",[6119],[6128,6108,6128,6108],"CKD-519 100mg",{"trials":6130,"activeCount":101},[],{"trials":6132,"activeCount":101},[],{"trials":6134,"activeCount":101},[],{"trials":6136,"activeCount":101},[],{"intervention":2283,"totalTrials":144,"cells":6138},{"EARLY_PHASE1":6139,"PHASE1":6141,"PHASE2":6147,"PHASE3":6149,"PHASE4":6151,"NA":6153},{"trials":6140,"activeCount":101},[],{"trials":6142,"activeCount":101},[6143],{"nctId":2276,"briefTitle":2277,"status":107,"phases":6144,"primaryCompletion":2279,"completion":2279,"start":1309,"enrollment":2280,"conditions":6145,"interventions":6146},[89],[1221],[2269,2283],{"trials":6148,"activeCount":101},[],{"trials":6150,"activeCount":101},[],{"trials":6152,"activeCount":101},[],{"trials":6154,"activeCount":101},[],{"intervention":6156,"totalTrials":144,"cells":6157},"D935 Cap. 1T",{"EARLY_PHASE1":6158,"PHASE1":6160,"PHASE2":6171,"PHASE3":6173,"PHASE4":6175,"NA":6177},{"trials":6159,"activeCount":101},[],{"trials":6161,"activeCount":101},[6162],{"nctId":6163,"briefTitle":6164,"status":126,"phases":6165,"primaryCompletion":6166,"completion":6166,"start":6167,"enrollment":3686,"conditions":6168,"interventions":6169},"NCT03748212","Clinical Trial to Evaluate Pharmacokinetic Profiles and Safety Between CKD-385 and D935 in Healthy Volunteers",[89],"2018-12","2018-10-24",[15],[6156,6170],"CKD-385 Tab. 1T",{"trials":6172,"activeCount":101},[],{"trials":6174,"activeCount":101},[],{"trials":6176,"activeCount":101},[],{"trials":6178,"activeCount":101},[],{"intervention":6170,"totalTrials":144,"cells":6180},{"EARLY_PHASE1":6181,"PHASE1":6183,"PHASE2":6189,"PHASE3":6191,"PHASE4":6193,"NA":6195},{"trials":6182,"activeCount":101},[],{"trials":6184,"activeCount":101},[6185],{"nctId":6163,"briefTitle":6164,"status":126,"phases":6186,"primaryCompletion":6166,"completion":6166,"start":6167,"enrollment":3686,"conditions":6187,"interventions":6188},[89],[15],[6156,6170],{"trials":6190,"activeCount":101},[],{"trials":6192,"activeCount":101},[],{"trials":6194,"activeCount":101},[],{"trials":6196,"activeCount":101},[],{"intervention":1910,"totalTrials":144,"cells":6198},{"EARLY_PHASE1":6199,"PHASE1":6201,"PHASE2":6207,"PHASE3":6209,"PHASE4":6211,"NA":6213},{"trials":6200,"activeCount":101},[],{"trials":6202,"activeCount":101},[6203],{"nctId":1902,"briefTitle":1903,"status":107,"phases":6204,"primaryCompletion":1905,"completion":1906,"start":1907,"enrollment":485,"conditions":6205,"interventions":6206},[89],[21],[1910,1911,1895],{"trials":6208,"activeCount":101},[],{"trials":6210,"activeCount":101},[],{"trials":6212,"activeCount":101},[],{"trials":6214,"activeCount":101},[],{"intervention":1911,"totalTrials":144,"cells":6216},{"EARLY_PHASE1":6217,"PHASE1":6219,"PHASE2":6225,"PHASE3":6227,"PHASE4":6229,"NA":6231},{"trials":6218,"activeCount":101},[],{"trials":6220,"activeCount":101},[6221],{"nctId":1902,"briefTitle":1903,"status":107,"phases":6222,"primaryCompletion":1905,"completion":1906,"start":1907,"enrollment":485,"conditions":6223,"interventions":6224},[89],[21],[1910,1911,1895],{"trials":6226,"activeCount":101},[],{"trials":6228,"activeCount":101},[],{"trials":6230,"activeCount":101},[],{"trials":6232,"activeCount":101},[],{"intervention":6234,"totalTrials":144,"cells":6235},"D064+D701",{"EARLY_PHASE1":6236,"PHASE1":6238,"PHASE2":6249,"PHASE3":6251,"PHASE4":6253,"NA":6255},{"trials":6237,"activeCount":101},[],{"trials":6239,"activeCount":101},[6240],{"nctId":6241,"briefTitle":6242,"status":107,"phases":6243,"primaryCompletion":5810,"completion":2494,"start":6244,"enrollment":415,"conditions":6245,"interventions":6246},"NCT05540912","Exploratory Trial to Evaluate the Pharmacokinetic Properties and Safety of CKD-828 in Healthy Subjects",[89],"2022-09-15",[15],[6234,6247,6248],"CKD-828 Formulation 1","CKD-828 Formulation 2",{"trials":6250,"activeCount":101},[],{"trials":6252,"activeCount":101},[],{"trials":6254,"activeCount":101},[],{"trials":6256,"activeCount":101},[],{"intervention":6247,"totalTrials":144,"cells":6258},{"EARLY_PHASE1":6259,"PHASE1":6261,"PHASE2":6267,"PHASE3":6269,"PHASE4":6271,"NA":6273},{"trials":6260,"activeCount":101},[],{"trials":6262,"activeCount":101},[6263],{"nctId":6241,"briefTitle":6242,"status":107,"phases":6264,"primaryCompletion":5810,"completion":2494,"start":6244,"enrollment":415,"conditions":6265,"interventions":6266},[89],[15],[6234,6247,6248],{"trials":6268,"activeCount":101},[],{"trials":6270,"activeCount":101},[],{"trials":6272,"activeCount":101},[],{"trials":6274,"activeCount":101},[],{"intervention":6248,"totalTrials":144,"cells":6276},{"EARLY_PHASE1":6277,"PHASE1":6279,"PHASE2":6285,"PHASE3":6287,"PHASE4":6289,"NA":6291},{"trials":6278,"activeCount":101},[],{"trials":6280,"activeCount":101},[6281],{"nctId":6241,"briefTitle":6242,"status":107,"phases":6282,"primaryCompletion":5810,"completion":2494,"start":6244,"enrollment":415,"conditions":6283,"interventions":6284},[89],[15],[6234,6247,6248],{"trials":6286,"activeCount":101},[],{"trials":6288,"activeCount":101},[],{"trials":6290,"activeCount":101},[],{"trials":6292,"activeCount":101},[],{"intervention":6294,"totalTrials":144,"cells":6295},"CKD-504",{"EARLY_PHASE1":6296,"PHASE1":6298,"PHASE2":6309,"PHASE3":6311,"PHASE4":6313,"NA":6315},{"trials":6297,"activeCount":101},[],{"trials":6299,"activeCount":101},[6300],{"nctId":6301,"briefTitle":6302,"status":126,"phases":6303,"primaryCompletion":6304,"completion":6304,"start":6305,"enrollment":5014,"conditions":6306,"interventions":6308},"NCT03713892","CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects",[89],"2020-12","2018-05-23",[6307],"Huntington Disease",[6294],{"trials":6310,"activeCount":101},[],{"trials":6312,"activeCount":101},[],{"trials":6314,"activeCount":101},[],{"trials":6316,"activeCount":101},[],{"intervention":6318,"totalTrials":144,"cells":6319},"D308, CKD-501",{"EARLY_PHASE1":6320,"PHASE1":6322,"PHASE2":6334,"PHASE3":6336,"PHASE4":6338,"NA":6340},{"trials":6321,"activeCount":101},[],{"trials":6323,"activeCount":101},[6324],{"nctId":6325,"briefTitle":6326,"status":107,"phases":6327,"primaryCompletion":6328,"completion":6329,"start":6330,"enrollment":4791,"conditions":6331,"interventions":6333},"NCT03616392","Clinical Trial to Evaluate the Drug Drug Interaction of CKD-501 and D308",[89],"2018-09-17","2018-11-13","2018-07-25",[6332],"Diabetes Mellitus, Type II",[6318],{"trials":6335,"activeCount":101},[],{"trials":6337,"activeCount":101},[],{"trials":6339,"activeCount":101},[],{"trials":6341,"activeCount":101},[],{"intervention":2316,"totalTrials":144,"cells":6343},{"EARLY_PHASE1":6344,"PHASE1":6346,"PHASE2":6352,"PHASE3":6354,"PHASE4":6356,"NA":6358},{"trials":6345,"activeCount":101},[],{"trials":6347,"activeCount":101},[6348],{"nctId":2307,"briefTitle":2308,"status":107,"phases":6349,"primaryCompletion":2310,"completion":2311,"start":2312,"enrollment":2313,"conditions":6350,"interventions":6351},[89],[21],[2153,2316],{"trials":6353,"activeCount":101},[],{"trials":6355,"activeCount":101},[],{"trials":6357,"activeCount":101},[],{"trials":6359,"activeCount":101},[],{"intervention":6361,"totalTrials":144,"cells":6362},"CKD-519 200mg \u002F Fasting, Standard Meal, High Fat Meal",{"EARLY_PHASE1":6363,"PHASE1":6365,"PHASE2":6374,"PHASE3":6376,"PHASE4":6378,"NA":6380},{"trials":6364,"activeCount":101},[],{"trials":6366,"activeCount":101},[6367],{"nctId":6368,"briefTitle":6369,"status":107,"phases":6370,"primaryCompletion":2043,"completion":2043,"start":779,"enrollment":6371,"conditions":6372,"interventions":6373},"NCT02484482","Study to Investigate the Effect of Food on the Pharmacokinetics\u002FPharmacodynamics and Safety of CKD-519(CKD-519 FDI)",[89],45,[34],[6361],{"trials":6375,"activeCount":101},[],{"trials":6377,"activeCount":101},[],{"trials":6379,"activeCount":101},[],{"trials":6381,"activeCount":101},[],{"intervention":4795,"totalTrials":144,"cells":6383},{"EARLY_PHASE1":6384,"PHASE1":6386,"PHASE2":6392,"PHASE3":6394,"PHASE4":6396,"NA":6398},{"trials":6385,"activeCount":101},[],{"trials":6387,"activeCount":101},[6388],{"nctId":4786,"briefTitle":4787,"status":107,"phases":6389,"primaryCompletion":4789,"completion":4789,"start":4790,"enrollment":4791,"conditions":6390,"interventions":6391},[89],[4793],[4779,4795],{"trials":6393,"activeCount":101},[],{"trials":6395,"activeCount":101},[],{"trials":6397,"activeCount":101},[],{"trials":6399,"activeCount":101},[],{"intervention":4660,"totalTrials":144,"cells":6401},{"EARLY_PHASE1":6402,"PHASE1":6404,"PHASE2":6410,"PHASE3":6412,"PHASE4":6414,"NA":6416},{"trials":6403,"activeCount":101},[],{"trials":6405,"activeCount":101},[6406],{"nctId":4654,"briefTitle":4655,"status":107,"phases":6407,"primaryCompletion":4657,"completion":3801,"start":110,"enrollment":594,"conditions":6408,"interventions":6409},[89],[2227],[4660,4647],{"trials":6411,"activeCount":101},[],{"trials":6413,"activeCount":101},[],{"trials":6415,"activeCount":101},[],{"trials":6417,"activeCount":101},[],{"intervention":6419,"totalTrials":144,"cells":6420},"CKD-355A",{"EARLY_PHASE1":6421,"PHASE1":6423,"PHASE2":6438,"PHASE3":6440,"PHASE4":6442,"NA":6444},{"trials":6422,"activeCount":101},[],{"trials":6424,"activeCount":101},[6425],{"nctId":6426,"briefTitle":6427,"status":107,"phases":6428,"primaryCompletion":6429,"completion":6430,"start":6431,"enrollment":675,"conditions":6432,"interventions":6434},"NCT03802162","A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355",[89],"2019-05-10","2019-08-31","2019-02-15",[6433],"Alzheimer's Disease (AD)",[6419,6435,6436,6437],"CKD-355B","D797","D324",{"trials":6439,"activeCount":101},[],{"trials":6441,"activeCount":101},[],{"trials":6443,"activeCount":101},[],{"trials":6445,"activeCount":101},[],{"intervention":6435,"totalTrials":144,"cells":6447},{"EARLY_PHASE1":6448,"PHASE1":6450,"PHASE2":6456,"PHASE3":6458,"PHASE4":6460,"NA":6462},{"trials":6449,"activeCount":101},[],{"trials":6451,"activeCount":101},[6452],{"nctId":6426,"briefTitle":6427,"status":107,"phases":6453,"primaryCompletion":6429,"completion":6430,"start":6431,"enrollment":675,"conditions":6454,"interventions":6455},[89],[6433],[6419,6435,6436,6437],{"trials":6457,"activeCount":101},[],{"trials":6459,"activeCount":101},[],{"trials":6461,"activeCount":101},[],{"trials":6463,"activeCount":101},[],{"intervention":6436,"totalTrials":144,"cells":6465},{"EARLY_PHASE1":6466,"PHASE1":6468,"PHASE2":6474,"PHASE3":6476,"PHASE4":6478,"NA":6480},{"trials":6467,"activeCount":101},[],{"trials":6469,"activeCount":101},[6470],{"nctId":6426,"briefTitle":6427,"status":107,"phases":6471,"primaryCompletion":6429,"completion":6430,"start":6431,"enrollment":675,"conditions":6472,"interventions":6473},[89],[6433],[6419,6435,6436,6437],{"trials":6475,"activeCount":101},[],{"trials":6477,"activeCount":101},[],{"trials":6479,"activeCount":101},[],{"trials":6481,"activeCount":101},[],{"intervention":6437,"totalTrials":144,"cells":6483},{"EARLY_PHASE1":6484,"PHASE1":6486,"PHASE2":6492,"PHASE3":6494,"PHASE4":6496,"NA":6498},{"trials":6485,"activeCount":101},[],{"trials":6487,"activeCount":101},[6488],{"nctId":6426,"briefTitle":6427,"status":107,"phases":6489,"primaryCompletion":6429,"completion":6430,"start":6431,"enrollment":675,"conditions":6490,"interventions":6491},[89],[6433],[6419,6435,6436,6437],{"trials":6493,"activeCount":101},[],{"trials":6495,"activeCount":101},[],{"trials":6497,"activeCount":101},[],{"trials":6499,"activeCount":101},[],{"intervention":4719,"totalTrials":144,"cells":6501},{"EARLY_PHASE1":6502,"PHASE1":6504,"PHASE2":6510,"PHASE3":6512,"PHASE4":6514,"NA":6516},{"trials":6503,"activeCount":101},[],{"trials":6505,"activeCount":101},[6506],{"nctId":4710,"briefTitle":4711,"status":107,"phases":6507,"primaryCompletion":4713,"completion":4714,"start":4715,"enrollment":4716,"conditions":6508,"interventions":6509},[89],[21],[1922,4719],{"trials":6511,"activeCount":101},[],{"trials":6513,"activeCount":101},[],{"trials":6515,"activeCount":101},[],{"trials":6517,"activeCount":101},[],{"intervention":6519,"totalTrials":144,"cells":6520},"Sequence 1",{"EARLY_PHASE1":6521,"PHASE1":6523,"PHASE2":6538,"PHASE3":6540,"PHASE4":6542,"NA":6544},{"trials":6522,"activeCount":101},[],{"trials":6524,"activeCount":101},[6525],{"nctId":6526,"briefTitle":6527,"status":126,"phases":6528,"primaryCompletion":6529,"completion":6529,"start":6530,"enrollment":415,"conditions":6531,"interventions":6532},"NCT03726866","A Study to Investigate Drug-Drug Interaction Between D326, D337 and CKD-828 in Healthy Subjects",[89],"2019-01-15","2018-08-31",[18,15],[6519,6533,6534,6535,6536,6537],"Sequence 2","Sequence 3","Sequence 4","Sequence 5","Sequence 6",{"trials":6539,"activeCount":101},[],{"trials":6541,"activeCount":101},[],{"trials":6543,"activeCount":101},[],{"trials":6545,"activeCount":101},[],{"intervention":6533,"totalTrials":144,"cells":6547},{"EARLY_PHASE1":6548,"PHASE1":6550,"PHASE2":6556,"PHASE3":6558,"PHASE4":6560,"NA":6562},{"trials":6549,"activeCount":101},[],{"trials":6551,"activeCount":101},[6552],{"nctId":6526,"briefTitle":6527,"status":126,"phases":6553,"primaryCompletion":6529,"completion":6529,"start":6530,"enrollment":415,"conditions":6554,"interventions":6555},[89],[18,15],[6519,6533,6534,6535,6536,6537],{"trials":6557,"activeCount":101},[],{"trials":6559,"activeCount":101},[],{"trials":6561,"activeCount":101},[],{"trials":6563,"activeCount":101},[],{"intervention":6534,"totalTrials":144,"cells":6565},{"EARLY_PHASE1":6566,"PHASE1":6568,"PHASE2":6574,"PHASE3":6576,"PHASE4":6578,"NA":6580},{"trials":6567,"activeCount":101},[],{"trials":6569,"activeCount":101},[6570],{"nctId":6526,"briefTitle":6527,"status":126,"phases":6571,"primaryCompletion":6529,"completion":6529,"start":6530,"enrollment":415,"conditions":6572,"interventions":6573},[89],[18,15],[6519,6533,6534,6535,6536,6537],{"trials":6575,"activeCount":101},[],{"trials":6577,"activeCount":101},[],{"trials":6579,"activeCount":101},[],{"trials":6581,"activeCount":101},[],{"intervention":6535,"totalTrials":144,"cells":6583},{"EARLY_PHASE1":6584,"PHASE1":6586,"PHASE2":6592,"PHASE3":6594,"PHASE4":6596,"NA":6598},{"trials":6585,"activeCount":101},[],{"trials":6587,"activeCount":101},[6588],{"nctId":6526,"briefTitle":6527,"status":126,"phases":6589,"primaryCompletion":6529,"completion":6529,"start":6530,"enrollment":415,"conditions":6590,"interventions":6591},[89],[18,15],[6519,6533,6534,6535,6536,6537],{"trials":6593,"activeCount":101},[],{"trials":6595,"activeCount":101},[],{"trials":6597,"activeCount":101},[],{"trials":6599,"activeCount":101},[],{"intervention":6536,"totalTrials":144,"cells":6601},{"EARLY_PHASE1":6602,"PHASE1":6604,"PHASE2":6610,"PHASE3":6612,"PHASE4":6614,"NA":6616},{"trials":6603,"activeCount":101},[],{"trials":6605,"activeCount":101},[6606],{"nctId":6526,"briefTitle":6527,"status":126,"phases":6607,"primaryCompletion":6529,"completion":6529,"start":6530,"enrollment":415,"conditions":6608,"interventions":6609},[89],[18,15],[6519,6533,6534,6535,6536,6537],{"trials":6611,"activeCount":101},[],{"trials":6613,"activeCount":101},[],{"trials":6615,"activeCount":101},[],{"trials":6617,"activeCount":101},[],{"intervention":6537,"totalTrials":144,"cells":6619},{"EARLY_PHASE1":6620,"PHASE1":6622,"PHASE2":6628,"PHASE3":6630,"PHASE4":6632,"NA":6634},{"trials":6621,"activeCount":101},[],{"trials":6623,"activeCount":101},[6624],{"nctId":6526,"briefTitle":6527,"status":126,"phases":6625,"primaryCompletion":6529,"completion":6529,"start":6530,"enrollment":415,"conditions":6626,"interventions":6627},[89],[18,15],[6519,6533,6534,6535,6536,6537],{"trials":6629,"activeCount":101},[],{"trials":6631,"activeCount":101},[],{"trials":6633,"activeCount":101},[],{"trials":6635,"activeCount":101},[],{"intervention":4965,"totalTrials":144,"cells":6637},{"EARLY_PHASE1":6638,"PHASE1":6640,"PHASE2":6646,"PHASE3":6648,"PHASE4":6650,"NA":6652},{"trials":6639,"activeCount":101},[],{"trials":6641,"activeCount":101},[6642],{"nctId":4956,"briefTitle":4957,"status":126,"phases":6643,"primaryCompletion":4959,"completion":4960,"start":4961,"enrollment":451,"conditions":6644,"interventions":6645},[89],[4963],[4949,4965],{"trials":6647,"activeCount":101},[],{"trials":6649,"activeCount":101},[],{"trials":6651,"activeCount":101},[],{"trials":6653,"activeCount":101},[],{"intervention":6655,"totalTrials":144,"cells":6656},"Vorico Injection 200mg",{"EARLY_PHASE1":6657,"PHASE1":6659,"PHASE2":6671,"PHASE3":6673,"PHASE4":6675,"NA":6677},{"trials":6658,"activeCount":101},[],{"trials":6660,"activeCount":101},[6661],{"nctId":6662,"briefTitle":6663,"status":107,"phases":6664,"primaryCompletion":1309,"completion":5718,"start":2044,"enrollment":594,"conditions":6665,"interventions":6669},"NCT02631954","Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers",[89],[6666,6667,6668],"Aspergillus Infections","Candida Infections","Fungal Infections",[6655,6670],"Vfend®(Voriconazole) IV 200mg",{"trials":6672,"activeCount":101},[],{"trials":6674,"activeCount":101},[],{"trials":6676,"activeCount":101},[],{"trials":6678,"activeCount":101},[],{"intervention":6670,"totalTrials":144,"cells":6680},{"EARLY_PHASE1":6681,"PHASE1":6683,"PHASE2":6689,"PHASE3":6691,"PHASE4":6693,"NA":6695},{"trials":6682,"activeCount":101},[],{"trials":6684,"activeCount":101},[6685],{"nctId":6662,"briefTitle":6663,"status":107,"phases":6686,"primaryCompletion":1309,"completion":5718,"start":2044,"enrollment":594,"conditions":6687,"interventions":6688},[89],[6666,6667,6668],[6655,6670],{"trials":6690,"activeCount":101},[],{"trials":6692,"activeCount":101},[],{"trials":6694,"activeCount":101},[],{"trials":6696,"activeCount":101},[],{"intervention":6698,"totalTrials":144,"cells":6699},"Tacrobell tab. 2mg",{"EARLY_PHASE1":6700,"PHASE1":6702,"PHASE2":6715,"PHASE3":6717,"PHASE4":6719,"NA":6721},{"trials":6701,"activeCount":101},[],{"trials":6703,"activeCount":101},[6704],{"nctId":6705,"briefTitle":6706,"status":107,"phases":6707,"primaryCompletion":6708,"completion":6709,"start":6710,"enrollment":6074,"conditions":6711,"interventions":6713},"NCT02336854","Tacrobell tab_Phase1_PK",[89],"2015-02-02","2015-03-19","2015-01-12",[6712],"Immunosuppressant(Organ Transplantation, RA)",[6698,6714],"Prograf cap. 2mg",{"trials":6716,"activeCount":101},[],{"trials":6718,"activeCount":101},[],{"trials":6720,"activeCount":101},[],{"trials":6722,"activeCount":101},[],{"intervention":6714,"totalTrials":144,"cells":6724},{"EARLY_PHASE1":6725,"PHASE1":6727,"PHASE2":6733,"PHASE3":6735,"PHASE4":6737,"NA":6739},{"trials":6726,"activeCount":101},[],{"trials":6728,"activeCount":101},[6729],{"nctId":6705,"briefTitle":6706,"status":107,"phases":6730,"primaryCompletion":6708,"completion":6709,"start":6710,"enrollment":6074,"conditions":6731,"interventions":6732},[89],[6712],[6698,6714],{"trials":6734,"activeCount":101},[],{"trials":6736,"activeCount":101},[],{"trials":6738,"activeCount":101},[],{"trials":6740,"activeCount":101},[],{"intervention":5339,"totalTrials":144,"cells":6742},{"EARLY_PHASE1":6743,"PHASE1":6745,"PHASE2":6751,"PHASE3":6753,"PHASE4":6755,"NA":6757},{"trials":6744,"activeCount":101},[],{"trials":6746,"activeCount":101},[6747],{"nctId":5331,"briefTitle":5332,"status":126,"phases":6748,"primaryCompletion":5334,"completion":5335,"start":5336,"enrollment":112,"conditions":6749,"interventions":6750},[89],[23],[5324,5339],{"trials":6752,"activeCount":101},[],{"trials":6754,"activeCount":101},[],{"trials":6756,"activeCount":101},[],{"trials":6758,"activeCount":101},[],{"intervention":5375,"totalTrials":144,"cells":6760},{"EARLY_PHASE1":6761,"PHASE1":6763,"PHASE2":6769,"PHASE3":6771,"PHASE4":6773,"NA":6775},{"trials":6762,"activeCount":101},[],{"trials":6764,"activeCount":101},[6765],{"nctId":5366,"briefTitle":5367,"status":126,"phases":6766,"primaryCompletion":5369,"completion":5370,"start":5371,"enrollment":415,"conditions":6767,"interventions":6768},[89],[441],[5359,5374,5375],{"trials":6770,"activeCount":101},[],{"trials":6772,"activeCount":101},[],{"trials":6774,"activeCount":101},[],{"trials":6776,"activeCount":101},[],{"intervention":6778,"totalTrials":144,"cells":6779},"CKD-391 10\u002F10mg",{"EARLY_PHASE1":6780,"PHASE1":6782,"PHASE2":6792,"PHASE3":6794,"PHASE4":6796,"NA":6798},{"trials":6781,"activeCount":101},[],{"trials":6783,"activeCount":101},[6784],{"nctId":6785,"briefTitle":6786,"status":107,"phases":6787,"primaryCompletion":6788,"completion":6788,"start":3684,"enrollment":16,"conditions":6789,"interventions":6790},"NCT04354987","Compare the Pharmacokinetics and Safety of CKD-391",[89],"2020-01-09",[2134],[6778,6791],"D090, D337",{"trials":6793,"activeCount":101},[],{"trials":6795,"activeCount":101},[],{"trials":6797,"activeCount":101},[],{"trials":6799,"activeCount":101},[],{"intervention":6791,"totalTrials":144,"cells":6801},{"EARLY_PHASE1":6802,"PHASE1":6804,"PHASE2":6810,"PHASE3":6812,"PHASE4":6814,"NA":6816},{"trials":6803,"activeCount":101},[],{"trials":6805,"activeCount":101},[6806],{"nctId":6785,"briefTitle":6786,"status":107,"phases":6807,"primaryCompletion":6788,"completion":6788,"start":3684,"enrollment":16,"conditions":6808,"interventions":6809},[89],[2134],[6778,6791],{"trials":6811,"activeCount":101},[],{"trials":6813,"activeCount":101},[],{"trials":6815,"activeCount":101},[],{"trials":6817,"activeCount":101},[],{"intervention":6819,"totalTrials":144,"cells":6820},"CKD-333 formulation I",{"EARLY_PHASE1":6821,"PHASE1":6823,"PHASE2":6835,"PHASE3":6837,"PHASE4":6839,"NA":6841},{"trials":6822,"activeCount":101},[],{"trials":6824,"activeCount":101},[6825],{"nctId":6826,"briefTitle":6827,"status":107,"phases":6828,"primaryCompletion":6829,"completion":2405,"start":6830,"enrollment":4559,"conditions":6831,"interventions":6832},"NCT03659149","Pharmacokinetics and Safety Profile of CKD-333",[89],"2018-10-05","2018-08-08",[15,18],[6819,6833,6834],"CKD-333 formulation II","CKD-330+D086",{"trials":6836,"activeCount":101},[],{"trials":6838,"activeCount":101},[],{"trials":6840,"activeCount":101},[],{"trials":6842,"activeCount":101},[],{"intervention":6833,"totalTrials":144,"cells":6844},{"EARLY_PHASE1":6845,"PHASE1":6847,"PHASE2":6853,"PHASE3":6855,"PHASE4":6857,"NA":6859},{"trials":6846,"activeCount":101},[],{"trials":6848,"activeCount":101},[6849],{"nctId":6826,"briefTitle":6827,"status":107,"phases":6850,"primaryCompletion":6829,"completion":2405,"start":6830,"enrollment":4559,"conditions":6851,"interventions":6852},[89],[15,18],[6819,6833,6834],{"trials":6854,"activeCount":101},[],{"trials":6856,"activeCount":101},[],{"trials":6858,"activeCount":101},[],{"trials":6860,"activeCount":101},[],{"intervention":6834,"totalTrials":144,"cells":6862},{"EARLY_PHASE1":6863,"PHASE1":6865,"PHASE2":6871,"PHASE3":6873,"PHASE4":6875,"NA":6877},{"trials":6864,"activeCount":101},[],{"trials":6866,"activeCount":101},[6867],{"nctId":6826,"briefTitle":6827,"status":107,"phases":6868,"primaryCompletion":6829,"completion":2405,"start":6830,"enrollment":4559,"conditions":6869,"interventions":6870},[89],[15,18],[6819,6833,6834],{"trials":6872,"activeCount":101},[],{"trials":6874,"activeCount":101},[],{"trials":6876,"activeCount":101},[],{"trials":6878,"activeCount":101},[],{"intervention":5489,"totalTrials":144,"cells":6880},{"EARLY_PHASE1":6881,"PHASE1":6883,"PHASE2":6889,"PHASE3":6891,"PHASE4":6893,"NA":6895},{"trials":6882,"activeCount":101},[],{"trials":6884,"activeCount":101},[6885],{"nctId":5482,"briefTitle":5483,"status":107,"phases":6886,"primaryCompletion":5485,"completion":5486,"start":5370,"enrollment":781,"conditions":6887,"interventions":6888},[89],[23],[5489,5490,5475],{"trials":6890,"activeCount":101},[],{"trials":6892,"activeCount":101},[],{"trials":6894,"activeCount":101},[],{"trials":6896,"activeCount":101},[],{"intervention":5490,"totalTrials":144,"cells":6898},{"EARLY_PHASE1":6899,"PHASE1":6901,"PHASE2":6907,"PHASE3":6909,"PHASE4":6911,"NA":6913},{"trials":6900,"activeCount":101},[],{"trials":6902,"activeCount":101},[6903],{"nctId":5482,"briefTitle":5483,"status":107,"phases":6904,"primaryCompletion":5485,"completion":5486,"start":5370,"enrollment":781,"conditions":6905,"interventions":6906},[89],[23],[5489,5490,5475],{"trials":6908,"activeCount":101},[],{"trials":6910,"activeCount":101},[],{"trials":6912,"activeCount":101},[],{"trials":6914,"activeCount":101},[],{"intervention":6916,"totalTrials":144,"cells":6917},"Lobeglitazone",{"EARLY_PHASE1":6918,"PHASE1":6920,"PHASE2":6929,"PHASE3":6931,"PHASE4":6933,"NA":6935},{"trials":6919,"activeCount":101},[],{"trials":6921,"activeCount":101},[6922],{"nctId":6923,"briefTitle":6924,"status":107,"phases":6925,"primaryCompletion":5310,"completion":129,"start":2548,"enrollment":594,"conditions":6926,"interventions":6927},"NCT02002611","Drug-drug Interaction Study(Lobeglitazone, Warfarin)",[89],[23],[6916,6928],"Warfarin",{"trials":6930,"activeCount":101},[],{"trials":6932,"activeCount":101},[],{"trials":6934,"activeCount":101},[],{"trials":6936,"activeCount":101},[],{"intervention":6928,"totalTrials":144,"cells":6938},{"EARLY_PHASE1":6939,"PHASE1":6941,"PHASE2":6947,"PHASE3":6949,"PHASE4":6951,"NA":6953},{"trials":6940,"activeCount":101},[],{"trials":6942,"activeCount":101},[6943],{"nctId":6923,"briefTitle":6924,"status":107,"phases":6944,"primaryCompletion":5310,"completion":129,"start":2548,"enrollment":594,"conditions":6945,"interventions":6946},[89],[23],[6916,6928],{"trials":6948,"activeCount":101},[],{"trials":6950,"activeCount":101},[],{"trials":6952,"activeCount":101},[],{"trials":6954,"activeCount":101},[],{"intervention":2344,"totalTrials":144,"cells":6956},{"EARLY_PHASE1":6957,"PHASE1":6959,"PHASE2":6965,"PHASE3":6967,"PHASE4":6969,"NA":6971},{"trials":6958,"activeCount":101},[],{"trials":6960,"activeCount":101},[6961],{"nctId":2336,"briefTitle":2337,"status":107,"phases":6962,"primaryCompletion":2339,"completion":2340,"start":2341,"enrollment":791,"conditions":6963,"interventions":6964},[89],[18,15],[2344,2026,2345],{"trials":6966,"activeCount":101},[],{"trials":6968,"activeCount":101},[],{"trials":6970,"activeCount":101},[],{"trials":6972,"activeCount":101},[],{"intervention":2345,"totalTrials":144,"cells":6974},{"EARLY_PHASE1":6975,"PHASE1":6977,"PHASE2":6983,"PHASE3":6985,"PHASE4":6987,"NA":6989},{"trials":6976,"activeCount":101},[],{"trials":6978,"activeCount":101},[6979],{"nctId":2336,"briefTitle":2337,"status":107,"phases":6980,"primaryCompletion":2339,"completion":2340,"start":2341,"enrollment":791,"conditions":6981,"interventions":6982},[89],[18,15],[2344,2026,2345],{"trials":6984,"activeCount":101},[],{"trials":6986,"activeCount":101},[],{"trials":6988,"activeCount":101},[],{"trials":6990,"activeCount":101},[],{"intervention":6992,"totalTrials":144,"cells":6993},"CKD-810, Taxotere inj.",{"EARLY_PHASE1":6994,"PHASE1":6996,"PHASE2":7005,"PHASE3":7007,"PHASE4":7009,"NA":7011},{"trials":6995,"activeCount":101},[],{"trials":6997,"activeCount":101},[6998],{"nctId":6999,"briefTitle":7000,"status":107,"phases":7001,"primaryCompletion":3856,"completion":1995,"start":109,"enrollment":16,"conditions":7002,"interventions":7004},"NCT01019941","Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer",[89],[7003],"Advanced Solid Cancers",[6992,6992],{"trials":7006,"activeCount":101},[],{"trials":7008,"activeCount":101},[],{"trials":7010,"activeCount":101},[],{"trials":7012,"activeCount":101},[],{"intervention":7014,"totalTrials":144,"cells":7015},"Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mg",{"EARLY_PHASE1":7016,"PHASE1":7018,"PHASE2":7027,"PHASE3":7029,"PHASE4":7031,"NA":7033},{"trials":7017,"activeCount":101},[],{"trials":7019,"activeCount":101},[7020],{"nctId":7021,"briefTitle":7022,"status":107,"phases":7023,"primaryCompletion":2044,"completion":2044,"start":2043,"enrollment":4666,"conditions":7024,"interventions":7025},"NCT02627027","A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25\u002F750 mg in Healthy Male Volunteers",[89],[6332],[7014,7026],"CKD-395 0.25\u002F750mg",{"trials":7028,"activeCount":101},[],{"trials":7030,"activeCount":101},[],{"trials":7032,"activeCount":101},[],{"trials":7034,"activeCount":101},[],{"intervention":7026,"totalTrials":144,"cells":7036},{"EARLY_PHASE1":7037,"PHASE1":7039,"PHASE2":7045,"PHASE3":7047,"PHASE4":7049,"NA":7051},{"trials":7038,"activeCount":101},[],{"trials":7040,"activeCount":101},[7041],{"nctId":7021,"briefTitle":7022,"status":107,"phases":7042,"primaryCompletion":2044,"completion":2044,"start":2043,"enrollment":4666,"conditions":7043,"interventions":7044},[89],[6332],[7014,7026],{"trials":7046,"activeCount":101},[],{"trials":7048,"activeCount":101},[],{"trials":7050,"activeCount":101},[],{"trials":7052,"activeCount":101},[],{"intervention":2373,"totalTrials":144,"cells":7054},{"EARLY_PHASE1":7055,"PHASE1":7057,"PHASE2":7063,"PHASE3":7065,"PHASE4":7067,"NA":7069},{"trials":7056,"activeCount":101},[],{"trials":7058,"activeCount":101},[7059],{"nctId":2366,"briefTitle":2367,"status":107,"phases":7060,"primaryCompletion":2369,"completion":2369,"start":2370,"enrollment":451,"conditions":7061,"interventions":7062},[89],[2227],[2373,2359],{"trials":7064,"activeCount":101},[],{"trials":7066,"activeCount":101},[],{"trials":7068,"activeCount":101},[],{"trials":7070,"activeCount":101},[],{"intervention":5500,"totalTrials":144,"cells":7072},{"EARLY_PHASE1":7073,"PHASE1":7075,"PHASE2":7081,"PHASE3":7083,"PHASE4":7085,"NA":7087},{"trials":7074,"activeCount":101},[],{"trials":7076,"activeCount":101},[7077],{"nctId":5492,"briefTitle":5493,"status":126,"phases":7078,"primaryCompletion":5495,"completion":3947,"start":5496,"enrollment":4666,"conditions":7079,"interventions":7080},[89],[5498],[5475,5500],{"trials":7082,"activeCount":101},[],{"trials":7084,"activeCount":101},[],{"trials":7086,"activeCount":101},[],{"trials":7088,"activeCount":101},[],{"intervention":5580,"totalTrials":144,"cells":7090},{"EARLY_PHASE1":7091,"PHASE1":7093,"PHASE2":7099,"PHASE3":7101,"PHASE4":7103,"NA":7105},{"trials":7092,"activeCount":101},[],{"trials":7094,"activeCount":101},[7095],{"nctId":5574,"briefTitle":5575,"status":107,"phases":7096,"primaryCompletion":1087,"completion":5577,"start":2100,"enrollment":451,"conditions":7097,"interventions":7098},[89],[15],[2049,5580],{"trials":7100,"activeCount":101},[],{"trials":7102,"activeCount":101},[],{"trials":7104,"activeCount":101},[],{"trials":7106,"activeCount":101},[],{"intervention":7108,"totalTrials":144,"cells":7109},"CKD-348 F1, CKD-348 F2, CKD-828, D326, D337",{"EARLY_PHASE1":7110,"PHASE1":7112,"PHASE2":7122,"PHASE3":7124,"PHASE4":7126,"NA":7128},{"trials":7111,"activeCount":101},[],{"trials":7113,"activeCount":101},[7114],{"nctId":7115,"briefTitle":7116,"status":107,"phases":7117,"primaryCompletion":7118,"completion":7118,"start":7119,"enrollment":19,"conditions":7120,"interventions":7121},"NCT04272502","Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers",[89],"2019-08-26","2019-06-04",[25],[7108],{"trials":7123,"activeCount":101},[],{"trials":7125,"activeCount":101},[],{"trials":7127,"activeCount":101},[],{"trials":7129,"activeCount":101},[],{"intervention":7131,"totalTrials":144,"cells":7132},"CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T",{"EARLY_PHASE1":7133,"PHASE1":7135,"PHASE2":7147,"PHASE3":7149,"PHASE4":7151,"NA":7153},{"trials":7134,"activeCount":101},[],{"trials":7136,"activeCount":101},[7137],{"nctId":7138,"briefTitle":7139,"status":107,"phases":7140,"primaryCompletion":5370,"completion":7141,"start":7142,"enrollment":594,"conditions":7143,"interventions":7144},"NCT04260438","Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects",[89],"2020-06-24","2020-04-08",[726],[7131,7145,7146],"CKD-393 0.5\u002F100\u002F1000mg formulation 1 Tab. 1T","CKD-393 0.5\u002F100\u002F1000mg formulation 2 Tab. 1T",{"trials":7148,"activeCount":101},[],{"trials":7150,"activeCount":101},[],{"trials":7152,"activeCount":101},[],{"trials":7154,"activeCount":101},[],{"intervention":7145,"totalTrials":144,"cells":7156},{"EARLY_PHASE1":7157,"PHASE1":7159,"PHASE2":7165,"PHASE3":7167,"PHASE4":7169,"NA":7171},{"trials":7158,"activeCount":101},[],{"trials":7160,"activeCount":101},[7161],{"nctId":7138,"briefTitle":7139,"status":107,"phases":7162,"primaryCompletion":5370,"completion":7141,"start":7142,"enrollment":594,"conditions":7163,"interventions":7164},[89],[726],[7131,7145,7146],{"trials":7166,"activeCount":101},[],{"trials":7168,"activeCount":101},[],{"trials":7170,"activeCount":101},[],{"trials":7172,"activeCount":101},[],{"intervention":7146,"totalTrials":144,"cells":7174},{"EARLY_PHASE1":7175,"PHASE1":7177,"PHASE2":7183,"PHASE3":7185,"PHASE4":7187,"NA":7189},{"trials":7176,"activeCount":101},[],{"trials":7178,"activeCount":101},[7179],{"nctId":7138,"briefTitle":7139,"status":107,"phases":7180,"primaryCompletion":5370,"completion":7141,"start":7142,"enrollment":594,"conditions":7181,"interventions":7182},[89],[726],[7131,7145,7146],{"trials":7184,"activeCount":101},[],{"trials":7186,"activeCount":101},[],{"trials":7188,"activeCount":101},[],{"trials":7190,"activeCount":101},[],{"intervention":7192,"totalTrials":144,"cells":7193},"CKD-828, D064, D701",{"EARLY_PHASE1":7194,"PHASE1":7196,"PHASE2":7207,"PHASE3":7209,"PHASE4":7211,"NA":7213},{"trials":7195,"activeCount":101},[],{"trials":7197,"activeCount":101},[7198],{"nctId":7199,"briefTitle":7200,"status":107,"phases":7201,"primaryCompletion":4513,"completion":7202,"start":7203,"enrollment":7204,"conditions":7205,"interventions":7206},"NCT05834595","A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828",[89],"2023-07-26","2023-05-02",43,[15],[7192],{"trials":7208,"activeCount":101},[],{"trials":7210,"activeCount":101},[],{"trials":7212,"activeCount":101},[],{"trials":7214,"activeCount":101},[],{"intervention":7216,"totalTrials":144,"cells":7217},"CKD-378 25\u002F1000mg",{"EARLY_PHASE1":7218,"PHASE1":7220,"PHASE2":7229,"PHASE3":7231,"PHASE4":7233,"NA":7235},{"trials":7219,"activeCount":101},[],{"trials":7221,"activeCount":101},[7222],{"nctId":7223,"briefTitle":7224,"status":107,"phases":7225,"primaryCompletion":423,"completion":413,"start":7226,"enrollment":485,"conditions":7227,"interventions":7228},"NCT06709807","Clinical Study to Evaluate the Food Effect of CKD-378 in Healthy Volunteers",[89],"2024-11-08",[417],[7216],{"trials":7230,"activeCount":101},[],{"trials":7232,"activeCount":101},[],{"trials":7234,"activeCount":101},[],{"trials":7236,"activeCount":101},[],{"intervention":7238,"totalTrials":144,"cells":7239},"Dilatrend SR",{"EARLY_PHASE1":7240,"PHASE1":7242,"PHASE2":7252,"PHASE3":7254,"PHASE4":7256,"NA":7258},{"trials":7241,"activeCount":101},[],{"trials":7243,"activeCount":101},[7244],{"nctId":7245,"briefTitle":7246,"status":107,"phases":7247,"primaryCompletion":7248,"completion":7248,"start":2370,"enrollment":415,"conditions":7249,"interventions":7251},"NCT01369472","Evaluating Dose-proportionality of Dilatrend Suspended-Release Capsule",[89],"2011-10",[7250],"Chronic Stable Angina",[7238],{"trials":7253,"activeCount":101},[],{"trials":7255,"activeCount":101},[],{"trials":7257,"activeCount":101},[],{"trials":7259,"activeCount":101},[],{"intervention":7261,"totalTrials":144,"cells":7262},"CKD-330 1 Tab. and D085 1 Tab.",{"EARLY_PHASE1":7263,"PHASE1":7265,"PHASE2":7276,"PHASE3":7278,"PHASE4":7280,"NA":7282},{"trials":7264,"activeCount":101},[],{"trials":7266,"activeCount":101},[7267],{"nctId":7268,"briefTitle":7269,"status":126,"phases":7270,"primaryCompletion":7271,"completion":2020,"start":7272,"enrollment":5837,"conditions":7273,"interventions":7274},"NCT04627207","A Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of CKD-333 or Co-administration of CKD-333 and D085 in Healthy Volunteers",[89],"2021-03","2020-11",[3688],[7261,7275],"CKD-333 1 Tab",{"trials":7277,"activeCount":101},[],{"trials":7279,"activeCount":101},[],{"trials":7281,"activeCount":101},[],{"trials":7283,"activeCount":101},[],{"intervention":7275,"totalTrials":144,"cells":7285},{"EARLY_PHASE1":7286,"PHASE1":7288,"PHASE2":7294,"PHASE3":7296,"PHASE4":7298,"NA":7300},{"trials":7287,"activeCount":101},[],{"trials":7289,"activeCount":101},[7290],{"nctId":7268,"briefTitle":7269,"status":126,"phases":7291,"primaryCompletion":7271,"completion":2020,"start":7272,"enrollment":5837,"conditions":7292,"interventions":7293},[89],[3688],[7261,7275],{"trials":7295,"activeCount":101},[],{"trials":7297,"activeCount":101},[],{"trials":7299,"activeCount":101},[],{"trials":7301,"activeCount":101},[],{"intervention":7303,"totalTrials":144,"cells":7304},"CKD-501, Ketoconazole",{"EARLY_PHASE1":7305,"PHASE1":7307,"PHASE2":7315,"PHASE3":7317,"PHASE4":7319,"NA":7321},{"trials":7306,"activeCount":101},[],{"trials":7308,"activeCount":101},[7309],{"nctId":7310,"briefTitle":7311,"status":107,"phases":7312,"primaryCompletion":2370,"completion":2370,"start":800,"enrollment":594,"conditions":7313,"interventions":7314},"NCT01330563","Drug-drug Interaction Study (CKD-501, Ketoconazole)",[89],[23],[7303],{"trials":7316,"activeCount":101},[],{"trials":7318,"activeCount":101},[],{"trials":7320,"activeCount":101},[],{"trials":7322,"activeCount":101},[],{"intervention":7324,"totalTrials":144,"cells":7325},"Duvie Tab. 0.5mg",{"EARLY_PHASE1":7326,"PHASE1":7328,"PHASE2":7337,"PHASE3":7339,"PHASE4":7341,"NA":7343},{"trials":7327,"activeCount":101},[],{"trials":7329,"activeCount":101},[7330],{"nctId":7331,"briefTitle":7332,"status":107,"phases":7333,"primaryCompletion":2292,"completion":2647,"start":2292,"enrollment":4579,"conditions":7334,"interventions":7335},"NCT02824874","CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)",[89],[6332],[7324,7336],"Duvie Tab. 0.5mg + Januvia Tab. 100mg",{"trials":7338,"activeCount":101},[],{"trials":7340,"activeCount":101},[],{"trials":7342,"activeCount":101},[],{"trials":7344,"activeCount":101},[],{"intervention":7336,"totalTrials":144,"cells":7346},{"EARLY_PHASE1":7347,"PHASE1":7349,"PHASE2":7355,"PHASE3":7357,"PHASE4":7359,"NA":7361},{"trials":7348,"activeCount":101},[],{"trials":7350,"activeCount":101},[7351],{"nctId":7331,"briefTitle":7332,"status":107,"phases":7352,"primaryCompletion":2292,"completion":2647,"start":2292,"enrollment":4579,"conditions":7353,"interventions":7354},[89],[6332],[7324,7336],{"trials":7356,"activeCount":101},[],{"trials":7358,"activeCount":101},[],{"trials":7360,"activeCount":101},[],{"trials":7362,"activeCount":101},[],{"intervention":7364,"totalTrials":144,"cells":7365},"CKD-828, D097, D337, CKD-348 T1, CKD-348 T2",{"EARLY_PHASE1":7366,"PHASE1":7368,"PHASE2":7380,"PHASE3":7382,"PHASE4":7384,"NA":7386},{"trials":7367,"activeCount":101},[],{"trials":7369,"activeCount":101},[7370],{"nctId":7371,"briefTitle":7372,"status":107,"phases":7373,"primaryCompletion":7374,"completion":7374,"start":7375,"enrollment":19,"conditions":7376,"interventions":7377},"NCT04304547","Clinical Study to Evauate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers",[89],"2020-04-02","2020-02-04",[25],[7364,7378,7379],"CKD-348 T1, CKD-348 T2, CKD-828, D097, D337,","CKD-348 T2, CKD-348 T1, CKD-828, D097, D337",{"trials":7381,"activeCount":101},[],{"trials":7383,"activeCount":101},[],{"trials":7385,"activeCount":101},[],{"trials":7387,"activeCount":101},[],{"intervention":7378,"totalTrials":144,"cells":7389},{"EARLY_PHASE1":7390,"PHASE1":7392,"PHASE2":7398,"PHASE3":7400,"PHASE4":7402,"NA":7404},{"trials":7391,"activeCount":101},[],{"trials":7393,"activeCount":101},[7394],{"nctId":7371,"briefTitle":7372,"status":107,"phases":7395,"primaryCompletion":7374,"completion":7374,"start":7375,"enrollment":19,"conditions":7396,"interventions":7397},[89],[25],[7364,7378,7379],{"trials":7399,"activeCount":101},[],{"trials":7401,"activeCount":101},[],{"trials":7403,"activeCount":101},[],{"trials":7405,"activeCount":101},[],{"intervention":7379,"totalTrials":144,"cells":7407},{"EARLY_PHASE1":7408,"PHASE1":7410,"PHASE2":7416,"PHASE3":7418,"PHASE4":7420,"NA":7422},{"trials":7409,"activeCount":101},[],{"trials":7411,"activeCount":101},[7412],{"nctId":7371,"briefTitle":7372,"status":107,"phases":7413,"primaryCompletion":7374,"completion":7374,"start":7375,"enrollment":19,"conditions":7414,"interventions":7415},[89],[25],[7364,7378,7379],{"trials":7417,"activeCount":101},[],{"trials":7419,"activeCount":101},[],{"trials":7421,"activeCount":101},[],{"trials":7423,"activeCount":101},[],{"intervention":4677,"totalTrials":144,"cells":7425},{"EARLY_PHASE1":7426,"PHASE1":7428,"PHASE2":7434,"PHASE3":7436,"PHASE4":7438,"NA":7440},{"trials":7427,"activeCount":101},[],{"trials":7429,"activeCount":101},[7430],{"nctId":4671,"briefTitle":4672,"status":107,"phases":7431,"primaryCompletion":2206,"completion":2206,"start":1986,"enrollment":4674,"conditions":7432,"interventions":7433},[89],[23],[4647,4677,4678],{"trials":7435,"activeCount":101},[],{"trials":7437,"activeCount":101},[],{"trials":7439,"activeCount":101},[],{"trials":7441,"activeCount":101},[],{"intervention":4678,"totalTrials":144,"cells":7443},{"EARLY_PHASE1":7444,"PHASE1":7446,"PHASE2":7452,"PHASE3":7454,"PHASE4":7456,"NA":7458},{"trials":7445,"activeCount":101},[],{"trials":7447,"activeCount":101},[7448],{"nctId":4671,"briefTitle":4672,"status":107,"phases":7449,"primaryCompletion":2206,"completion":2206,"start":1986,"enrollment":4674,"conditions":7450,"interventions":7451},[89],[23],[4647,4677,4678],{"trials":7453,"activeCount":101},[],{"trials":7455,"activeCount":101},[],{"trials":7457,"activeCount":101},[],{"trials":7459,"activeCount":101},[],{"intervention":5659,"totalTrials":144,"cells":7461},{"EARLY_PHASE1":7462,"PHASE1":7464,"PHASE2":7470,"PHASE3":7472,"PHASE4":7474,"NA":7476},{"trials":7463,"activeCount":101},[],{"trials":7465,"activeCount":101},[7466],{"nctId":5653,"briefTitle":5654,"status":107,"phases":7467,"primaryCompletion":2008,"completion":2369,"start":1995,"enrollment":675,"conditions":7468,"interventions":7469},[89],[5657],[5659,5646,5660],{"trials":7471,"activeCount":101},[],{"trials":7473,"activeCount":101},[],{"trials":7475,"activeCount":101},[],{"trials":7477,"activeCount":101},[],{"intervention":5660,"totalTrials":144,"cells":7479},{"EARLY_PHASE1":7480,"PHASE1":7482,"PHASE2":7488,"PHASE3":7490,"PHASE4":7492,"NA":7494},{"trials":7481,"activeCount":101},[],{"trials":7483,"activeCount":101},[7484],{"nctId":5653,"briefTitle":5654,"status":107,"phases":7485,"primaryCompletion":2008,"completion":2369,"start":1995,"enrollment":675,"conditions":7486,"interventions":7487},[89],[5657],[5659,5646,5660],{"trials":7489,"activeCount":101},[],{"trials":7491,"activeCount":101},[],{"trials":7493,"activeCount":101},[],{"trials":7495,"activeCount":101},[],{"intervention":7497,"totalTrials":144,"cells":7498},"CKD-371",{"EARLY_PHASE1":7499,"PHASE1":7501,"PHASE2":7512,"PHASE3":7514,"PHASE4":7516,"NA":7518},{"trials":7500,"activeCount":101},[],{"trials":7502,"activeCount":101},[7503],{"nctId":7504,"briefTitle":7505,"status":107,"phases":7506,"primaryCompletion":7507,"completion":7508,"start":7509,"enrollment":451,"conditions":7510,"interventions":7511},"NCT05544214","Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects",[89],"2022-11-14","2022-11-17","2022-10-21",[4963],[7497],{"trials":7513,"activeCount":101},[],{"trials":7515,"activeCount":101},[],{"trials":7517,"activeCount":101},[],{"trials":7519,"activeCount":101},[],{"intervention":7521,"totalTrials":144,"cells":7522},"Empagliflozin 25mg",{"EARLY_PHASE1":7523,"PHASE1":7525,"PHASE2":7535,"PHASE3":7537,"PHASE4":7539,"NA":7541},{"trials":7524,"activeCount":101},[],{"trials":7526,"activeCount":101},[7527],{"nctId":7528,"briefTitle":7529,"status":126,"phases":7530,"primaryCompletion":2068,"completion":2068,"start":2067,"enrollment":415,"conditions":7531,"interventions":7532},"NCT02854748","Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin",[89],[6332],[7521,7533,7534],"Lobeglitazone 0.5mg","Empagliflozin 25mg\u002FLobeglitazone 0.5mg",{"trials":7536,"activeCount":101},[],{"trials":7538,"activeCount":101},[],{"trials":7540,"activeCount":101},[],{"trials":7542,"activeCount":101},[],{"intervention":7533,"totalTrials":144,"cells":7544},{"EARLY_PHASE1":7545,"PHASE1":7547,"PHASE2":7553,"PHASE3":7555,"PHASE4":7557,"NA":7559},{"trials":7546,"activeCount":101},[],{"trials":7548,"activeCount":101},[7549],{"nctId":7528,"briefTitle":7529,"status":126,"phases":7550,"primaryCompletion":2068,"completion":2068,"start":2067,"enrollment":415,"conditions":7551,"interventions":7552},[89],[6332],[7521,7533,7534],{"trials":7554,"activeCount":101},[],{"trials":7556,"activeCount":101},[],{"trials":7558,"activeCount":101},[],{"trials":7560,"activeCount":101},[],{"intervention":7534,"totalTrials":144,"cells":7562},{"EARLY_PHASE1":7563,"PHASE1":7565,"PHASE2":7571,"PHASE3":7573,"PHASE4":7575,"NA":7577},{"trials":7564,"activeCount":101},[],{"trials":7566,"activeCount":101},[7567],{"nctId":7528,"briefTitle":7529,"status":126,"phases":7568,"primaryCompletion":2068,"completion":2068,"start":2067,"enrollment":415,"conditions":7569,"interventions":7570},[89],[6332],[7521,7533,7534],{"trials":7572,"activeCount":101},[],{"trials":7574,"activeCount":101},[],{"trials":7576,"activeCount":101},[],{"trials":7578,"activeCount":101},[],{"intervention":5691,"totalTrials":144,"cells":7580},{"EARLY_PHASE1":7581,"PHASE1":7583,"PHASE2":7589,"PHASE3":7591,"PHASE4":7593,"NA":7595},{"trials":7582,"activeCount":101},[],{"trials":7584,"activeCount":101},[7585],{"nctId":5685,"briefTitle":5686,"status":107,"phases":7586,"primaryCompletion":2193,"completion":5688,"start":1568,"enrollment":594,"conditions":7587,"interventions":7588},[89],[28,3154],[5678,5691],{"trials":7590,"activeCount":101},[],{"trials":7592,"activeCount":101},[],{"trials":7594,"activeCount":101},[],{"trials":7596,"activeCount":101},[],{"intervention":7598,"totalTrials":144,"cells":7599},"D930, D565",{"EARLY_PHASE1":7600,"PHASE1":7602,"PHASE2":7613,"PHASE3":7615,"PHASE4":7617,"NA":7619},{"trials":7601,"activeCount":101},[],{"trials":7603,"activeCount":101},[7604],{"nctId":7605,"briefTitle":7606,"status":107,"phases":7607,"primaryCompletion":7608,"completion":7609,"start":7610,"enrollment":19,"conditions":7611,"interventions":7612},"NCT03034486","The Pharmacokinetics of D565 and the Drug Effect of D565 on Pharmacokinetic Characteristics of D930",[89],"2017-03-17","2017-03-20","2017-02-17",[25],[7598],{"trials":7614,"activeCount":101},[],{"trials":7616,"activeCount":101},[],{"trials":7618,"activeCount":101},[],{"trials":7620,"activeCount":101},[],{"intervention":7622,"totalTrials":144,"cells":7623},"CKD-333, formula I",{"EARLY_PHASE1":7624,"PHASE1":7626,"PHASE2":7639,"PHASE3":7641,"PHASE4":7643,"NA":7645},{"trials":7625,"activeCount":101},[],{"trials":7627,"activeCount":101},[7628],{"nctId":7629,"briefTitle":7630,"status":126,"phases":7631,"primaryCompletion":7632,"completion":7633,"start":7634,"enrollment":9,"conditions":7635,"interventions":7636},"NCT03849287","Compare the Pharmacokinetics and Safety of CKD-333 With Co-administration CKD-330 and D090 in Healthy Male Adults",[89],"2019-03-29","2019-04-06","2019-02-25",[15,18],[7622,7637,7638],"CKD-333, formula II","CKD-330, D090",{"trials":7640,"activeCount":101},[],{"trials":7642,"activeCount":101},[],{"trials":7644,"activeCount":101},[],{"trials":7646,"activeCount":101},[],{"intervention":7637,"totalTrials":144,"cells":7648},{"EARLY_PHASE1":7649,"PHASE1":7651,"PHASE2":7657,"PHASE3":7659,"PHASE4":7661,"NA":7663},{"trials":7650,"activeCount":101},[],{"trials":7652,"activeCount":101},[7653],{"nctId":7629,"briefTitle":7630,"status":126,"phases":7654,"primaryCompletion":7632,"completion":7633,"start":7634,"enrollment":9,"conditions":7655,"interventions":7656},[89],[15,18],[7622,7637,7638],{"trials":7658,"activeCount":101},[],{"trials":7660,"activeCount":101},[],{"trials":7662,"activeCount":101},[],{"trials":7664,"activeCount":101},[],{"intervention":7638,"totalTrials":144,"cells":7666},{"EARLY_PHASE1":7667,"PHASE1":7669,"PHASE2":7675,"PHASE3":7677,"PHASE4":7679,"NA":7681},{"trials":7668,"activeCount":101},[],{"trials":7670,"activeCount":101},[7671],{"nctId":7629,"briefTitle":7630,"status":126,"phases":7672,"primaryCompletion":7632,"completion":7633,"start":7634,"enrollment":9,"conditions":7673,"interventions":7674},[89],[15,18],[7622,7637,7638],{"trials":7676,"activeCount":101},[],{"trials":7678,"activeCount":101},[],{"trials":7680,"activeCount":101},[],{"trials":7682,"activeCount":101},[],{"intervention":7684,"totalTrials":144,"cells":7685},"CKD-510",{"EARLY_PHASE1":7686,"PHASE1":7688,"PHASE2":7698,"PHASE3":7700,"PHASE4":7702,"NA":7704},{"trials":7687,"activeCount":101},[],{"trials":7689,"activeCount":101},[7690],{"nctId":7691,"briefTitle":7692,"status":107,"phases":7693,"primaryCompletion":7694,"completion":7694,"start":7695,"enrollment":3716,"conditions":7696,"interventions":7697},"NCT05526742","A Study to Evaluate the Relative Bioavailability of Formulations of CKD-510 and to Assess the Effect of Food on the CKD-510 Tablet Formulation in Healthy Subjects",[89],"2022-09-13","2022-08-24",[6119],[7684,7684,7684],{"trials":7699,"activeCount":101},[],{"trials":7701,"activeCount":101},[],{"trials":7703,"activeCount":101},[],{"trials":7705,"activeCount":101},[],{"intervention":5721,"totalTrials":144,"cells":7707},{"EARLY_PHASE1":7708,"PHASE1":7710,"PHASE2":7716,"PHASE3":7718,"PHASE4":7720,"NA":7722},{"trials":7709,"activeCount":101},[],{"trials":7711,"activeCount":101},[7712],{"nctId":5715,"briefTitle":5716,"status":107,"phases":7713,"primaryCompletion":2279,"completion":2279,"start":5718,"enrollment":9,"conditions":7714,"interventions":7715},[89],[3290],[5708,5721],{"trials":7717,"activeCount":101},[],{"trials":7719,"activeCount":101},[],{"trials":7721,"activeCount":101},[],{"trials":7723,"activeCount":101},[],{"intervention":5751,"totalTrials":144,"cells":7725},{"EARLY_PHASE1":7726,"PHASE1":7728,"PHASE2":7734,"PHASE3":7736,"PHASE4":7738,"NA":7740},{"trials":7727,"activeCount":101},[],{"trials":7729,"activeCount":101},[7730],{"nctId":5744,"briefTitle":5745,"status":107,"phases":7731,"primaryCompletion":5747,"completion":5748,"start":5164,"enrollment":594,"conditions":7732,"interventions":7733},[89],[4963],[5751,5752,4983],{"trials":7735,"activeCount":101},[],{"trials":7737,"activeCount":101},[],{"trials":7739,"activeCount":101},[],{"trials":7741,"activeCount":101},[],{"intervention":5752,"totalTrials":144,"cells":7743},{"EARLY_PHASE1":7744,"PHASE1":7746,"PHASE2":7752,"PHASE3":7754,"PHASE4":7756,"NA":7758},{"trials":7745,"activeCount":101},[],{"trials":7747,"activeCount":101},[7748],{"nctId":5744,"briefTitle":5745,"status":107,"phases":7749,"primaryCompletion":5747,"completion":5748,"start":5164,"enrollment":594,"conditions":7750,"interventions":7751},[89],[4963],[5751,5752,4983],{"trials":7753,"activeCount":101},[],{"trials":7755,"activeCount":101},[],{"trials":7757,"activeCount":101},[],{"trials":7759,"activeCount":101},[],{"intervention":5158,"totalTrials":144,"cells":7761},{"EARLY_PHASE1":7762,"PHASE1":7764,"PHASE2":7770,"PHASE3":7772,"PHASE4":7774,"NA":7776},{"trials":7763,"activeCount":101},[],{"trials":7765,"activeCount":101},[7766],{"nctId":5149,"briefTitle":5150,"status":107,"phases":7767,"primaryCompletion":5152,"completion":5153,"start":5154,"enrollment":485,"conditions":7768,"interventions":7769},[89],[5156],[5142,5158],{"trials":7771,"activeCount":101},[],{"trials":7773,"activeCount":101},[],{"trials":7775,"activeCount":101},[],{"trials":7777,"activeCount":101},[],{"intervention":5128,"totalTrials":144,"cells":7779},{"EARLY_PHASE1":7780,"PHASE1":7782,"PHASE2":7788,"PHASE3":7790,"PHASE4":7792,"NA":7794},{"trials":7781,"activeCount":101},[],{"trials":7783,"activeCount":101},[7784],{"nctId":5123,"briefTitle":5124,"status":126,"phases":7785,"primaryCompletion":1193,"completion":1193,"start":3956,"enrollment":781,"conditions":7786,"interventions":7787},[89],[4793],[5128,5128,4803],{"trials":7789,"activeCount":101},[],{"trials":7791,"activeCount":101},[],{"trials":7793,"activeCount":101},[],{"trials":7795,"activeCount":101},[],{"intervention":7797,"totalTrials":144,"cells":7798},"CKD-341",{"EARLY_PHASE1":7799,"PHASE1":7801,"PHASE2":7811,"PHASE3":7813,"PHASE4":7815,"NA":7817},{"trials":7800,"activeCount":101},[],{"trials":7802,"activeCount":101},[7803],{"nctId":7804,"briefTitle":7805,"status":107,"phases":7806,"primaryCompletion":7807,"completion":7808,"start":2569,"enrollment":415,"conditions":7809,"interventions":7810},"NCT05571813","Exploratory Trial to Evaluate the Pharmacokinetic Properties and Safety of CKD-341 in Healthy Subjects",[89],"2022-12-04","2022-12-23",[15],[7797],{"trials":7812,"activeCount":101},[],{"trials":7814,"activeCount":101},[],{"trials":7816,"activeCount":101},[],{"trials":7818,"activeCount":101},[],{"intervention":5313,"totalTrials":144,"cells":7820},{"EARLY_PHASE1":7821,"PHASE1":7823,"PHASE2":7829,"PHASE3":7831,"PHASE4":7833,"NA":7835},{"trials":7822,"activeCount":101},[],{"trials":7824,"activeCount":101},[7825],{"nctId":5307,"briefTitle":5308,"status":107,"phases":7826,"primaryCompletion":1063,"completion":1063,"start":5310,"enrollment":1949,"conditions":7827,"interventions":7828},[89],[15,3154],[5313,5007,5314,5314],{"trials":7830,"activeCount":101},[],{"trials":7832,"activeCount":101},[],{"trials":7834,"activeCount":101},[],{"trials":7836,"activeCount":101},[],{"intervention":5314,"totalTrials":144,"cells":7838},{"EARLY_PHASE1":7839,"PHASE1":7841,"PHASE2":7847,"PHASE3":7849,"PHASE4":7851,"NA":7853},{"trials":7840,"activeCount":101},[],{"trials":7842,"activeCount":101},[7843],{"nctId":5307,"briefTitle":5308,"status":107,"phases":7844,"primaryCompletion":1063,"completion":1063,"start":5310,"enrollment":1949,"conditions":7845,"interventions":7846},[89],[15,3154],[5313,5007,5314,5314],{"trials":7848,"activeCount":101},[],{"trials":7850,"activeCount":101},[],{"trials":7852,"activeCount":101},[],{"trials":7854,"activeCount":101},[],{"intervention":946,"totalTrials":144,"cells":7856},{"EARLY_PHASE1":7857,"PHASE1":7859,"PHASE2":7865,"PHASE3":7867,"PHASE4":7869,"NA":7871},{"trials":7858,"activeCount":101},[],{"trials":7860,"activeCount":101},[7861],{"nctId":936,"briefTitle":937,"status":107,"phases":7862,"primaryCompletion":939,"completion":940,"start":941,"enrollment":415,"conditions":7863,"interventions":7864},[89],[943,944],[946,929],{"trials":7866,"activeCount":101},[],{"trials":7868,"activeCount":101},[],{"trials":7870,"activeCount":101},[],{"trials":7872,"activeCount":101},[],{"intervention":7874,"totalTrials":144,"cells":7875},"D745, D759, D150",{"EARLY_PHASE1":7876,"PHASE1":7878,"PHASE2":7890,"PHASE3":7892,"PHASE4":7894,"NA":7896},{"trials":7877,"activeCount":101},[],{"trials":7879,"activeCount":101},[7880],{"nctId":7881,"briefTitle":7882,"status":107,"phases":7883,"primaryCompletion":7884,"completion":7885,"start":7886,"enrollment":594,"conditions":7887,"interventions":7889},"NCT05928637","A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of D745, D759, and D150",[89],"2023-08-29","2023-09-05","2023-07-10",[7888],"Diabetes type2",[7874],{"trials":7891,"activeCount":101},[],{"trials":7893,"activeCount":101},[],{"trials":7895,"activeCount":101},[],{"trials":7897,"activeCount":101},[],{"intervention":5802,"totalTrials":144,"cells":7899},{"EARLY_PHASE1":7900,"PHASE1":7902,"PHASE2":7908,"PHASE3":7910,"PHASE4":7912,"NA":7914},{"trials":7901,"activeCount":101},[],{"trials":7903,"activeCount":101},[7904],{"nctId":5795,"briefTitle":5796,"status":107,"phases":7905,"primaryCompletion":5798,"completion":5798,"start":1846,"enrollment":2280,"conditions":7906,"interventions":7907},[89],[5800],[5802,5803,5788],{"trials":7909,"activeCount":101},[],{"trials":7911,"activeCount":101},[],{"trials":7913,"activeCount":101},[],{"trials":7915,"activeCount":101},[],{"intervention":5803,"totalTrials":144,"cells":7917},{"EARLY_PHASE1":7918,"PHASE1":7920,"PHASE2":7926,"PHASE3":7928,"PHASE4":7930,"NA":7932},{"trials":7919,"activeCount":101},[],{"trials":7921,"activeCount":101},[7922],{"nctId":5795,"briefTitle":5796,"status":107,"phases":7923,"primaryCompletion":5798,"completion":5798,"start":1846,"enrollment":2280,"conditions":7924,"interventions":7925},[89],[5800],[5802,5803,5788],{"trials":7927,"activeCount":101},[],{"trials":7929,"activeCount":101},[],{"trials":7931,"activeCount":101},[],{"trials":7933,"activeCount":101},[],{"intervention":7935,"totalTrials":144,"cells":7936},"1",{"EARLY_PHASE1":7937,"PHASE1":7939,"PHASE2":7952,"PHASE3":7954,"PHASE4":7956,"NA":7958},{"trials":7938,"activeCount":101},[],{"trials":7940,"activeCount":101},[7941],{"nctId":7942,"briefTitle":7943,"status":107,"phases":7944,"primaryCompletion":780,"completion":780,"start":5577,"enrollment":9,"conditions":7945,"interventions":7946},"NCT02288338","CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy Volunteers",[89],[25],[7935,7935,7935,7947,7947,7947,7948,7948,7948,7949,7949,7949,7950,7950,7950,7951,7951,7951],"2","3","4","5","6",{"trials":7953,"activeCount":101},[],{"trials":7955,"activeCount":101},[],{"trials":7957,"activeCount":101},[],{"trials":7959,"activeCount":101},[],{"intervention":7947,"totalTrials":144,"cells":7961},{"EARLY_PHASE1":7962,"PHASE1":7964,"PHASE2":7970,"PHASE3":7972,"PHASE4":7974,"NA":7976},{"trials":7963,"activeCount":101},[],{"trials":7965,"activeCount":101},[7966],{"nctId":7942,"briefTitle":7943,"status":107,"phases":7967,"primaryCompletion":780,"completion":780,"start":5577,"enrollment":9,"conditions":7968,"interventions":7969},[89],[25],[7935,7935,7935,7947,7947,7947,7948,7948,7948,7949,7949,7949,7950,7950,7950,7951,7951,7951],{"trials":7971,"activeCount":101},[],{"trials":7973,"activeCount":101},[],{"trials":7975,"activeCount":101},[],{"trials":7977,"activeCount":101},[],{"intervention":7948,"totalTrials":144,"cells":7979},{"EARLY_PHASE1":7980,"PHASE1":7982,"PHASE2":7988,"PHASE3":7990,"PHASE4":7992,"NA":7994},{"trials":7981,"activeCount":101},[],{"trials":7983,"activeCount":101},[7984],{"nctId":7942,"briefTitle":7943,"status":107,"phases":7985,"primaryCompletion":780,"completion":780,"start":5577,"enrollment":9,"conditions":7986,"interventions":7987},[89],[25],[7935,7935,7935,7947,7947,7947,7948,7948,7948,7949,7949,7949,7950,7950,7950,7951,7951,7951],{"trials":7989,"activeCount":101},[],{"trials":7991,"activeCount":101},[],{"trials":7993,"activeCount":101},[],{"trials":7995,"activeCount":101},[],{"intervention":7949,"totalTrials":144,"cells":7997},{"EARLY_PHASE1":7998,"PHASE1":8000,"PHASE2":8006,"PHASE3":8008,"PHASE4":8010,"NA":8012},{"trials":7999,"activeCount":101},[],{"trials":8001,"activeCount":101},[8002],{"nctId":7942,"briefTitle":7943,"status":107,"phases":8003,"primaryCompletion":780,"completion":780,"start":5577,"enrollment":9,"conditions":8004,"interventions":8005},[89],[25],[7935,7935,7935,7947,7947,7947,7948,7948,7948,7949,7949,7949,7950,7950,7950,7951,7951,7951],{"trials":8007,"activeCount":101},[],{"trials":8009,"activeCount":101},[],{"trials":8011,"activeCount":101},[],{"trials":8013,"activeCount":101},[],{"intervention":7950,"totalTrials":144,"cells":8015},{"EARLY_PHASE1":8016,"PHASE1":8018,"PHASE2":8024,"PHASE3":8026,"PHASE4":8028,"NA":8030},{"trials":8017,"activeCount":101},[],{"trials":8019,"activeCount":101},[8020],{"nctId":7942,"briefTitle":7943,"status":107,"phases":8021,"primaryCompletion":780,"completion":780,"start":5577,"enrollment":9,"conditions":8022,"interventions":8023},[89],[25],[7935,7935,7935,7947,7947,7947,7948,7948,7948,7949,7949,7949,7950,7950,7950,7951,7951,7951],{"trials":8025,"activeCount":101},[],{"trials":8027,"activeCount":101},[],{"trials":8029,"activeCount":101},[],{"trials":8031,"activeCount":101},[],{"intervention":7951,"totalTrials":144,"cells":8033},{"EARLY_PHASE1":8034,"PHASE1":8036,"PHASE2":8042,"PHASE3":8044,"PHASE4":8046,"NA":8048},{"trials":8035,"activeCount":101},[],{"trials":8037,"activeCount":101},[8038],{"nctId":7942,"briefTitle":7943,"status":107,"phases":8039,"primaryCompletion":780,"completion":780,"start":5577,"enrollment":9,"conditions":8040,"interventions":8041},[89],[25],[7935,7935,7935,7947,7947,7947,7948,7948,7948,7949,7949,7949,7950,7950,7950,7951,7951,7951],{"trials":8043,"activeCount":101},[],{"trials":8045,"activeCount":101},[],{"trials":8047,"activeCount":101},[],{"trials":8049,"activeCount":101},[],{"intervention":8051,"totalTrials":144,"cells":8052},"Treat Regimen",{"EARLY_PHASE1":8053,"PHASE1":8055,"PHASE2":8064,"PHASE3":8066,"PHASE4":8068,"NA":8070},{"trials":8054,"activeCount":101},[],{"trials":8056,"activeCount":101},[8057],{"nctId":8058,"briefTitle":8059,"status":126,"phases":8060,"primaryCompletion":1150,"completion":1465,"start":8061,"enrollment":4810,"conditions":8062,"interventions":8063},"NCT03150316","CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma",[89],"2017-05-10",[5256],[8051],{"trials":8065,"activeCount":101},[],{"trials":8067,"activeCount":101},[],{"trials":8069,"activeCount":101},[],{"trials":8071,"activeCount":101},[],{"intervention":8073,"totalTrials":144,"cells":8074},"CKD-330 16\u002F10mg Tab. 1T and D086 Tab. 1T",{"EARLY_PHASE1":8075,"PHASE1":8077,"PHASE2":8090,"PHASE3":8092,"PHASE4":8094,"NA":8096},{"trials":8076,"activeCount":101},[],{"trials":8078,"activeCount":101},[8079],{"nctId":8080,"briefTitle":8081,"status":107,"phases":8082,"primaryCompletion":8083,"completion":8084,"start":8085,"enrollment":594,"conditions":8086,"interventions":8087},"NCT04019743","Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of CKD-333 in Healthy Volunteers",[89],"2019-08-30","2019-09-04","2019-07-28",[15,18],[8073,8088,8089],"CKD-333 16\u002F10\u002F40mg formulation 1 Tab. 1T","CKD-333 16\u002F10\u002F40mg formulation 2 Tab. 1T",{"trials":8091,"activeCount":101},[],{"trials":8093,"activeCount":101},[],{"trials":8095,"activeCount":101},[],{"trials":8097,"activeCount":101},[],{"intervention":8088,"totalTrials":144,"cells":8099},{"EARLY_PHASE1":8100,"PHASE1":8102,"PHASE2":8108,"PHASE3":8110,"PHASE4":8112,"NA":8114},{"trials":8101,"activeCount":101},[],{"trials":8103,"activeCount":101},[8104],{"nctId":8080,"briefTitle":8081,"status":107,"phases":8105,"primaryCompletion":8083,"completion":8084,"start":8085,"enrollment":594,"conditions":8106,"interventions":8107},[89],[15,18],[8073,8088,8089],{"trials":8109,"activeCount":101},[],{"trials":8111,"activeCount":101},[],{"trials":8113,"activeCount":101},[],{"trials":8115,"activeCount":101},[],{"intervention":8089,"totalTrials":144,"cells":8117},{"EARLY_PHASE1":8118,"PHASE1":8120,"PHASE2":8126,"PHASE3":8128,"PHASE4":8130,"NA":8132},{"trials":8119,"activeCount":101},[],{"trials":8121,"activeCount":101},[8122],{"nctId":8080,"briefTitle":8081,"status":107,"phases":8123,"primaryCompletion":8083,"completion":8084,"start":8085,"enrollment":594,"conditions":8124,"interventions":8125},[89],[15,18],[8073,8088,8089],{"trials":8127,"activeCount":101},[],{"trials":8129,"activeCount":101},[],{"trials":8131,"activeCount":101},[],{"trials":8133,"activeCount":101},[],{"intervention":8135,"totalTrials":144,"cells":8136},"CKD-382, D860, D027",{"EARLY_PHASE1":8137,"PHASE1":8139,"PHASE2":8150,"PHASE3":8152,"PHASE4":8154,"NA":8156},{"trials":8138,"activeCount":101},[],{"trials":8140,"activeCount":101},[8141],{"nctId":8142,"briefTitle":8143,"status":126,"phases":8144,"primaryCompletion":8145,"completion":8145,"start":8146,"enrollment":8147,"conditions":8148,"interventions":8149},"NCT05108038","A Study to Evaluate the PK, PD and Safety of CKD-382 in Healthy Subjects",[89],"2022-02","2021-10-07",42,[4793],[8135],{"trials":8151,"activeCount":101},[],{"trials":8153,"activeCount":101},[],{"trials":8155,"activeCount":101},[],{"trials":8157,"activeCount":101},[],{"intervention":8159,"totalTrials":144,"cells":8160},"CKD-516 inj",{"EARLY_PHASE1":8161,"PHASE1":8163,"PHASE2":8172,"PHASE3":8174,"PHASE4":8176,"NA":8178},{"trials":8162,"activeCount":101},[],{"trials":8164,"activeCount":101},[8165],{"nctId":8166,"briefTitle":8167,"status":107,"phases":8168,"primaryCompletion":1986,"completion":1986,"start":4657,"enrollment":415,"conditions":8169,"interventions":8171},"NCT01028859","Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers",[89],[8170],"Unspecified Adult Solid Tumor, Protocol Specific",[8159],{"trials":8173,"activeCount":101},[],{"trials":8175,"activeCount":101},[],{"trials":8177,"activeCount":101},[],{"trials":8179,"activeCount":101},[],{"intervention":5841,"totalTrials":144,"cells":8181},{"EARLY_PHASE1":8182,"PHASE1":8184,"PHASE2":8190,"PHASE3":8192,"PHASE4":8194,"NA":8196},{"trials":8183,"activeCount":101},[],{"trials":8185,"activeCount":101},[8186],{"nctId":5831,"briefTitle":5832,"status":126,"phases":8187,"primaryCompletion":5834,"completion":5835,"start":5836,"enrollment":5837,"conditions":8188,"interventions":8189},[89],[5839],[5841,5824],{"trials":8191,"activeCount":101},[],{"trials":8193,"activeCount":101},[],{"trials":8195,"activeCount":101},[],{"trials":8197,"activeCount":101},[],{"intervention":8199,"totalTrials":144,"cells":8200},"CKD-501 and D759",{"EARLY_PHASE1":8201,"PHASE1":8203,"PHASE2":8215,"PHASE3":8217,"PHASE4":8219,"NA":8221},{"trials":8202,"activeCount":101},[],{"trials":8204,"activeCount":101},[8205],{"nctId":8206,"briefTitle":8207,"status":126,"phases":8208,"primaryCompletion":8209,"completion":8210,"start":8211,"enrollment":4666,"conditions":8212,"interventions":8213},"NCT04246190","A Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-396",[89],"2020-04-10","2020-07-16","2020-02-24",[441],[8199,8214],"CKD-396",{"trials":8216,"activeCount":101},[],{"trials":8218,"activeCount":101},[],{"trials":8220,"activeCount":101},[],{"trials":8222,"activeCount":101},[],{"intervention":8214,"totalTrials":144,"cells":8224},{"EARLY_PHASE1":8225,"PHASE1":8227,"PHASE2":8233,"PHASE3":8235,"PHASE4":8237,"NA":8239},{"trials":8226,"activeCount":101},[],{"trials":8228,"activeCount":101},[8229],{"nctId":8206,"briefTitle":8207,"status":126,"phases":8230,"primaryCompletion":8209,"completion":8210,"start":8211,"enrollment":4666,"conditions":8231,"interventions":8232},[89],[441],[8199,8214],{"trials":8234,"activeCount":101},[],{"trials":8236,"activeCount":101},[],{"trials":8238,"activeCount":101},[],{"trials":8240,"activeCount":101},[],{"intervention":8242,"totalTrials":144,"cells":8243},"CKD-702",{"EARLY_PHASE1":8244,"PHASE1":8246,"PHASE2":8258,"PHASE3":8260,"PHASE4":8262,"NA":8264},{"trials":8245,"activeCount":101},[],{"trials":8247,"activeCount":101},[8248],{"nctId":8249,"briefTitle":8250,"status":126,"phases":8251,"primaryCompletion":8252,"completion":8253,"start":8254,"enrollment":8255,"conditions":8256,"interventions":8257},"NCT04667975","The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy",[89],"2021-08-15","2024-08-30","2020-05-21",74,[393],[8242],{"trials":8259,"activeCount":101},[],{"trials":8261,"activeCount":101},[],{"trials":8263,"activeCount":101},[],{"trials":8265,"activeCount":101},[],{"intervention":8267,"totalTrials":144,"cells":8268},"CKD-378, QD, PO",{"EARLY_PHASE1":8269,"PHASE1":8271,"PHASE2":8282,"PHASE3":8284,"PHASE4":8286,"NA":8288},{"trials":8270,"activeCount":101},[],{"trials":8272,"activeCount":101},[8273],{"nctId":8274,"briefTitle":8275,"status":107,"phases":8276,"primaryCompletion":8277,"completion":8278,"start":8279,"enrollment":485,"conditions":8280,"interventions":8281},"NCT06386328","A Clinical Trial to Evaluate the Food Effect of CKD-378",[89],"2024-06-03","2024-06-13","2024-05-03",[4963],[8267],{"trials":8283,"activeCount":101},[],{"trials":8285,"activeCount":101},[],{"trials":8287,"activeCount":101},[],{"trials":8289,"activeCount":101},[],{"intervention":8291,"totalTrials":144,"cells":8292},"Dilatrend SR capsule 32mg",{"EARLY_PHASE1":8293,"PHASE1":8295,"PHASE2":8305,"PHASE3":8307,"PHASE4":8309,"NA":8311},{"trials":8294,"activeCount":101},[],{"trials":8296,"activeCount":101},[8297],{"nctId":8298,"briefTitle":8299,"status":126,"phases":8300,"primaryCompletion":2193,"completion":8301,"start":1568,"enrollment":781,"conditions":8302,"interventions":8303},"NCT01819870","Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg",[89],"2013-08",[28,7250,1055],[8291,8304],"Dilatrend IR tablet 25mg",{"trials":8306,"activeCount":101},[],{"trials":8308,"activeCount":101},[],{"trials":8310,"activeCount":101},[],{"trials":8312,"activeCount":101},[],{"intervention":8304,"totalTrials":144,"cells":8314},{"EARLY_PHASE1":8315,"PHASE1":8317,"PHASE2":8323,"PHASE3":8325,"PHASE4":8327,"NA":8329},{"trials":8316,"activeCount":101},[],{"trials":8318,"activeCount":101},[8319],{"nctId":8298,"briefTitle":8299,"status":126,"phases":8320,"primaryCompletion":2193,"completion":8301,"start":1568,"enrollment":781,"conditions":8321,"interventions":8322},[89],[28,7250,1055],[8291,8304],{"trials":8324,"activeCount":101},[],{"trials":8326,"activeCount":101},[],{"trials":8328,"activeCount":101},[],{"trials":8330,"activeCount":101},[],{"intervention":4478,"totalTrials":144,"cells":8332},{"EARLY_PHASE1":8333,"PHASE1":8335,"PHASE2":8341,"PHASE3":8343,"PHASE4":8345,"NA":8347},{"trials":8334,"activeCount":101},[],{"trials":8336,"activeCount":101},[8337],{"nctId":4470,"briefTitle":4471,"status":107,"phases":8338,"primaryCompletion":4473,"completion":4474,"start":4475,"enrollment":415,"conditions":8339,"interventions":8340},[89],[15,18],[4478,4479,4434],{"trials":8342,"activeCount":101},[],{"trials":8344,"activeCount":101},[],{"trials":8346,"activeCount":101},[],{"trials":8348,"activeCount":101},[],{"intervention":4479,"totalTrials":144,"cells":8350},{"EARLY_PHASE1":8351,"PHASE1":8353,"PHASE2":8359,"PHASE3":8361,"PHASE4":8363,"NA":8365},{"trials":8352,"activeCount":101},[],{"trials":8354,"activeCount":101},[8355],{"nctId":4470,"briefTitle":4471,"status":107,"phases":8356,"primaryCompletion":4473,"completion":4474,"start":4475,"enrollment":415,"conditions":8357,"interventions":8358},[89],[15,18],[4478,4479,4434],{"trials":8360,"activeCount":101},[],{"trials":8362,"activeCount":101},[],{"trials":8364,"activeCount":101},[],{"trials":8366,"activeCount":101},[],{"intervention":8368,"totalTrials":144,"cells":8369},"Part A, Reference",{"EARLY_PHASE1":8370,"PHASE1":8372,"PHASE2":8384,"PHASE3":8386,"PHASE4":8388,"NA":8390},{"trials":8371,"activeCount":101},[],{"trials":8373,"activeCount":101},[8374],{"nctId":8375,"briefTitle":8376,"status":107,"phases":8377,"primaryCompletion":8083,"completion":8378,"start":8379,"enrollment":8380,"conditions":8381,"interventions":8382},"NCT04156685","Pharmacokinetics, Safety and Tolerability of CKD-387 10\u002F500mg BE Phase1",[89],"2019-10-02","2019-08-06",58,[441],[8368,8368,8383,8383],"Part B, Reference",{"trials":8385,"activeCount":101},[],{"trials":8387,"activeCount":101},[],{"trials":8389,"activeCount":101},[],{"trials":8391,"activeCount":101},[],{"intervention":8383,"totalTrials":144,"cells":8393},{"EARLY_PHASE1":8394,"PHASE1":8396,"PHASE2":8402,"PHASE3":8404,"PHASE4":8406,"NA":8408},{"trials":8395,"activeCount":101},[],{"trials":8397,"activeCount":101},[8398],{"nctId":8375,"briefTitle":8376,"status":107,"phases":8399,"primaryCompletion":8083,"completion":8378,"start":8379,"enrollment":8380,"conditions":8400,"interventions":8401},[89],[441],[8368,8368,8383,8383],{"trials":8403,"activeCount":101},[],{"trials":8405,"activeCount":101},[],{"trials":8407,"activeCount":101},[],{"trials":8409,"activeCount":101},[],{"intervention":8411,"totalTrials":144,"cells":8412},"CKD-341, D958",{"EARLY_PHASE1":8413,"PHASE1":8415,"PHASE2":8424,"PHASE3":8426,"PHASE4":8428,"NA":8430},{"trials":8414,"activeCount":101},[],{"trials":8416,"activeCount":101},[8417],{"nctId":8418,"briefTitle":8419,"status":107,"phases":8420,"primaryCompletion":1916,"completion":5808,"start":8421,"enrollment":781,"conditions":8422,"interventions":8423},"NCT05921435","Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic After Oral Administration of CKD-341 and D958 in Healthy Adults",[89],"2023-06-20",[15],[8411],{"trials":8425,"activeCount":101},[],{"trials":8427,"activeCount":101},[],{"trials":8429,"activeCount":101},[],{"trials":8431,"activeCount":101},[],{"intervention":8433,"totalTrials":144,"cells":8434},"CKD-320, D012",{"EARLY_PHASE1":8435,"PHASE1":8437,"PHASE2":8448,"PHASE3":8450,"PHASE4":8452,"NA":8454},{"trials":8436,"activeCount":101},[],{"trials":8438,"activeCount":101},[8439],{"nctId":8440,"briefTitle":8441,"status":126,"phases":8442,"primaryCompletion":8443,"completion":8444,"start":8445,"enrollment":8147,"conditions":8446,"interventions":8447},"NCT04035538","A Clinical Study to Compare the Safety and Pharmacokinetics of CKD-320 and D012",[89],"2019-11","2019-12","2019-08",[15],[8433],{"trials":8449,"activeCount":101},[],{"trials":8451,"activeCount":101},[],{"trials":8453,"activeCount":101},[],{"trials":8455,"activeCount":101},[],{"intervention":4885,"totalTrials":144,"cells":8457},{"EARLY_PHASE1":8458,"PHASE1":8460,"PHASE2":8466,"PHASE3":8468,"PHASE4":8470,"NA":8472},{"trials":8459,"activeCount":101},[],{"trials":8461,"activeCount":101},[8462],{"nctId":4877,"briefTitle":4878,"status":107,"phases":8463,"primaryCompletion":4880,"completion":4881,"start":4882,"enrollment":415,"conditions":8464,"interventions":8465},[89],[31],[4885,443],{"trials":8467,"activeCount":101},[],{"trials":8469,"activeCount":101},[],{"trials":8471,"activeCount":101},[],{"trials":8473,"activeCount":101},[],{"intervention":8475,"totalTrials":144,"cells":8476},"D308 10mg Tab.",{"EARLY_PHASE1":8477,"PHASE1":8479,"PHASE2":8491,"PHASE3":8493,"PHASE4":8495,"NA":8497},{"trials":8478,"activeCount":101},[],{"trials":8480,"activeCount":101},[8481],{"nctId":8482,"briefTitle":8483,"status":126,"phases":8484,"primaryCompletion":8485,"completion":8486,"start":8487,"enrollment":3726,"conditions":8488,"interventions":8489},"NCT03601910","Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-380 10mg and D308 10mg",[89],"2018-09-21","2018-11-09","2018-07-16",[4963],[8475,8490],"CKD-380 10mg Tab.",{"trials":8492,"activeCount":101},[],{"trials":8494,"activeCount":101},[],{"trials":8496,"activeCount":101},[],{"trials":8498,"activeCount":101},[],{"intervention":8490,"totalTrials":144,"cells":8500},{"EARLY_PHASE1":8501,"PHASE1":8503,"PHASE2":8509,"PHASE3":8511,"PHASE4":8513,"NA":8515},{"trials":8502,"activeCount":101},[],{"trials":8504,"activeCount":101},[8505],{"nctId":8482,"briefTitle":8483,"status":126,"phases":8506,"primaryCompletion":8485,"completion":8486,"start":8487,"enrollment":3726,"conditions":8507,"interventions":8508},[89],[4963],[8475,8490],{"trials":8510,"activeCount":101},[],{"trials":8512,"activeCount":101},[],{"trials":8514,"activeCount":101},[],{"trials":8516,"activeCount":101},[],{"intervention":8518,"totalTrials":144,"cells":8519},"Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG",{"EARLY_PHASE1":8520,"PHASE1":8522,"PHASE2":8533,"PHASE3":8535,"PHASE4":8537,"NA":8539},{"trials":8521,"activeCount":101},[],{"trials":8523,"activeCount":101},[8524],{"nctId":8525,"briefTitle":8526,"status":107,"phases":8527,"primaryCompletion":8528,"completion":8529,"start":8530,"enrollment":6371,"conditions":8531,"interventions":8532},"NCT06483243","Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.",[89],"2024-04-29","2024-05-17","2024-04-04",[23],[8518],{"trials":8534,"activeCount":101},[],{"trials":8536,"activeCount":101},[],{"trials":8538,"activeCount":101},[],{"trials":8540,"activeCount":101},[],{"intervention":8542,"totalTrials":144,"cells":8543},"CKD-378, QD, PO Drug: D745, D150, QD, PO",{"EARLY_PHASE1":8544,"PHASE1":8546,"PHASE2":8556,"PHASE3":8558,"PHASE4":8560,"NA":8562},{"trials":8545,"activeCount":101},[],{"trials":8547,"activeCount":101},[8548],{"nctId":8549,"briefTitle":8550,"status":107,"phases":8551,"primaryCompletion":8552,"completion":7885,"start":8553,"enrollment":594,"conditions":8554,"interventions":8555},"NCT05741437","A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-378",[89],"2023-08-31","2023-04-11",[4539],[8542],{"trials":8557,"activeCount":101},[],{"trials":8559,"activeCount":101},[],{"trials":8561,"activeCount":101},[],{"trials":8563,"activeCount":101},[],{"intervention":5813,"totalTrials":144,"cells":8565},{"EARLY_PHASE1":8566,"PHASE1":8568,"PHASE2":8574,"PHASE3":8576,"PHASE4":8578,"NA":8580},{"trials":8567,"activeCount":101},[],{"trials":8569,"activeCount":101},[8570],{"nctId":5805,"briefTitle":5806,"status":107,"phases":8571,"primaryCompletion":5808,"completion":5809,"start":5810,"enrollment":4791,"conditions":8572,"interventions":8573},[89],[5800],[5813,5813,5814,5814,5788],{"trials":8575,"activeCount":101},[],{"trials":8577,"activeCount":101},[],{"trials":8579,"activeCount":101},[],{"trials":8581,"activeCount":101},[],{"intervention":5814,"totalTrials":144,"cells":8583},{"EARLY_PHASE1":8584,"PHASE1":8586,"PHASE2":8592,"PHASE3":8594,"PHASE4":8596,"NA":8598},{"trials":8585,"activeCount":101},[],{"trials":8587,"activeCount":101},[8588],{"nctId":5805,"briefTitle":5806,"status":107,"phases":8589,"primaryCompletion":5808,"completion":5809,"start":5810,"enrollment":4791,"conditions":8590,"interventions":8591},[89],[5800],[5813,5813,5814,5814,5788],{"trials":8593,"activeCount":101},[],{"trials":8595,"activeCount":101},[],{"trials":8597,"activeCount":101},[],{"trials":8599,"activeCount":101},[],{"intervention":8601,"totalTrials":144,"cells":8602},"LeuplinⓡInj",{"EARLY_PHASE1":8603,"PHASE1":8605,"PHASE2":8616,"PHASE3":8618,"PHASE4":8620,"NA":8622},{"trials":8604,"activeCount":101},[],{"trials":8606,"activeCount":101},[8607],{"nctId":8608,"briefTitle":8609,"status":107,"phases":8610,"primaryCompletion":8611,"completion":8611,"start":2292,"enrollment":8,"conditions":8612,"interventions":8614},"NCT03233932","CKD-841 Pharmacokinetic\u002FPharmacodynamic Study",[89],"2017-07",[8613],"Postmenopausal Disorder",[8601,8615],"CKD-841",{"trials":8617,"activeCount":101},[],{"trials":8619,"activeCount":101},[],{"trials":8621,"activeCount":101},[],{"trials":8623,"activeCount":101},[],{"intervention":8615,"totalTrials":144,"cells":8625},{"EARLY_PHASE1":8626,"PHASE1":8628,"PHASE2":8634,"PHASE3":8636,"PHASE4":8638,"NA":8640},{"trials":8627,"activeCount":101},[],{"trials":8629,"activeCount":101},[8630],{"nctId":8608,"briefTitle":8609,"status":107,"phases":8631,"primaryCompletion":8611,"completion":8611,"start":2292,"enrollment":8,"conditions":8632,"interventions":8633},[89],[8613],[8601,8615],{"trials":8635,"activeCount":101},[],{"trials":8637,"activeCount":101},[],{"trials":8639,"activeCount":101},[],{"trials":8641,"activeCount":101},[],{"intervention":8643,"totalTrials":144,"cells":8644},"Drug: CKD-391, QD, PO",{"EARLY_PHASE1":8645,"PHASE1":8647,"PHASE2":8655,"PHASE3":8657,"PHASE4":8659,"NA":8661},{"trials":8646,"activeCount":101},[],{"trials":8648,"activeCount":101},[8649],{"nctId":8650,"briefTitle":8651,"status":107,"phases":8652,"primaryCompletion":4568,"completion":4512,"start":4242,"enrollment":791,"conditions":8653,"interventions":8654},"NCT05634447","A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391",[89],[18],[8643],{"trials":8656,"activeCount":101},[],{"trials":8658,"activeCount":101},[],{"trials":8660,"activeCount":101},[],{"trials":8662,"activeCount":101},[],{"intervention":8664,"totalTrials":144,"cells":8665},"Dilatrend 64mg",{"EARLY_PHASE1":8666,"PHASE1":8668,"PHASE2":8677,"PHASE3":8679,"PHASE4":8681,"NA":8683},{"trials":8667,"activeCount":101},[],{"trials":8669,"activeCount":101},[8670],{"nctId":8671,"briefTitle":8672,"status":107,"phases":8673,"primaryCompletion":2206,"completion":2206,"start":8674,"enrollment":594,"conditions":8675,"interventions":8676},"NCT01340248","A Randomized, Open-label, Single-dose, Crossover Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of Dilatrend SR 64mg Capsule After Oral Administration in Healthy Male Volunteers",[89],"2011-07",[7250],[8664],{"trials":8678,"activeCount":101},[],{"trials":8680,"activeCount":101},[],{"trials":8682,"activeCount":101},[],{"trials":8684,"activeCount":101},[],{"intervention":2103,"totalTrials":144,"cells":8686},{"EARLY_PHASE1":8687,"PHASE1":8689,"PHASE2":8695,"PHASE3":8697,"PHASE4":8699,"NA":8701},{"trials":8688,"activeCount":101},[],{"trials":8690,"activeCount":101},[8691],{"nctId":2097,"briefTitle":2098,"status":107,"phases":8692,"primaryCompletion":2100,"completion":2100,"start":129,"enrollment":594,"conditions":8693,"interventions":8694},[89],[15],[2060,2103],{"trials":8696,"activeCount":101},[],{"trials":8698,"activeCount":101},[],{"trials":8700,"activeCount":101},[],{"trials":8702,"activeCount":101},[],{"intervention":5698,"totalTrials":144,"cells":8704},{"EARLY_PHASE1":8705,"PHASE1":8707,"PHASE2":8713,"PHASE3":8715,"PHASE4":8717,"NA":8719},{"trials":8706,"activeCount":101},[],{"trials":8708,"activeCount":101},[8709],{"nctId":5693,"briefTitle":5694,"status":107,"phases":8710,"primaryCompletion":2193,"completion":5688,"start":1568,"enrollment":594,"conditions":8711,"interventions":8712},[89],[28,3154],[5678,5698],{"trials":8714,"activeCount":101},[],{"trials":8716,"activeCount":101},[],{"trials":8718,"activeCount":101},[],{"trials":8720,"activeCount":101},[],{"intervention":5386,"totalTrials":144,"cells":8722},{"EARLY_PHASE1":8723,"PHASE1":8725,"PHASE2":8731,"PHASE3":8733,"PHASE4":8735,"NA":8737},{"trials":8724,"activeCount":101},[],{"trials":8726,"activeCount":101},[8727],{"nctId":5377,"briefTitle":5378,"status":126,"phases":8728,"primaryCompletion":5380,"completion":5380,"start":5381,"enrollment":415,"conditions":8729,"interventions":8730},[89],[15,18],[5384,5385,5386],{"trials":8732,"activeCount":101},[],{"trials":8734,"activeCount":101},[],{"trials":8736,"activeCount":101},[],{"trials":8738,"activeCount":101},[],{"intervention":6004,"totalTrials":144,"cells":8740},{"EARLY_PHASE1":8741,"PHASE1":8743,"PHASE2":8749,"PHASE3":8751,"PHASE4":8753,"NA":8755},{"trials":8742,"activeCount":101},[],{"trials":8744,"activeCount":101},[8745],{"nctId":6000,"briefTitle":4850,"status":107,"phases":8746,"primaryCompletion":2922,"completion":2647,"start":2069,"enrollment":781,"conditions":8747,"interventions":8748},[89],[34],[6004,5993],{"trials":8750,"activeCount":101},[],{"trials":8752,"activeCount":101},[],{"trials":8754,"activeCount":101},[],{"trials":8756,"activeCount":101},[],{"intervention":6034,"totalTrials":144,"cells":8758},{"EARLY_PHASE1":8759,"PHASE1":8761,"PHASE2":8767,"PHASE3":8769,"PHASE4":8771,"NA":8773},{"trials":8760,"activeCount":101},[],{"trials":8762,"activeCount":101},[8763],{"nctId":6029,"briefTitle":6030,"status":107,"phases":8764,"primaryCompletion":778,"completion":2043,"start":852,"enrollment":451,"conditions":8765,"interventions":8766},[89],[15],[6034,6022],{"trials":8768,"activeCount":101},[],{"trials":8770,"activeCount":101},[],{"trials":8772,"activeCount":101},[],{"trials":8774,"activeCount":101},[],{"intervention":8776,"totalTrials":144,"cells":8777},"Memantine Tab. 10mg",{"EARLY_PHASE1":8778,"PHASE1":8780,"PHASE2":8793,"PHASE3":8795,"PHASE4":8797,"NA":8799},{"trials":8779,"activeCount":101},[],{"trials":8781,"activeCount":101},[8782],{"nctId":8783,"briefTitle":8784,"status":107,"phases":8785,"primaryCompletion":8786,"completion":8787,"start":8788,"enrollment":4579,"conditions":8789,"interventions":8791},"NCT03569579","CKD-355 Drug-drug Interaction Study (CKD-355 DDI P1)",[89],"2018-05-21","2018-06-04","2018-04-16",[8790],"Central Nervous System Diseases",[8776,8792],"Memantine Tab. 10mg + Donepezil Tab. 10mg",{"trials":8794,"activeCount":101},[],{"trials":8796,"activeCount":101},[],{"trials":8798,"activeCount":101},[],{"trials":8800,"activeCount":101},[],{"intervention":8792,"totalTrials":144,"cells":8802},{"EARLY_PHASE1":8803,"PHASE1":8805,"PHASE2":8811,"PHASE3":8813,"PHASE4":8815,"NA":8817},{"trials":8804,"activeCount":101},[],{"trials":8806,"activeCount":101},[8807],{"nctId":8783,"briefTitle":8784,"status":107,"phases":8808,"primaryCompletion":8786,"completion":8787,"start":8788,"enrollment":4579,"conditions":8809,"interventions":8810},[89],[8790],[8776,8792],{"trials":8812,"activeCount":101},[],{"trials":8814,"activeCount":101},[],{"trials":8816,"activeCount":101},[],{"trials":8818,"activeCount":101},[],{"intervention":8820,"totalTrials":144,"cells":8821},"D113",{"EARLY_PHASE1":8822,"PHASE1":8824,"PHASE2":8838,"PHASE3":8840,"PHASE4":8842,"NA":8844},{"trials":8823,"activeCount":101},[],{"trials":8825,"activeCount":101},[8826],{"nctId":8827,"briefTitle":8828,"status":107,"phases":8829,"primaryCompletion":8830,"completion":8831,"start":8832,"enrollment":8833,"conditions":8834,"interventions":8836},"NCT05089279","Study to Evaluate the Safety and Pharmacokinetics of CKD-349 in Healthy Adult Volunteers",[89],"2022-01-18","2022-04-06","2021-11-03",71,[8835],"Chronic Heart Failure",[8820,8837],"CKD-349",{"trials":8839,"activeCount":101},[],{"trials":8841,"activeCount":101},[],{"trials":8843,"activeCount":101},[],{"trials":8845,"activeCount":101},[],{"intervention":8837,"totalTrials":144,"cells":8847},{"EARLY_PHASE1":8848,"PHASE1":8850,"PHASE2":8856,"PHASE3":8858,"PHASE4":8860,"NA":8862},{"trials":8849,"activeCount":101},[],{"trials":8851,"activeCount":101},[8852],{"nctId":8827,"briefTitle":8828,"status":107,"phases":8853,"primaryCompletion":8830,"completion":8831,"start":8832,"enrollment":8833,"conditions":8854,"interventions":8855},[89],[8835],[8820,8837],{"trials":8857,"activeCount":101},[],{"trials":8859,"activeCount":101},[],{"trials":8861,"activeCount":101},[],{"trials":8863,"activeCount":101},[],{"intervention":8865,"totalTrials":144,"cells":8866},"CKD-501 0.5 mg tablet, Glimepiride 4 mg",{"EARLY_PHASE1":8867,"PHASE1":8869,"PHASE2":8879,"PHASE3":8881,"PHASE4":8883,"NA":8885},{"trials":8868,"activeCount":101},[],{"trials":8870,"activeCount":101},[8871],{"nctId":8872,"briefTitle":8873,"status":107,"phases":8874,"primaryCompletion":3855,"completion":3856,"start":1878,"enrollment":594,"conditions":8875,"interventions":8877},"NCT01133431","The Pharmacokinetic Interaction Between CKD-501 and Sulfonylurea",[89],[8876],"Healthy Male Volunteer",[8865,8878],"CKD-501 placebo tablet, Glimepiride 4 mg",{"trials":8880,"activeCount":101},[],{"trials":8882,"activeCount":101},[],{"trials":8884,"activeCount":101},[],{"trials":8886,"activeCount":101},[],{"intervention":8878,"totalTrials":144,"cells":8888},{"EARLY_PHASE1":8889,"PHASE1":8891,"PHASE2":8897,"PHASE3":8899,"PHASE4":8901,"NA":8903},{"trials":8890,"activeCount":101},[],{"trials":8892,"activeCount":101},[8893],{"nctId":8872,"briefTitle":8873,"status":107,"phases":8894,"primaryCompletion":3855,"completion":3856,"start":1878,"enrollment":594,"conditions":8895,"interventions":8896},[89],[8876],[8865,8878],{"trials":8898,"activeCount":101},[],{"trials":8900,"activeCount":101},[],{"trials":8902,"activeCount":101},[],{"trials":8904,"activeCount":101},[],{"intervention":8906,"totalTrials":144,"cells":8907},"D578",{"EARLY_PHASE1":8908,"PHASE1":8910,"PHASE2":8922,"PHASE3":8924,"PHASE4":8926,"NA":8928},{"trials":8909,"activeCount":101},[],{"trials":8911,"activeCount":101},[8912],{"nctId":8913,"briefTitle":8914,"status":107,"phases":8915,"primaryCompletion":8787,"completion":8916,"start":8917,"enrollment":485,"conditions":8918,"interventions":8920},"NCT03671941","Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-357 and D578 in Healthy Volunteers",[89],"2018-06-18","2018-05-25",[8919],"Acute Coronary Syndrome",[8906,8921],"CKD-357",{"trials":8923,"activeCount":101},[],{"trials":8925,"activeCount":101},[],{"trials":8927,"activeCount":101},[],{"trials":8929,"activeCount":101},[],{"intervention":8921,"totalTrials":144,"cells":8931},{"EARLY_PHASE1":8932,"PHASE1":8934,"PHASE2":8940,"PHASE3":8942,"PHASE4":8944,"NA":8946},{"trials":8933,"activeCount":101},[],{"trials":8935,"activeCount":101},[8936],{"nctId":8913,"briefTitle":8914,"status":107,"phases":8937,"primaryCompletion":8787,"completion":8916,"start":8917,"enrollment":485,"conditions":8938,"interventions":8939},[89],[8919],[8906,8921],{"trials":8941,"activeCount":101},[],{"trials":8943,"activeCount":101},[],{"trials":8945,"activeCount":101},[],{"trials":8947,"activeCount":101},[],{"intervention":4895,"totalTrials":144,"cells":8949},{"EARLY_PHASE1":8950,"PHASE1":8952,"PHASE2":8958,"PHASE3":8960,"PHASE4":8962,"NA":8964},{"trials":8951,"activeCount":101},[],{"trials":8953,"activeCount":101},[8954],{"nctId":4887,"briefTitle":4888,"status":107,"phases":8955,"primaryCompletion":4890,"completion":4891,"start":4892,"enrollment":485,"conditions":8956,"interventions":8957},[89],[31],[4895,443],{"trials":8959,"activeCount":101},[],{"trials":8961,"activeCount":101},[],{"trials":8963,"activeCount":101},[],{"trials":8965,"activeCount":101},[],{"intervention":8967,"totalTrials":144,"cells":8968},"Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg",{"EARLY_PHASE1":8969,"PHASE1":8971,"PHASE2":8980,"PHASE3":8982,"PHASE4":8984,"NA":8986},{"trials":8970,"activeCount":101},[],{"trials":8972,"activeCount":101},[8973],{"nctId":8974,"briefTitle":8975,"status":107,"phases":8976,"primaryCompletion":2922,"completion":2292,"start":4665,"enrollment":4666,"conditions":8977,"interventions":8978},"NCT02685774","A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25\u002F500mg in Healthy Male Volunteers",[89],[6332],[8967,8979],"CKD-395 0.25\u002F500mg",{"trials":8981,"activeCount":101},[],{"trials":8983,"activeCount":101},[],{"trials":8985,"activeCount":101},[],{"trials":8987,"activeCount":101},[],{"intervention":8979,"totalTrials":144,"cells":8989},{"EARLY_PHASE1":8990,"PHASE1":8992,"PHASE2":8998,"PHASE3":9000,"PHASE4":9002,"NA":9004},{"trials":8991,"activeCount":101},[],{"trials":8993,"activeCount":101},[8994],{"nctId":8974,"briefTitle":8975,"status":107,"phases":8995,"primaryCompletion":2922,"completion":2292,"start":4665,"enrollment":4666,"conditions":8996,"interventions":8997},[89],[6332],[8967,8979],{"trials":8999,"activeCount":101},[],{"trials":9001,"activeCount":101},[],{"trials":9003,"activeCount":101},[],{"trials":9005,"activeCount":101},[],{"intervention":9007,"totalTrials":144,"cells":9008},"XELJANZ 5Mg",{"EARLY_PHASE1":9009,"PHASE1":9011,"PHASE2":9021,"PHASE3":9023,"PHASE4":9025,"NA":9027},{"trials":9010,"activeCount":101},[],{"trials":9012,"activeCount":101},[9013],{"nctId":9014,"briefTitle":9015,"status":107,"phases":9016,"primaryCompletion":7632,"completion":9017,"start":4547,"enrollment":2280,"conditions":9018,"interventions":9019},"NCT03868072","Study to Evaluate the Bioequivalence of Pfizer Korea Inc. \"XELJANZ 5Mg Tablet\" in Healthy Volunteers",[89],"2019-04-20",[1692],[9007,9020],"Chong Kun Dang Tofacitinib",{"trials":9022,"activeCount":101},[],{"trials":9024,"activeCount":101},[],{"trials":9026,"activeCount":101},[],{"trials":9028,"activeCount":101},[],{"intervention":9020,"totalTrials":144,"cells":9030},{"EARLY_PHASE1":9031,"PHASE1":9033,"PHASE2":9039,"PHASE3":9041,"PHASE4":9043,"NA":9045},{"trials":9032,"activeCount":101},[],{"trials":9034,"activeCount":101},[9035],{"nctId":9014,"briefTitle":9015,"status":107,"phases":9036,"primaryCompletion":7632,"completion":9017,"start":4547,"enrollment":2280,"conditions":9037,"interventions":9038},[89],[1692],[9007,9020],{"trials":9040,"activeCount":101},[],{"trials":9042,"activeCount":101},[],{"trials":9044,"activeCount":101},[],{"trials":9046,"activeCount":101},[],{"intervention":9048,"totalTrials":144,"cells":9049},"CKD-378",{"EARLY_PHASE1":9050,"PHASE1":9052,"PHASE2":9060,"PHASE3":9062,"PHASE4":9064,"NA":9066},{"trials":9051,"activeCount":101},[],{"trials":9053,"activeCount":101},[9054],{"nctId":9055,"briefTitle":9056,"status":107,"phases":9057,"primaryCompletion":3109,"completion":7886,"start":828,"enrollment":4589,"conditions":9058,"interventions":9059},"NCT05881213","Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-378 and Co-administration of D745, D150, D029 in Healthy Adults",[89],[4539],[9048],{"trials":9061,"activeCount":101},[],{"trials":9063,"activeCount":101},[],{"trials":9065,"activeCount":101},[],{"trials":9067,"activeCount":101},[],{"intervention":5667,"totalTrials":144,"cells":9069},{"EARLY_PHASE1":9070,"PHASE1":9072,"PHASE2":9078,"PHASE3":9080,"PHASE4":9082,"NA":9084},{"trials":9071,"activeCount":101},[],{"trials":9073,"activeCount":101},[9074],{"nctId":5662,"briefTitle":5663,"status":107,"phases":9075,"primaryCompletion":2369,"completion":2369,"start":2206,"enrollment":675,"conditions":9076,"interventions":9077},[89],[5657],[5667,5668],{"trials":9079,"activeCount":101},[],{"trials":9081,"activeCount":101},[],{"trials":9083,"activeCount":101},[],{"trials":9085,"activeCount":101},[],{"intervention":9087,"totalTrials":144,"cells":9088},"CKD-398",{"EARLY_PHASE1":9089,"PHASE1":9091,"PHASE2":9103,"PHASE3":9105,"PHASE4":9107,"NA":9109},{"trials":9090,"activeCount":101},[],{"trials":9092,"activeCount":101},[9093],{"nctId":9094,"briefTitle":9095,"status":107,"phases":9096,"primaryCompletion":9097,"completion":9098,"start":9099,"enrollment":451,"conditions":9100,"interventions":9101},"NCT04869800","Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg",[89],"2021-06-07","2021-06-15","2021-05-27",[23],[9087,9102],"CKD-501, D745",{"trials":9104,"activeCount":101},[],{"trials":9106,"activeCount":101},[],{"trials":9108,"activeCount":101},[],{"trials":9110,"activeCount":101},[],{"intervention":9102,"totalTrials":144,"cells":9112},{"EARLY_PHASE1":9113,"PHASE1":9115,"PHASE2":9121,"PHASE3":9123,"PHASE4":9125,"NA":9127},{"trials":9114,"activeCount":101},[],{"trials":9116,"activeCount":101},[9117],{"nctId":9094,"briefTitle":9095,"status":107,"phases":9118,"primaryCompletion":9097,"completion":9098,"start":9099,"enrollment":451,"conditions":9119,"interventions":9120},[89],[23],[9087,9102],{"trials":9122,"activeCount":101},[],{"trials":9124,"activeCount":101},[],{"trials":9126,"activeCount":101},[],{"trials":9128,"activeCount":101},[],{"intervention":9130,"totalTrials":144,"cells":9131},"CKD-519 50mg 2Tabs.",{"EARLY_PHASE1":9132,"PHASE1":9134,"PHASE2":9144,"PHASE3":9146,"PHASE4":9148,"NA":9150},{"trials":9133,"activeCount":101},[],{"trials":9135,"activeCount":101},[9136],{"nctId":9137,"briefTitle":9138,"status":107,"phases":9139,"primaryCompletion":2279,"completion":2279,"start":1309,"enrollment":415,"conditions":9140,"interventions":9141},"NCT02623868","Study to Assess PK\u002FPD Character, Safety\u002FTolerability of CKD-519 New Formulation in Healthy Male Subject.",[89],[34],[9130,9142,9143],"CKD-519 100mg 1Tab.","CKD-519 100mg 1Cap.",{"trials":9145,"activeCount":101},[],{"trials":9147,"activeCount":101},[],{"trials":9149,"activeCount":101},[],{"trials":9151,"activeCount":101},[],{"intervention":9142,"totalTrials":144,"cells":9153},{"EARLY_PHASE1":9154,"PHASE1":9156,"PHASE2":9162,"PHASE3":9164,"PHASE4":9166,"NA":9168},{"trials":9155,"activeCount":101},[],{"trials":9157,"activeCount":101},[9158],{"nctId":9137,"briefTitle":9138,"status":107,"phases":9159,"primaryCompletion":2279,"completion":2279,"start":1309,"enrollment":415,"conditions":9160,"interventions":9161},[89],[34],[9130,9142,9143],{"trials":9163,"activeCount":101},[],{"trials":9165,"activeCount":101},[],{"trials":9167,"activeCount":101},[],{"trials":9169,"activeCount":101},[],{"intervention":9143,"totalTrials":144,"cells":9171},{"EARLY_PHASE1":9172,"PHASE1":9174,"PHASE2":9180,"PHASE3":9182,"PHASE4":9184,"NA":9186},{"trials":9173,"activeCount":101},[],{"trials":9175,"activeCount":101},[9176],{"nctId":9137,"briefTitle":9138,"status":107,"phases":9177,"primaryCompletion":2279,"completion":2279,"start":1309,"enrollment":415,"conditions":9178,"interventions":9179},[89],[34],[9130,9142,9143],{"trials":9181,"activeCount":101},[],{"trials":9183,"activeCount":101},[],{"trials":9185,"activeCount":101},[],{"trials":9187,"activeCount":101},[],{"intervention":5349,"totalTrials":144,"cells":9189},{"EARLY_PHASE1":9190,"PHASE1":9192,"PHASE2":9198,"PHASE3":9200,"PHASE4":9202,"NA":9204},{"trials":9191,"activeCount":101},[],{"trials":9193,"activeCount":101},[9194],{"nctId":5341,"briefTitle":5342,"status":126,"phases":9195,"primaryCompletion":5344,"completion":5345,"start":5346,"enrollment":4666,"conditions":9196,"interventions":9197},[89],[441],[5324,5349],{"trials":9199,"activeCount":101},[],{"trials":9201,"activeCount":101},[],{"trials":9203,"activeCount":101},[],{"trials":9205,"activeCount":101},[],{"intervention":9207,"totalTrials":144,"cells":9208},"T",{"EARLY_PHASE1":9209,"PHASE1":9211,"PHASE2":9221,"PHASE3":9223,"PHASE4":9225,"NA":9227},{"trials":9210,"activeCount":101},[],{"trials":9212,"activeCount":101},[9213],{"nctId":9214,"briefTitle":9215,"status":107,"phases":9216,"primaryCompletion":9217,"completion":6329,"start":912,"enrollment":6371,"conditions":9218,"interventions":9219},"NCT03793985","Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D086 and D337",[89],"2018-10-23",[2134],[9207,9220],"R",{"trials":9222,"activeCount":101},[],{"trials":9224,"activeCount":101},[],{"trials":9226,"activeCount":101},[],{"trials":9228,"activeCount":101},[],{"intervention":9220,"totalTrials":144,"cells":9230},{"EARLY_PHASE1":9231,"PHASE1":9233,"PHASE2":9239,"PHASE3":9241,"PHASE4":9243,"NA":9245},{"trials":9232,"activeCount":101},[],{"trials":9234,"activeCount":101},[9235],{"nctId":9214,"briefTitle":9215,"status":107,"phases":9236,"primaryCompletion":9217,"completion":6329,"start":912,"enrollment":6371,"conditions":9237,"interventions":9238},[89],[2134],[9207,9220],{"trials":9240,"activeCount":101},[],{"trials":9242,"activeCount":101},[],{"trials":9244,"activeCount":101},[],{"trials":9246,"activeCount":101},[],{"intervention":9248,"totalTrials":144,"cells":9249},"Candesartan 32mg",{"EARLY_PHASE1":9250,"PHASE1":9252,"PHASE2":9261,"PHASE3":9263,"PHASE4":9265,"NA":9267},{"trials":9251,"activeCount":101},[],{"trials":9253,"activeCount":101},[9254],{"nctId":9255,"briefTitle":9256,"status":107,"phases":9257,"primaryCompletion":1087,"completion":1087,"start":1028,"enrollment":594,"conditions":9258,"interventions":9259},"NCT02064621","CKD-330 Drug-Drug Interaction Study (Candesartan)",[89],[15],[9248,9260],"Candesartan 32mg\u002FAmlodipine 10mg",{"trials":9262,"activeCount":101},[],{"trials":9264,"activeCount":101},[],{"trials":9266,"activeCount":101},[],{"trials":9268,"activeCount":101},[],{"intervention":9260,"totalTrials":144,"cells":9270},{"EARLY_PHASE1":9271,"PHASE1":9273,"PHASE2":9279,"PHASE3":9281,"PHASE4":9283,"NA":9285},{"trials":9272,"activeCount":101},[],{"trials":9274,"activeCount":101},[9275],{"nctId":9255,"briefTitle":9256,"status":107,"phases":9276,"primaryCompletion":1087,"completion":1087,"start":1028,"enrollment":594,"conditions":9277,"interventions":9278},[89],[15],[9248,9260],{"trials":9280,"activeCount":101},[],{"trials":9282,"activeCount":101},[],{"trials":9284,"activeCount":101},[],{"trials":9286,"activeCount":101},[],{"intervention":6041,"totalTrials":144,"cells":9288},{"EARLY_PHASE1":9289,"PHASE1":9291,"PHASE2":9297,"PHASE3":9299,"PHASE4":9301,"NA":9303},{"trials":9290,"activeCount":101},[],{"trials":9292,"activeCount":101},[9293],{"nctId":6036,"briefTitle":6037,"status":107,"phases":9294,"primaryCompletion":778,"completion":2043,"start":852,"enrollment":451,"conditions":9295,"interventions":9296},[89],[15],[6041,6022],{"trials":9298,"activeCount":101},[],{"trials":9300,"activeCount":101},[],{"trials":9302,"activeCount":101},[],{"trials":9304,"activeCount":101},[],{"intervention":9306,"totalTrials":144,"cells":9307},"CKD-841 A-1 3.75mg",{"EARLY_PHASE1":9308,"PHASE1":9310,"PHASE2":9324,"PHASE3":9326,"PHASE4":9328,"NA":9330},{"trials":9309,"activeCount":101},[],{"trials":9311,"activeCount":101},[9312],{"nctId":9313,"briefTitle":9314,"status":126,"phases":9315,"primaryCompletion":9316,"completion":9317,"start":2020,"enrollment":451,"conditions":9318,"interventions":9320},"NCT04840745","The Safety and Pharmacokinetic\u002FPharmacodynamic Study of CKD-841 in Postmenopausal Female, Phase 1",[89],"2021-10","2021-11",[9319],"Early Puberty",[9306,9321,9322,9323],"CKD-841 A-1 1.88mg","CKD-841 D 2.92mg","Leuplin Inj. 3.75 mg",{"trials":9325,"activeCount":101},[],{"trials":9327,"activeCount":101},[],{"trials":9329,"activeCount":101},[],{"trials":9331,"activeCount":101},[],{"intervention":9321,"totalTrials":144,"cells":9333},{"EARLY_PHASE1":9334,"PHASE1":9336,"PHASE2":9342,"PHASE3":9344,"PHASE4":9346,"NA":9348},{"trials":9335,"activeCount":101},[],{"trials":9337,"activeCount":101},[9338],{"nctId":9313,"briefTitle":9314,"status":126,"phases":9339,"primaryCompletion":9316,"completion":9317,"start":2020,"enrollment":451,"conditions":9340,"interventions":9341},[89],[9319],[9306,9321,9322,9323],{"trials":9343,"activeCount":101},[],{"trials":9345,"activeCount":101},[],{"trials":9347,"activeCount":101},[],{"trials":9349,"activeCount":101},[],{"intervention":9322,"totalTrials":144,"cells":9351},{"EARLY_PHASE1":9352,"PHASE1":9354,"PHASE2":9360,"PHASE3":9362,"PHASE4":9364,"NA":9366},{"trials":9353,"activeCount":101},[],{"trials":9355,"activeCount":101},[9356],{"nctId":9313,"briefTitle":9314,"status":126,"phases":9357,"primaryCompletion":9316,"completion":9317,"start":2020,"enrollment":451,"conditions":9358,"interventions":9359},[89],[9319],[9306,9321,9322,9323],{"trials":9361,"activeCount":101},[],{"trials":9363,"activeCount":101},[],{"trials":9365,"activeCount":101},[],{"trials":9367,"activeCount":101},[],{"intervention":9323,"totalTrials":144,"cells":9369},{"EARLY_PHASE1":9370,"PHASE1":9372,"PHASE2":9378,"PHASE3":9380,"PHASE4":9382,"NA":9384},{"trials":9371,"activeCount":101},[],{"trials":9373,"activeCount":101},[9374],{"nctId":9313,"briefTitle":9314,"status":126,"phases":9375,"primaryCompletion":9316,"completion":9317,"start":2020,"enrollment":451,"conditions":9376,"interventions":9377},[89],[9319],[9306,9321,9322,9323],{"trials":9379,"activeCount":101},[],{"trials":9381,"activeCount":101},[],{"trials":9383,"activeCount":101},[],{"trials":9385,"activeCount":101},[],{"intervention":5851,"totalTrials":144,"cells":9387},{"EARLY_PHASE1":9388,"PHASE1":9390,"PHASE2":9396,"PHASE3":9398,"PHASE4":9400,"NA":9402},{"trials":9389,"activeCount":101},[],{"trials":9391,"activeCount":101},[9392],{"nctId":5843,"briefTitle":5844,"status":126,"phases":9393,"primaryCompletion":5846,"completion":5847,"start":5848,"enrollment":5837,"conditions":9394,"interventions":9395},[89],[5839],[5851,5824],{"trials":9397,"activeCount":101},[],{"trials":9399,"activeCount":101},[],{"trials":9401,"activeCount":101},[],{"trials":9403,"activeCount":101},[],{"intervention":9405,"totalTrials":144,"cells":9406},"CKD-379(Empagliflozin+sitagliptin+metformin) Test drug",{"EARLY_PHASE1":9407,"PHASE1":9409,"PHASE2":9420,"PHASE3":9422,"PHASE4":9424,"NA":9426},{"trials":9408,"activeCount":101},[],{"trials":9410,"activeCount":101},[9411],{"nctId":9412,"briefTitle":9413,"status":107,"phases":9414,"primaryCompletion":9415,"completion":9415,"start":9416,"enrollment":112,"conditions":9417,"interventions":9418},"NCT06204107","A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379",[89],"2023-12-06","2023-11-21",[23],[9405,9419],"CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug",{"trials":9421,"activeCount":101},[],{"trials":9423,"activeCount":101},[],{"trials":9425,"activeCount":101},[],{"trials":9427,"activeCount":101},[],{"intervention":9419,"totalTrials":144,"cells":9429},{"EARLY_PHASE1":9430,"PHASE1":9432,"PHASE2":9438,"PHASE3":9440,"PHASE4":9442,"NA":9444},{"trials":9431,"activeCount":101},[],{"trials":9433,"activeCount":101},[9434],{"nctId":9412,"briefTitle":9413,"status":107,"phases":9435,"primaryCompletion":9415,"completion":9415,"start":9416,"enrollment":112,"conditions":9436,"interventions":9437},[89],[23],[9405,9419],{"trials":9439,"activeCount":101},[],{"trials":9441,"activeCount":101},[],{"trials":9443,"activeCount":101},[],{"trials":9445,"activeCount":101},[],{"intervention":4857,"totalTrials":144,"cells":9447},{"EARLY_PHASE1":9448,"PHASE1":9450,"PHASE2":9456,"PHASE3":9458,"PHASE4":9460,"NA":9462},{"trials":9449,"activeCount":101},[],{"trials":9451,"activeCount":101},[9452],{"nctId":4849,"briefTitle":4850,"status":107,"phases":9453,"primaryCompletion":4852,"completion":4853,"start":4854,"enrollment":675,"conditions":9454,"interventions":9455},[89],[18],[4857,3690],{"trials":9457,"activeCount":101},[],{"trials":9459,"activeCount":101},[],{"trials":9461,"activeCount":101},[],{"trials":9463,"activeCount":101},[],{"intervention":464,"totalTrials":144,"cells":9465},{"EARLY_PHASE1":9466,"PHASE1":9468,"PHASE2":9474,"PHASE3":9476,"PHASE4":9478,"NA":9480},{"trials":9467,"activeCount":101},[],{"trials":9469,"activeCount":101},[9470],{"nctId":456,"briefTitle":457,"status":107,"phases":9471,"primaryCompletion":459,"completion":460,"start":461,"enrollment":415,"conditions":9472,"interventions":9473},[89],[31],[41,464],{"trials":9475,"activeCount":101},[],{"trials":9477,"activeCount":101},[],{"trials":9479,"activeCount":101},[],{"trials":9481,"activeCount":101},[],{"intervention":9483,"totalTrials":144,"cells":9484},"CKD-370",{"EARLY_PHASE1":9485,"PHASE1":9487,"PHASE2":9498,"PHASE3":9500,"PHASE4":9502,"NA":9504},{"trials":9486,"activeCount":101},[],{"trials":9488,"activeCount":101},[9489],{"nctId":9490,"briefTitle":9491,"status":126,"phases":9492,"primaryCompletion":9493,"completion":4303,"start":9494,"enrollment":112,"conditions":9495,"interventions":9496},"NCT03849495","Pharmacokinetics and Safety\u002FTolerability After Oral Administration of CKD-370 and D745 in Healthy Adults",[89],"2019-03-17","2019-02-19",[23],[9483,9497],"D745",{"trials":9499,"activeCount":101},[],{"trials":9501,"activeCount":101},[],{"trials":9503,"activeCount":101},[],{"trials":9505,"activeCount":101},[],{"intervention":9497,"totalTrials":144,"cells":9507},{"EARLY_PHASE1":9508,"PHASE1":9510,"PHASE2":9516,"PHASE3":9518,"PHASE4":9520,"NA":9522},{"trials":9509,"activeCount":101},[],{"trials":9511,"activeCount":101},[9512],{"nctId":9490,"briefTitle":9491,"status":126,"phases":9513,"primaryCompletion":9493,"completion":4303,"start":9494,"enrollment":112,"conditions":9514,"interventions":9515},[89],[23],[9483,9497],{"trials":9517,"activeCount":101},[],{"trials":9519,"activeCount":101},[],{"trials":9521,"activeCount":101},[],{"trials":9523,"activeCount":101},[],{"intervention":9525,"totalTrials":144,"cells":9526},"CKD-828, D064, D702",{"EARLY_PHASE1":9527,"PHASE1":9529,"PHASE2":9540,"PHASE3":9542,"PHASE4":9544,"NA":9546},{"trials":9528,"activeCount":101},[],{"trials":9530,"activeCount":101},[9531],{"nctId":9532,"briefTitle":9533,"status":107,"phases":9534,"primaryCompletion":9535,"completion":9536,"start":9537,"enrollment":16,"conditions":9538,"interventions":9539},"NCT05881707","A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828 20\u002F1.25mg",[89],"2023-09-02","2023-09-27","2023-07-04",[15],[9525],{"trials":9541,"activeCount":101},[],{"trials":9543,"activeCount":101},[],{"trials":9545,"activeCount":101},[],{"trials":9547,"activeCount":101},[],{"intervention":9549,"totalTrials":144,"cells":9550},"Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg",{"EARLY_PHASE1":9551,"PHASE1":9553,"PHASE2":9562,"PHASE3":9564,"PHASE4":9566,"NA":9568},{"trials":9552,"activeCount":101},[],{"trials":9554,"activeCount":101},[9555],{"nctId":9556,"briefTitle":9557,"status":107,"phases":9558,"primaryCompletion":2043,"completion":2043,"start":4927,"enrollment":4666,"conditions":9559,"interventions":9560},"NCT02565368","A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5\u002F1000 mg in Healthy Male Volunteers",[89],[6332],[9549,9561],"CKD-395 0.5\u002F1000mg",{"trials":9563,"activeCount":101},[],{"trials":9565,"activeCount":101},[],{"trials":9567,"activeCount":101},[],{"trials":9569,"activeCount":101},[],{"intervention":9561,"totalTrials":144,"cells":9571},{"EARLY_PHASE1":9572,"PHASE1":9574,"PHASE2":9580,"PHASE3":9582,"PHASE4":9584,"NA":9586},{"trials":9573,"activeCount":101},[],{"trials":9575,"activeCount":101},[9576],{"nctId":9556,"briefTitle":9557,"status":107,"phases":9577,"primaryCompletion":2043,"completion":2043,"start":4927,"enrollment":4666,"conditions":9578,"interventions":9579},[89],[6332],[9549,9561],{"trials":9581,"activeCount":101},[],{"trials":9583,"activeCount":101},[],{"trials":9585,"activeCount":101},[],{"trials":9587,"activeCount":101},[],{"intervention":115,"totalTrials":144,"cells":9589},{"EARLY_PHASE1":9590,"PHASE1":9592,"PHASE2":9598,"PHASE3":9600,"PHASE4":9602,"NA":9604},{"trials":9591,"activeCount":101},[],{"trials":9593,"activeCount":101},[9594],{"nctId":105,"briefTitle":106,"status":107,"phases":9595,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":9596,"interventions":9597},[89],[25],[115,116],{"trials":9599,"activeCount":101},[],{"trials":9601,"activeCount":101},[],{"trials":9603,"activeCount":101},[],{"trials":9605,"activeCount":101},[],{"intervention":9607,"totalTrials":144,"cells":9608},"CKD-341, D956",{"EARLY_PHASE1":9609,"PHASE1":9611,"PHASE2":9621,"PHASE3":9623,"PHASE4":9625,"NA":9627},{"trials":9610,"activeCount":101},[],{"trials":9612,"activeCount":101},[9613],{"nctId":9614,"briefTitle":9615,"status":107,"phases":9616,"primaryCompletion":9617,"completion":9618,"start":2744,"enrollment":5837,"conditions":9619,"interventions":9620},"NCT06281132","Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic After Oral Administration of CKD-341 and D956 in Healthy Adults",[89],"2024-05-07","2024-05-14",[15],[9607],{"trials":9622,"activeCount":101},[],{"trials":9624,"activeCount":101},[],{"trials":9626,"activeCount":101},[],{"trials":9628,"activeCount":101},[],{"intervention":5178,"totalTrials":144,"cells":9630},{"EARLY_PHASE1":9631,"PHASE1":9633,"PHASE2":9639,"PHASE3":9641,"PHASE4":9643,"NA":9645},{"trials":9632,"activeCount":101},[],{"trials":9634,"activeCount":101},[9635],{"nctId":5169,"briefTitle":5170,"status":107,"phases":9636,"primaryCompletion":5172,"completion":5173,"start":5174,"enrollment":5175,"conditions":9637,"interventions":9638},[89],[31],[5142,5178],{"trials":9640,"activeCount":101},[],{"trials":9642,"activeCount":101},[],{"trials":9644,"activeCount":101},[],{"trials":9646,"activeCount":101},[],{"intervention":4506,"totalTrials":144,"cells":9648},{"EARLY_PHASE1":9649,"PHASE1":9651,"PHASE2":9657,"PHASE3":9659,"PHASE4":9661,"NA":9663},{"trials":9650,"activeCount":101},[],{"trials":9652,"activeCount":101},[9653],{"nctId":4499,"briefTitle":4500,"status":107,"phases":9654,"primaryCompletion":1847,"completion":4502,"start":4503,"enrollment":451,"conditions":9655,"interventions":9656},[89],[21],[4506,4507,4434],{"trials":9658,"activeCount":101},[],{"trials":9660,"activeCount":101},[],{"trials":9662,"activeCount":101},[],{"trials":9664,"activeCount":101},[],{"intervention":4507,"totalTrials":144,"cells":9666},{"EARLY_PHASE1":9667,"PHASE1":9669,"PHASE2":9675,"PHASE3":9677,"PHASE4":9679,"NA":9681},{"trials":9668,"activeCount":101},[],{"trials":9670,"activeCount":101},[9671],{"nctId":4499,"briefTitle":4500,"status":107,"phases":9672,"primaryCompletion":1847,"completion":4502,"start":4503,"enrollment":451,"conditions":9673,"interventions":9674},[89],[21],[4506,4507,4434],{"trials":9676,"activeCount":101},[],{"trials":9678,"activeCount":101},[],{"trials":9680,"activeCount":101},[],{"trials":9682,"activeCount":101},[],{"intervention":9684,"totalTrials":144,"cells":9685},"Luckyvec 400mg film coated",{"EARLY_PHASE1":9686,"PHASE1":9688,"PHASE2":9699,"PHASE3":9701,"PHASE4":9703,"NA":9705},{"trials":9687,"activeCount":101},[],{"trials":9689,"activeCount":101},[9690],{"nctId":9691,"briefTitle":9692,"status":107,"phases":9693,"primaryCompletion":1995,"completion":1995,"start":1996,"enrollment":415,"conditions":9694,"interventions":9697},"NCT01270984","Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects",[89],[9695,9696],"Chronic Myeloid Leukemia","Gastrointestinal Stromal Tumors",[9684,9698],"Glivec 100mg film coated",{"trials":9700,"activeCount":101},[],{"trials":9702,"activeCount":101},[],{"trials":9704,"activeCount":101},[],{"trials":9706,"activeCount":101},[],{"intervention":9698,"totalTrials":144,"cells":9708},{"EARLY_PHASE1":9709,"PHASE1":9711,"PHASE2":9717,"PHASE3":9719,"PHASE4":9721,"NA":9723},{"trials":9710,"activeCount":101},[],{"trials":9712,"activeCount":101},[9713],{"nctId":9691,"briefTitle":9692,"status":107,"phases":9714,"primaryCompletion":1995,"completion":1995,"start":1996,"enrollment":415,"conditions":9715,"interventions":9716},[89],[9695,9696],[9684,9698],{"trials":9718,"activeCount":101},[],{"trials":9720,"activeCount":101},[],{"trials":9722,"activeCount":101},[],{"trials":9724,"activeCount":101},[],{"intervention":9726,"totalTrials":144,"cells":9727},"Rosuvastatin 20 mg",{"EARLY_PHASE1":9728,"PHASE1":9730,"PHASE2":9742,"PHASE3":9744,"PHASE4":9746,"NA":9748},{"trials":9729,"activeCount":101},[],{"trials":9731,"activeCount":101},[9732],{"nctId":9733,"briefTitle":9734,"status":107,"phases":9735,"primaryCompletion":9736,"completion":9736,"start":9737,"enrollment":415,"conditions":9738,"interventions":9739},"NCT03175835","Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects",[89],"2017-06-19","2017-05-08",[18],[9726,9740,9741],"CKD-519 200 mg","Rosuvastatin 20 mg & CKD-519 200 mg",{"trials":9743,"activeCount":101},[],{"trials":9745,"activeCount":101},[],{"trials":9747,"activeCount":101},[],{"trials":9749,"activeCount":101},[],{"intervention":9740,"totalTrials":144,"cells":9751},{"EARLY_PHASE1":9752,"PHASE1":9754,"PHASE2":9760,"PHASE3":9762,"PHASE4":9764,"NA":9766},{"trials":9753,"activeCount":101},[],{"trials":9755,"activeCount":101},[9756],{"nctId":9733,"briefTitle":9734,"status":107,"phases":9757,"primaryCompletion":9736,"completion":9736,"start":9737,"enrollment":415,"conditions":9758,"interventions":9759},[89],[18],[9726,9740,9741],{"trials":9761,"activeCount":101},[],{"trials":9763,"activeCount":101},[],{"trials":9765,"activeCount":101},[],{"trials":9767,"activeCount":101},[],{"intervention":9741,"totalTrials":144,"cells":9769},{"EARLY_PHASE1":9770,"PHASE1":9772,"PHASE2":9778,"PHASE3":9780,"PHASE4":9782,"NA":9784},{"trials":9771,"activeCount":101},[],{"trials":9773,"activeCount":101},[9774],{"nctId":9733,"briefTitle":9734,"status":107,"phases":9775,"primaryCompletion":9736,"completion":9736,"start":9737,"enrollment":415,"conditions":9776,"interventions":9777},[89],[18],[9726,9740,9741],{"trials":9779,"activeCount":101},[],{"trials":9781,"activeCount":101},[],{"trials":9783,"activeCount":101},[],{"trials":9785,"activeCount":101},[],{"intervention":4939,"totalTrials":144,"cells":9787},{"EARLY_PHASE1":9788,"PHASE1":9790,"PHASE2":9796,"PHASE3":9798,"PHASE4":9800,"NA":9802},{"trials":9789,"activeCount":101},[],{"trials":9791,"activeCount":101},[9792],{"nctId":4931,"briefTitle":4932,"status":107,"phases":9793,"primaryCompletion":4934,"completion":4935,"start":4936,"enrollment":4716,"conditions":9794,"interventions":9795},[89],[18],[4909,4939],{"trials":9797,"activeCount":101},[],{"trials":9799,"activeCount":101},[],{"trials":9801,"activeCount":101},[],{"trials":9803,"activeCount":101},[],{"intervention":4694,"totalTrials":144,"cells":9805},{"EARLY_PHASE1":9806,"PHASE1":9808,"PHASE2":9814,"PHASE3":9816,"PHASE4":9818,"NA":9820},{"trials":9807,"activeCount":101},[],{"trials":9809,"activeCount":101},[9810],{"nctId":4687,"briefTitle":4688,"status":107,"phases":9811,"primaryCompletion":4690,"completion":4690,"start":4691,"enrollment":781,"conditions":9812,"interventions":9813},[89],[31],[4647,4694,443],{"trials":9815,"activeCount":101},[],{"trials":9817,"activeCount":101},[],{"trials":9819,"activeCount":101},[],{"trials":9821,"activeCount":101},[],{"intervention":9823,"totalTrials":144,"cells":9824},"D309",{"EARLY_PHASE1":9825,"PHASE1":9827,"PHASE2":9840,"PHASE3":9842,"PHASE4":9844,"NA":9846},{"trials":9826,"activeCount":101},[],{"trials":9828,"activeCount":101},[9829],{"nctId":9830,"briefTitle":9831,"status":107,"phases":9832,"primaryCompletion":9833,"completion":9834,"start":9835,"enrollment":2313,"conditions":9836,"interventions":9838},"NCT04673682","A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-845",[89],"2022-05-17","2022-06-07","2020-11-16",[9837],"Hypogonadism",[9823,9839],"CKD-845",{"trials":9841,"activeCount":101},[],{"trials":9843,"activeCount":101},[],{"trials":9845,"activeCount":101},[],{"trials":9847,"activeCount":101},[],{"intervention":9839,"totalTrials":144,"cells":9849},{"EARLY_PHASE1":9850,"PHASE1":9852,"PHASE2":9858,"PHASE3":9860,"PHASE4":9862,"NA":9864},{"trials":9851,"activeCount":101},[],{"trials":9853,"activeCount":101},[9854],{"nctId":9830,"briefTitle":9831,"status":107,"phases":9855,"primaryCompletion":9833,"completion":9834,"start":9835,"enrollment":2313,"conditions":9856,"interventions":9857},[89],[9837],[9823,9839],{"trials":9859,"activeCount":101},[],{"trials":9861,"activeCount":101},[],{"trials":9863,"activeCount":101},[],{"trials":9865,"activeCount":101},[],{"intervention":9867,"totalTrials":144,"cells":9868},"CKD-393 formulation I",{"EARLY_PHASE1":9869,"PHASE1":9871,"PHASE2":9883,"PHASE3":9885,"PHASE4":9887,"NA":9889},{"trials":9870,"activeCount":101},[],{"trials":9872,"activeCount":101},[9873],{"nctId":9874,"briefTitle":9875,"status":107,"phases":9876,"primaryCompletion":9877,"completion":5847,"start":9878,"enrollment":4666,"conditions":9879,"interventions":9880},"NCT04768673","A Study to Investigate the PK and Safety of CKD-393",[89],"2021-04-22","2021-03-26",[4539],[9867,9881,9882],"CKD-393 formulation II","D501, D759, H053",{"trials":9884,"activeCount":101},[],{"trials":9886,"activeCount":101},[],{"trials":9888,"activeCount":101},[],{"trials":9890,"activeCount":101},[],{"intervention":9881,"totalTrials":144,"cells":9892},{"EARLY_PHASE1":9893,"PHASE1":9895,"PHASE2":9901,"PHASE3":9903,"PHASE4":9905,"NA":9907},{"trials":9894,"activeCount":101},[],{"trials":9896,"activeCount":101},[9897],{"nctId":9874,"briefTitle":9875,"status":107,"phases":9898,"primaryCompletion":9877,"completion":5847,"start":9878,"enrollment":4666,"conditions":9899,"interventions":9900},[89],[4539],[9867,9881,9882],{"trials":9902,"activeCount":101},[],{"trials":9904,"activeCount":101},[],{"trials":9906,"activeCount":101},[],{"trials":9908,"activeCount":101},[],{"intervention":9882,"totalTrials":144,"cells":9910},{"EARLY_PHASE1":9911,"PHASE1":9913,"PHASE2":9919,"PHASE3":9921,"PHASE4":9923,"NA":9925},{"trials":9912,"activeCount":101},[],{"trials":9914,"activeCount":101},[9915],{"nctId":9874,"briefTitle":9875,"status":107,"phases":9916,"primaryCompletion":9877,"completion":5847,"start":9878,"enrollment":4666,"conditions":9917,"interventions":9918},[89],[4539],[9867,9881,9882],{"trials":9920,"activeCount":101},[],{"trials":9922,"activeCount":101},[],{"trials":9924,"activeCount":101},[],{"trials":9926,"activeCount":101},[],{"intervention":9928,"totalTrials":144,"cells":9929},"Januvia Tab. 100mg",{"EARLY_PHASE1":9930,"PHASE1":9932,"PHASE2":9942,"PHASE3":9944,"PHASE4":9946,"NA":9948},{"trials":9931,"activeCount":101},[],{"trials":9933,"activeCount":101},[9934],{"nctId":9935,"briefTitle":9936,"status":107,"phases":9937,"primaryCompletion":2292,"completion":2647,"start":2292,"enrollment":4579,"conditions":9938,"interventions":9940},"NCT02827890","CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1)",[89],[9939],"Diabetes Mellitus Type 2",[9928,9941],"Januvia Tab. 100mg + Duvie Tab. 0.5mg",{"trials":9943,"activeCount":101},[],{"trials":9945,"activeCount":101},[],{"trials":9947,"activeCount":101},[],{"trials":9949,"activeCount":101},[],{"intervention":9941,"totalTrials":144,"cells":9951},{"EARLY_PHASE1":9952,"PHASE1":9954,"PHASE2":9960,"PHASE3":9962,"PHASE4":9964,"NA":9966},{"trials":9953,"activeCount":101},[],{"trials":9955,"activeCount":101},[9956],{"nctId":9935,"briefTitle":9936,"status":107,"phases":9957,"primaryCompletion":2292,"completion":2647,"start":2292,"enrollment":4579,"conditions":9958,"interventions":9959},[89],[9939],[9928,9941],{"trials":9961,"activeCount":101},[],{"trials":9963,"activeCount":101},[],{"trials":9965,"activeCount":101},[],{"trials":9967,"activeCount":101},[],{"intervention":9969,"totalTrials":144,"cells":9970},"D569 Tab.",{"EARLY_PHASE1":9971,"PHASE1":9973,"PHASE2":9985,"PHASE3":9987,"PHASE4":9989,"NA":9991},{"trials":9972,"activeCount":101},[],{"trials":9974,"activeCount":101},[9975],{"nctId":9976,"briefTitle":9977,"status":107,"phases":9978,"primaryCompletion":9979,"completion":9980,"start":9981,"enrollment":9,"conditions":9982,"interventions":9983},"NCT03858725","Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-374 5 mg in Healthy Volunteers",[89],"2019-04-05","2019-05-08","2019-02-26",[1692],[9969,9984],"CKD-374 5mg Tab.",{"trials":9986,"activeCount":101},[],{"trials":9988,"activeCount":101},[],{"trials":9990,"activeCount":101},[],{"trials":9992,"activeCount":101},[],{"intervention":9984,"totalTrials":144,"cells":9994},{"EARLY_PHASE1":9995,"PHASE1":9997,"PHASE2":10003,"PHASE3":10005,"PHASE4":10007,"NA":10009},{"trials":9996,"activeCount":101},[],{"trials":9998,"activeCount":101},[9999],{"nctId":9976,"briefTitle":9977,"status":107,"phases":10000,"primaryCompletion":9979,"completion":9980,"start":9981,"enrollment":9,"conditions":10001,"interventions":10002},[89],[1692],[9969,9984],{"trials":10004,"activeCount":101},[],{"trials":10006,"activeCount":101},[],{"trials":10008,"activeCount":101},[],{"trials":10010,"activeCount":101},[],{"intervention":2229,"totalTrials":144,"cells":10012},{"EARLY_PHASE1":10013,"PHASE1":10015,"PHASE2":10021,"PHASE3":10023,"PHASE4":10025,"NA":10027},{"trials":10014,"activeCount":101},[],{"trials":10016,"activeCount":101},[10017],{"nctId":2223,"briefTitle":2224,"status":107,"phases":10018,"primaryCompletion":2206,"completion":2206,"start":1985,"enrollment":594,"conditions":10019,"interventions":10020},[89],[2227],[2229,2188],{"trials":10022,"activeCount":101},[],{"trials":10024,"activeCount":101},[],{"trials":10026,"activeCount":101},[],{"trials":10028,"activeCount":101},[],{"intervention":10030,"totalTrials":144,"cells":10031},"CKD-510 single dose",{"EARLY_PHASE1":10032,"PHASE1":10034,"PHASE2":10047,"PHASE3":10049,"PHASE4":10051,"NA":10053},{"trials":10033,"activeCount":101},[],{"trials":10035,"activeCount":101},[10036],{"nctId":10037,"briefTitle":10038,"status":107,"phases":10039,"primaryCompletion":10040,"completion":10040,"start":10041,"enrollment":10042,"conditions":10043,"interventions":10044},"NCT04746287","Evaluation of the Safety and Tolerability of CKD-510 in Healthy Subjects",[89],"2021-08-24","2020-01-14",87,[6119],[10030,10045,10046],"CKD-510 food effect","CKD-510 multiple dose",{"trials":10048,"activeCount":101},[],{"trials":10050,"activeCount":101},[],{"trials":10052,"activeCount":101},[],{"trials":10054,"activeCount":101},[],{"intervention":10045,"totalTrials":144,"cells":10056},{"EARLY_PHASE1":10057,"PHASE1":10059,"PHASE2":10065,"PHASE3":10067,"PHASE4":10069,"NA":10071},{"trials":10058,"activeCount":101},[],{"trials":10060,"activeCount":101},[10061],{"nctId":10037,"briefTitle":10038,"status":107,"phases":10062,"primaryCompletion":10040,"completion":10040,"start":10041,"enrollment":10042,"conditions":10063,"interventions":10064},[89],[6119],[10030,10045,10046],{"trials":10066,"activeCount":101},[],{"trials":10068,"activeCount":101},[],{"trials":10070,"activeCount":101},[],{"trials":10072,"activeCount":101},[],{"intervention":10046,"totalTrials":144,"cells":10074},{"EARLY_PHASE1":10075,"PHASE1":10077,"PHASE2":10083,"PHASE3":10085,"PHASE4":10087,"NA":10089},{"trials":10076,"activeCount":101},[],{"trials":10078,"activeCount":101},[10079],{"nctId":10037,"briefTitle":10038,"status":107,"phases":10080,"primaryCompletion":10040,"completion":10040,"start":10041,"enrollment":10042,"conditions":10081,"interventions":10082},[89],[6119],[10030,10045,10046],{"trials":10084,"activeCount":101},[],{"trials":10086,"activeCount":101},[],{"trials":10088,"activeCount":101},[],{"trials":10090,"activeCount":101},[],{"intervention":2137,"totalTrials":144,"cells":10092},{"EARLY_PHASE1":10093,"PHASE1":10095,"PHASE2":10101,"PHASE3":10103,"PHASE4":10105,"NA":10107},{"trials":10094,"activeCount":101},[],{"trials":10096,"activeCount":101},[10097],{"nctId":2128,"briefTitle":2129,"status":107,"phases":10098,"primaryCompletion":1750,"completion":2131,"start":1749,"enrollment":2132,"conditions":10099,"interventions":10100},[89],[15,2134],[2136,2121,2137],{"trials":10102,"activeCount":101},[],{"trials":10104,"activeCount":101},[],{"trials":10106,"activeCount":101},[],{"trials":10108,"activeCount":101},[],{"intervention":10110,"totalTrials":144,"cells":10111},"CKD-349 F1 Tab.",{"EARLY_PHASE1":10112,"PHASE1":10114,"PHASE2":10128,"PHASE3":10130,"PHASE4":10132,"NA":10134},{"trials":10113,"activeCount":101},[],{"trials":10115,"activeCount":101},[10116],{"nctId":10117,"briefTitle":10118,"status":107,"phases":10119,"primaryCompletion":10120,"completion":10121,"start":10122,"enrollment":4674,"conditions":10123,"interventions":10125},"NCT04952506","Clinical Study to Compare the Pharmacokinetics and Safety of D113 With CKD-349 in Healthy Volunteers",[89],"2021-07-29","2021-08-20","2021-07-19",[10124],"Chronic Renal Failure",[10110,10126,10127],"CKD-349 F2 Tab.","D113 Tab.",{"trials":10129,"activeCount":101},[],{"trials":10131,"activeCount":101},[],{"trials":10133,"activeCount":101},[],{"trials":10135,"activeCount":101},[],{"intervention":10126,"totalTrials":144,"cells":10137},{"EARLY_PHASE1":10138,"PHASE1":10140,"PHASE2":10146,"PHASE3":10148,"PHASE4":10150,"NA":10152},{"trials":10139,"activeCount":101},[],{"trials":10141,"activeCount":101},[10142],{"nctId":10117,"briefTitle":10118,"status":107,"phases":10143,"primaryCompletion":10120,"completion":10121,"start":10122,"enrollment":4674,"conditions":10144,"interventions":10145},[89],[10124],[10110,10126,10127],{"trials":10147,"activeCount":101},[],{"trials":10149,"activeCount":101},[],{"trials":10151,"activeCount":101},[],{"trials":10153,"activeCount":101},[],{"intervention":10127,"totalTrials":144,"cells":10155},{"EARLY_PHASE1":10156,"PHASE1":10158,"PHASE2":10164,"PHASE3":10166,"PHASE4":10168,"NA":10170},{"trials":10157,"activeCount":101},[],{"trials":10159,"activeCount":101},[10160],{"nctId":10117,"briefTitle":10118,"status":107,"phases":10161,"primaryCompletion":10120,"completion":10121,"start":10122,"enrollment":4674,"conditions":10162,"interventions":10163},[89],[10124],[10110,10126,10127],{"trials":10165,"activeCount":101},[],{"trials":10167,"activeCount":101},[],{"trials":10169,"activeCount":101},[],{"trials":10171,"activeCount":101},[],{"intervention":10173,"totalTrials":144,"cells":10174},"CKD-516 inj.",{"EARLY_PHASE1":10175,"PHASE1":10177,"PHASE2":10185,"PHASE3":10187,"PHASE4":10189,"NA":10191},{"trials":10176,"activeCount":101},[],{"trials":10178,"activeCount":101},[10179],{"nctId":10180,"briefTitle":8167,"status":107,"phases":10181,"primaryCompletion":1052,"completion":1052,"start":1064,"enrollment":10182,"conditions":10183,"interventions":10184},"NCT01560325",[89],21,[8170],[10173],{"trials":10186,"activeCount":101},[],{"trials":10188,"activeCount":101},[],{"trials":10190,"activeCount":101},[],{"trials":10192,"activeCount":101},[],{"intervention":5930,"totalTrials":144,"cells":10194},{"EARLY_PHASE1":10195,"PHASE1":10197,"PHASE2":10203,"PHASE3":10205,"PHASE4":10207,"NA":10209},{"trials":10196,"activeCount":101},[],{"trials":10198,"activeCount":101},[10199],{"nctId":5923,"briefTitle":5924,"status":107,"phases":10200,"primaryCompletion":5926,"completion":5927,"start":3742,"enrollment":415,"conditions":10201,"interventions":10202},[89],[31],[5930,454],{"trials":10204,"activeCount":101},[],{"trials":10206,"activeCount":101},[],{"trials":10208,"activeCount":101},[],{"trials":10210,"activeCount":101},[],{"intervention":10212,"totalTrials":144,"cells":10213},"CKD-395 0.5(Lobeglitazone)\u002F1000(Metformin)mg 1T",{"EARLY_PHASE1":10214,"PHASE1":10216,"PHASE2":10224,"PHASE3":10226,"PHASE4":10228,"NA":10230},{"trials":10215,"activeCount":101},[],{"trials":10217,"activeCount":101},[10218],{"nctId":10219,"briefTitle":10220,"status":107,"phases":10221,"primaryCompletion":1309,"completion":5718,"start":1309,"enrollment":4666,"conditions":10222,"interventions":10223},"NCT02648854","Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male Volunteers",[89],[6332],[10212,10212],{"trials":10225,"activeCount":101},[],{"trials":10227,"activeCount":101},[],{"trials":10229,"activeCount":101},[],{"trials":10231,"activeCount":101},[],{"intervention":6128,"totalTrials":144,"cells":10233},{"EARLY_PHASE1":10234,"PHASE1":10236,"PHASE2":10242,"PHASE3":10244,"PHASE4":10246,"NA":10248},{"trials":10235,"activeCount":101},[],{"trials":10237,"activeCount":101},[10238],{"nctId":6122,"briefTitle":6123,"status":107,"phases":10239,"primaryCompletion":6125,"completion":5254,"start":2067,"enrollment":781,"conditions":10240,"interventions":10241},[89],[6119],[6128,6108,6128,6108],{"trials":10243,"activeCount":101},[],{"trials":10245,"activeCount":101},[],{"trials":10247,"activeCount":101},[],{"trials":10249,"activeCount":101},[],{"intervention":10251,"totalTrials":144,"cells":10252},"D352",{"EARLY_PHASE1":10253,"PHASE1":10255,"PHASE2":10267,"PHASE3":10269,"PHASE4":10271,"NA":10273},{"trials":10254,"activeCount":101},[],{"trials":10256,"activeCount":101},[10257],{"nctId":10258,"briefTitle":10259,"status":107,"phases":10260,"primaryCompletion":10261,"completion":10262,"start":10263,"enrollment":2280,"conditions":10264,"interventions":10265},"NCT06758661","Clinical Study to Evaluate Drug-drug Interaction and Safety After Co-administration of D352 and D794 in Healthy Adult Volunteers",[89],"2025-01-24","2025-02-03","2024-11-27",[34],[10251,10266],"D794",{"trials":10268,"activeCount":101},[],{"trials":10270,"activeCount":101},[],{"trials":10272,"activeCount":101},[],{"trials":10274,"activeCount":101},[],{"intervention":10266,"totalTrials":144,"cells":10276},{"EARLY_PHASE1":10277,"PHASE1":10279,"PHASE2":10285,"PHASE3":10287,"PHASE4":10289,"NA":10291},{"trials":10278,"activeCount":101},[],{"trials":10280,"activeCount":101},[10281],{"nctId":10258,"briefTitle":10259,"status":107,"phases":10282,"primaryCompletion":10261,"completion":10262,"start":10263,"enrollment":2280,"conditions":10283,"interventions":10284},[89],[34],[10251,10266],{"trials":10286,"activeCount":101},[],{"trials":10288,"activeCount":101},[],{"trials":10290,"activeCount":101},[],{"trials":10292,"activeCount":101},[],{"intervention":10294,"totalTrials":144,"cells":10295},"Lipitor Tab. 40mg",{"EARLY_PHASE1":10296,"PHASE1":10298,"PHASE2":10310,"PHASE3":10312,"PHASE4":10314,"NA":10316},{"trials":10297,"activeCount":101},[],{"trials":10299,"activeCount":101},[10300],{"nctId":10301,"briefTitle":10302,"status":107,"phases":10303,"primaryCompletion":10304,"completion":10305,"start":10306,"enrollment":415,"conditions":10307,"interventions":10308},"NCT02422030","CKD-337(2) Drug-drug Interaction Study",[89],"2015-03-22","2015-04-30","2015-03-17",[25],[10294,10309],"Trilipix 135mg",{"trials":10311,"activeCount":101},[],{"trials":10313,"activeCount":101},[],{"trials":10315,"activeCount":101},[],{"trials":10317,"activeCount":101},[],{"intervention":10309,"totalTrials":144,"cells":10319},{"EARLY_PHASE1":10320,"PHASE1":10322,"PHASE2":10328,"PHASE3":10330,"PHASE4":10332,"NA":10334},{"trials":10321,"activeCount":101},[],{"trials":10323,"activeCount":101},[10324],{"nctId":10301,"briefTitle":10302,"status":107,"phases":10325,"primaryCompletion":10304,"completion":10305,"start":10306,"enrollment":415,"conditions":10326,"interventions":10327},[89],[25],[10294,10309],{"trials":10329,"activeCount":101},[],{"trials":10331,"activeCount":101},[],{"trials":10333,"activeCount":101},[],{"trials":10335,"activeCount":101},[],{"intervention":10337,"totalTrials":144,"cells":10338},"Duvie(Lobeglitazone) tab 0.5mg",{"EARLY_PHASE1":10339,"PHASE1":10341,"PHASE2":10343,"PHASE3":10345,"PHASE4":10347,"NA":10349},{"trials":10340,"activeCount":101},[],{"trials":10342,"activeCount":101},[],{"trials":10344,"activeCount":101},[],{"trials":10346,"activeCount":101},[],{"trials":10348,"activeCount":101},[],{"trials":10350,"activeCount":101},[10351],{"nctId":10352,"briefTitle":10353,"status":107,"phases":10354,"primaryCompletion":10355,"completion":10355,"start":10356,"enrollment":10357,"conditions":10358,"interventions":10359},"NCT05043467","Retrospective Study to Evaluate the Safety of Duvie in Korean Patients With Type 2 Diabetes Mellitus",[],"2020-06-19","2019-01-02",2228,[1851],[10337],{"intervention":10361,"totalTrials":144,"cells":10362},"Tacrobell capsule 1mg",{"EARLY_PHASE1":10363,"PHASE1":10365,"PHASE2":10367,"PHASE3":10369,"PHASE4":10371,"NA":10373},{"trials":10364,"activeCount":101},[],{"trials":10366,"activeCount":101},[],{"trials":10368,"activeCount":101},[],{"trials":10370,"activeCount":101},[],{"trials":10372,"activeCount":101},[],{"trials":10374,"activeCount":101},[10375],{"nctId":10376,"briefTitle":10377,"status":107,"phases":10378,"primaryCompletion":8301,"completion":4405,"start":8301,"enrollment":6074,"conditions":10379,"interventions":10381},"NCT01910077","Bioequivalence Study of Tacrobell Capsule 1mg to Prograf Capsule 1mg",[93],[10380],"Immunosuppression",[10361,10382],"Prograf capsule 1mg",{"intervention":10382,"totalTrials":144,"cells":10384},{"EARLY_PHASE1":10385,"PHASE1":10387,"PHASE2":10389,"PHASE3":10391,"PHASE4":10393,"NA":10395},{"trials":10386,"activeCount":101},[],{"trials":10388,"activeCount":101},[],{"trials":10390,"activeCount":101},[],{"trials":10392,"activeCount":101},[],{"trials":10394,"activeCount":101},[],{"trials":10396,"activeCount":101},[10397],{"nctId":10376,"briefTitle":10377,"status":107,"phases":10398,"primaryCompletion":8301,"completion":4405,"start":8301,"enrollment":6074,"conditions":10399,"interventions":10400},[93],[10380],[10361,10382]]